naltrexone has been researched along with Addiction, Opioid in 806 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 74 (9.18) | 18.7374 |
| 1990's | 57 (7.07) | 18.2507 |
| 2000's | 130 (16.13) | 29.6817 |
| 2010's | 319 (39.58) | 24.3611 |
| 2020's | 226 (28.04) | 2.80 |
| Authors | Studies |
|---|---|
| Adapa, ID; Auh, JS; Berzetei-Gurske, IP; Brandt, SR; Craymer, K; Farrington, L; Haggart, D; Kennedy, JM; O'Brien, A; Polgar, WE; Rodriguez, L; Schwartz, RW; Toll, L; White, A | 1 |
| Dunphy, CC; Guy, GP; Xu, L; Zhang, K | 1 |
| Akerman, SC; Liu, CC; Saxon, AJ; Silverman, BL; Sullivan, MA; Vocci, FJ | 1 |
| Dasgupta, N; Saucier, R; Wolfe, D | 2 |
| Fox, LM; Lee, JD; Nelson, LS; Smith, SW; Wightman, RS | 1 |
| Brewer, C | 3 |
| Bisaga, A; Carpenter, KM; Choi, CJ; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Sullivan, MA | 1 |
| Otte, A; Park, K | 1 |
| Boney, TY; Bonnie, RJ; Chen, DT; Friedmann, PD; Gordon, M; Kinlock, TW; Lee, JD; Murphy, SM; Nunes, EV; O'Brien, CP; Polsky, D | 1 |
| Benth, JŠ; Fadnes, LT; Gaulen, Z; Kunøe, N; Latif, ZE; Opheim, A; Solli, KK; Tanum, L | 1 |
| Komrowski, MD; Sekhri, NK | 1 |
| Childress, AR; Langleben, DD; O'Brien, CP; Shi, Z; Wiers, CE | 1 |
| Cinemre, B; Coşkun, MN; Erdoğan, A; Kulaksızoğlu, B; Kuloğlu, MM; Topcuoğlu, M | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE | 1 |
| Gainer, DM; Miller, SC; Nahhas, RW; Silverstein, SM; Vanderhoof, SO; Vanderhoof, T; Wright, MD | 1 |
| Light, T; Madden, EF; Prevedel, S; Sulzer, SH | 1 |
| Hochheimer, M; Unick, GJ | 1 |
| Brenna, IH; Fadnes, LT; Gaulen, Z; Kunoe, N; Opheim, A; Šaltytė Benth, J; Solli, KK; Tanum, L | 1 |
| Cook, RR; Fanucchi, L; Foot, C; King, C; Korthuis, PT; Lucas, GM; Lum, PJ; Rodriguez, A; Tookes, H; Torralva, R; Vergara-Rodriguez, P; Waddell, EN | 1 |
| Brown, R; Haram, E; Horst, J; Jacobson, N; Kim, H; Kim, JS; Knudsen, HK; Madden, LM; Molfenter, T | 1 |
| Buie, R; Chastain, C; Dear, ML; Edwards, DA; Kast, KA; Limper, HM; Lindsell, CJ; Marcovitz, DE; Sullivan, W; White, KD | 1 |
| McClellan, C; Moriya, A; Simon, K | 1 |
| Allen, LR; Manini, AF; Nobel, I; Richardson, LD; Shastry, S; Vidal, K | 1 |
| Akerman, SC; Douaihy, AB; Legedza, A; Mannelli, P; Sullivan, MA; Zavod, A | 1 |
| Baker, R; Fanucchi, LC; Hoffman, KA; Jacobs, P; Korthuis, PT; Kunkel, LE; Lum, PJ; McCarty, D; Ponce Terashima, J | 1 |
| Brenna, IH; Fadnes, LT; Gaulen, Z; Šaltytė Benth, J; Tanum, L | 1 |
| Cotton, AJ; Kurtz, FB; Lo, K; Waldbauer, L | 1 |
| Anderson, BJ; Bailey, GL; Conti, M; Herman, DS; Stein, MD; VanNoppen, D | 1 |
| Barrow, J; Choudhary, A; Simon, L; Ticku, S; Tobey, M | 1 |
| Laks, J; Peterkin, A; Weinstein, ZM | 1 |
| Birkeland, B; Brenna, IH; Løberg, EM; Marciuch, A; Røstad, B; Solli, KK; Tanum, L; Veseth, M; Weimand, B | 1 |
| Bromberg, DJ; Karamouzian, M; Pilarinos, A | 1 |
| Choo, TH; Langleben, DD; Nunes, EV; Pavlicova, M; Rotrosen, J; Shulman, M; Wang, AL | 1 |
| Fishman, M; Lertch, E; Ludwig, A; Mitchell, SG; Monico, LB; Schwartz, RP | 1 |
| Ashmead, R; Bailey, E; Bickert, T; Bonny, AE; Doogan, NJ; Mack, A; Schmidt, S; Tossone, K; Zhang, P | 1 |
| Chaisson, CE; Ciemins, E; LaRochelle, MR; Linas, BP; Morgan, JR; Quinn, EK; Stempniewicz, N; Walley, AY; White, LF | 1 |
| Asher, A; Board, A; Cremer, LJ; Guy, GP; Parker, EM; Schieber, L | 1 |
| Amaducci, AM; Beauchamp, GA; Hanisak, JL; Koons, AL; Laskosky, J; Maron, BM; McLoughlin, TM | 1 |
| Fradkin, D; Kameg, B; Lepore, M | 1 |
| Bachrach, K; Bielavitz, S; Collins, JA; Cook, RR; Fanucchi, LC; Hoffman, KA; Jacobs, P; Jelstrom, E; Korthuis, PT; Kunkel, LE; Lucas, GM; Lum, PJ; Matthews, A; McCarty, D; Oden, N; Payne, EH; Rodriguez, AE; Sorensen, JL; Tookes, H; Vergara-Rodriguez, P; Waddell, EN | 1 |
| Akerman, SC; Barbieri, V; Bisaga, A; Fratantonio, J; Hu, MC; Nunes, EV; Shulman, M; Sullivan, MA | 1 |
| Akerman, SC; Douaihy, AB; Fratantonio, J; Legedza, A; Mannelli, P; Sullivan, MA; Zavod, A | 1 |
| Beck, M; Kay, A; Shmuts, R | 1 |
| Digbeu, B; Kuo, YF; Priyadarshni, S; Raji, MA; Yu, X | 1 |
| Domino, ME; Grove, LR; Rao, N | 1 |
| Akbarali, HI; Baird, TR; Dewey, WL; Elder, H; Kang, M; Marsh, SA; Negus, SS; Peace, MR; Poklis, JL; Santos, EJ | 1 |
| Graham, DP; Hamon, SC; Hillhouse, M; Kosten, TR; Lawson, WB; Ling, W; Nielsen, DA; Nielsen, EM; Rotrosen, J; Saxon, AJ; Settles-Reaves, BD; Shmueli-Blumberg, D; Shores-Wilson, K; Trivedi, MH; Walker, R | 1 |
| Anderson-Harper, R; Duello, A; Gochez-Kerr, T; Lohmann, B; Miles, J; Richardson, K; Winograd, RP; Wood, CA | 1 |
| Biondi, BE; Schlossberg, EF; Shaw, A; Springer, SA; Vander Wyk, B | 1 |
| Dromgoole, D; Ghanem, N; Hussein, A; Jermyn, RT | 1 |
| Douros, A; Farhat, I; Lim, J; Panagiotoglou, D | 1 |
| Carter, I; DeWitt, C; Forsgren, E; McCollough, M; Philippine, T; Taira, BR | 1 |
| Anguiano, V; Joudrey, PJ; Kolak, M; Lin, Q; Paykin, S; Wang, EA | 1 |
| Daunert, S; Deo, S; Dikici, E; Peyravian, N; Sun, E; Toborek, M | 1 |
| Bierut, LJ; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 2 |
| Campbell, ANC; Choo, TH; Cook, RR; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Shulman, M; Tsui, JI | 1 |
| Anselin, L; Kolak, M; Lin, Q; Pollack, H; Schneider, J; Taylor, B; Watts, B | 1 |
| Biondi, BE; Di Paola, A; Forray, A; Frank, CA; Shaw, A; Springer, SA; Taweh, N | 1 |
| Burnham, EL; Chockalingam, L; Jolley, SE | 1 |
| Bunting, AM; Choo, TH; Krawczyk, N; Lee, JD; McNeely, J; Nunes, E; Pavlicova, M; Rotrosen, J; Tofighi, B | 1 |
| Angermaier, G; Carswell, N; Castaneda, C; Delgado, F | 1 |
| Birkeland, B; Brenna, IH; Marciuch, A; Røstad, BK; Solli, KK; Tanum, L; Weimand, B | 1 |
| Abare, M; Chyorny, A; Olson, M; Wilhelm-Leen, E; Will, J | 1 |
| Berro, LF; Freeman, KB; Rowlett, JK; Talley, JT; Zamarripa, CA | 1 |
| Casey, SK; Irvin, JR; Kane, MT; Kehoe, L; McGovern, S; Powell, EA; Regan, S; Rodriguez, W; Wakeman, SE; Yacorps, GM | 1 |
| Jalali, A; Jeng, PJ; Ku, YC; Murphy, SM; Polsky, D; Poole, S; Woody, GE | 1 |
| Berk, J; Clarke, JG; Fritsche, J; Kang, A; Martin, RA; Rich, JD | 1 |
| Andraka-Christou, B; Buche, J; Haffajee, RL; Page, C; Schoebel, V | 1 |
| Campbell, ANC; Choo, TH; Fishman, M; Greiner, MG; Lee, JD; Novo, P; Nunes, EV; Opara, O; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M | 1 |
| Di Paola, A; Lier, AJ; Seval, N; Springer, SA; Vander Wyk, B | 1 |
| Agius, E; Kollin, R; Lee, G; Madden, EF; Pasman, E; Resko, SM; Rodriguez, B | 1 |
| Blanco, C; Compton, WM; Hodges, K; Jones, CM; Ling, SM; Losby, JL; Shoff, C | 1 |
| Clausen, T; Karlsson, AT; Solli, KK; Tanum, L; Vederhus, JK; Weimand, B | 1 |
| McKew, JC; Sadee, W | 1 |
| Brown, R; Haram, E; Horst, J; Jacobson, N; Kim, H; Kim, JS; Kisicki, A; Knudsen, HK; Madden, LM; Molfenter, T; Toy, A | 1 |
| Marcus, MM; St Onge, CM; Taylor, KM; Townsend, EA | 1 |
| Bolton, J; Hoang, H; Laiteerapong, N; Marsh, J; Murugesan, M; Nocon, R; Peterson, L; Pollack, H | 1 |
| Acuña, AM; Leyrer-Jackson, JM; Olive, MF | 1 |
| Cheng, A; Garrity, K; Hey, SP; Lee, JD; Lindquist, K; Malone, M; McDonald, R; McNeely, J; Pace, N; Roberts, T; Schatz, D; Sugarman, A; Tofighi, B; Vittitow, A; Williams, O | 1 |
| Ciraldo, K; DeFries, T; Gasper, J; Martin, M; Seraydarian, M | 1 |
| Lambeth, PS; Margolis, EB; Moulton, MG; O'Meara, MJ | 1 |
| Díaz, I; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Williams, NT | 1 |
| Batki, SL; Baxley, C; Becker, W; Borsari, B; Herbst, E; Manuel, JK; Pennington, D; Reavis, JV; Seal, K | 1 |
| Konakanchi, JS; Sethi, R | 1 |
| Choo, TH; Fishman, M; Lee, JD; Nunes, E; Pavlicova, M; Rotrosen, J; Vest, N; Wenzel, K | 1 |
| Di Cerbo, A; Iannitti, T; Morales-Medina, JC; Pugliese, N; Zizzadoro, C | 1 |
| Arah, OA; Cook, RR; Foot, C; Humphreys, K; Korthuis, PT; Levander, XA; Luo, SX; Rudolph, KE; Tsui, JI | 1 |
| Arai, K; Ide, S; Ikeda, K; Iwase, N; Kojima, M; Taniko, K; Ushiyama, S | 1 |
| Balise, RR; Brandt, L; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Odom, GJ | 1 |
| Bisaga, A; Dresser, L; Fishman, M; Ghitza, UE; Greiner, MG; Hamilton, A; Hefner, K; Ho, R; Jelstrom, E; Nunes, EV; Opara, O; Potter, K; Rotrosen, J; Scheele, C; Shulman, M; Tafessu, HM; Voronca, DC | 1 |
| Batty, E; Booty, M; Eddens, K; Knudsen, HK; Oser, CB; Perry, B; Rockett, M; Staton, M | 1 |
| Rodriguez, CP; Suzuki, J | 1 |
| Chatterjee, A; Linas, BP; Macmadu, A; Madushani, RWMA; Murphy, SM; Potee, RA; Ryan, D; Savinkina, A; Walley, AY; Weitz, M | 1 |
| Childress, AR; Kampman, KM; Langleben, DD; Li, X; Shi, Z; Wiers, CE | 1 |
| Batty, E; Booty, MD; Harp, K; Knudsen, HK; Oser, CB; Staton, M | 1 |
| Cox, KM; Doyle, M; Marsch, LA; McLeman, BM; Murray, OB; Ryer, J; Saunders, EC; Watts, D | 1 |
| Cornett, EM; Edinoff, AN; Flanagan, CJ; Jackson, ED; Kaye, AD; Kaye, AM; Pearl, NZ; Sinnathamby, ES; Wenger, DM | 1 |
| Allen, MI; Banks, ML; Cornelissen, JC; Nader, MA; Newman, AH; Woodlief, K | 1 |
| Barnett, ML; Chyn, D; Hardy, B; Huskamp, HA; Lewinson, T; Meara, E; Mehrotra, A; Morden, NE; Onsando, M | 1 |
| Cadet, T; Jalali, A; Jeng, PJ; Murphy, SM; Poole, S; Woody, G | 1 |
| Campbell, ANC; Fishman, M; Gopaldas, M; Jalali, A; Murphy, SM; Nunes, EV; Rotrosen, J; Wenzel, K | 1 |
| Jain, L; Modesto-Lowe, V | 1 |
| Creech, ZA; Koushik, SS; Noss, B; Poliwoda, S; Truong, GTD; Urits, I; Viswanath, O | 1 |
| Barbosa-Leiker, C; Burlew, K; Campbell, ANC; Choo, TH; Greenfield, SF; Kathryn McHugh, R; Mennenga, S; Nunes, EV; Paschen-Wolff, M; Pavlicova, M; Rotrosen, J; Ruglass, LM | 1 |
| Berger, NA; Davis, PB; Kaelber, DC; Volkow, ND; Wang, L; Xu, R | 1 |
| Balise, RR; Castillo, F; Feaster, DJ; Hu, MC; Liu, Y; Luo, SX; Nunes, EV; Rotrosen, J; Saxon, AJ; Weiss, RD | 1 |
| Boyett, B; Hassman, D; Learned, SM; Rutrick, D; Shinde, S; Zhao, Y | 1 |
| Blokhina, E; Bushara, N; Cheng, DM; Gnatienko, N; Krupitsky, E; Lioznov, D; Lunze, K; Quinn, E; Raj, A; Rosen, S; Samet, JH; Truong, V | 1 |
| Cooke, E; Galati, BM; Kelly, JC; Rogers, CE; Wenzinger, M | 1 |
| Benth, JŠ; Fadnes, LT; Gaulen, Z; Kloster, PS; Kunøe, N; Opheim, A; Solli, KK; Tanum, L | 1 |
| Baston, KE; Ganetsky, VS; Haroz, R; Heil, J; Hunter, K; Milburn, C; Salzman, M; Schmidt, R | 1 |
| Addis, M; Altschuler, A; Arnsten, JH; Bart, G; Bobb, JF; Boudreau, DM; Braciszewski, JM; Bradley, KA; Burganowski, RP; Caldeiro, RM; Campbell, CI; Cunningham, CO; Dryden, D; Ghiroli, MM; Glass, JE; Hamilton, LK; Horigian, VE; Hu, Y; Hyun, N; Idu, AE; Labelle, CT; LaHue, JS; Lapham, GT; Lee, AK; Liebschutz, JM; Liu, DS; Loree, AM; Matthews, AG; McCormack, J; McNeely, J; Merrill, JO; Murphy, MT; Murphy, SM; Northrup, TF; Phillips, RC; Qiu, H; Samet, JH; Saxon, AJ; Schwartz, RP; Shea, M; Shmueli-Blumberg, D; Silva, AJ; Stotts, AL; Szapocznik, J; Tsui, JI; Wartko, PD; Weinstein, ZM; Wong, MT; Yu, O; Zare-Mehrjerdi, M | 1 |
| Lin, MP; Manini, AF; Richardson, LD; Shastry, S | 1 |
| Bell, J; Strang, J | 1 |
| Chemi, C; Dickson, V; Lee, JD; Suhail-Sindhu, S; Tofighi, B; Williams, AR | 1 |
| Fogelman, N; Hermes, G; Hyman, SM; Kosten, TR; Sinha, R | 1 |
| Camenga, DR; Colon-Rivera, HA; Muvvala, SB | 1 |
| Alam, F; Dhadley, S; Roberts, P; Townley, J; Webster, R; Wright, N | 1 |
| Gold, MS; Oesterle, TS; Rummans, TA; Thusius, NJ | 1 |
| Ashford, RD; Bergman, BG; Kelly, JF | 1 |
| Badolato, R; Flannery, M; Garment, AR; Giftos, J; Lee, JD; McDonald, RD; Tofighi, B; Velasquez, M; Vittitow, A | 1 |
| Coffa, D; Snyder, H | 1 |
| Cannaert, A; Deventer, M; Fogarty, M; Mohr, ALA; Stove, CP | 1 |
| Bagley, SM; Bernson, D; Hadland, SE; Land, T; Larochelle, MR; Patel, A; Samet, JH; Silverstein, M; Walley, AY; Wang, N; Xuan, Z | 1 |
| Humphreys, K; Shover, CL | 1 |
| Byrd, DJ; Campbell, TB; Clarke, TJ; Jones, CM; McCance-Katz, EF; Ohuoha, C | 1 |
| Barbosa-Leiker, C; Burlew, K; Campbell, ANC; Fitzpatrick, S; Greenfield, SF; Nunes, EV; Pavlicova, M; Rotrosen, J; Ruglass, LM; Scodes, J | 1 |
| Boss, R; Buchanan, AL; Coderre, T; Goedel, WC; Krieger, MS; Lebeau, R; Marshall, BDL; Paull, K; Rich, JD; Thompson, C; Yedinak, JL | 1 |
| Baker, R; Hoffman, KA; Korthuis, PT; Kunkel, LE; Lum, PJ; McCarty, D; Waddell, EN | 1 |
| Brown, JN; Elias, AM; Pepin, MJ | 1 |
| Kunøe, N | 1 |
| Blanco, C; Volkow, ND | 1 |
| Brezel, ER; Fox, AD; Powell, T | 1 |
| Bergman, J; Doyle, RJ; Kangas, BD; Porter, EN; Withey, SL | 1 |
| Felix, C; Olsen, Y; Sharfstein, JM | 1 |
| Bisaga, A; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Sibai, M | 1 |
| Altomare, J; Bahji, A; Carlone, D | 1 |
| Banta-Green, CJ; Floyd, AS; Hoeft, TJ; Sears, JM; Tsui, JI; Williams, JR | 1 |
| Caritis, SN; Venkataramanan, R | 1 |
| Amlung, J; Lowder, EM; Ray, BR | 1 |
| Johnson, JA; Liebschutz, JW; Martin, B; Montgomery, MW; Mosquera, M; Price, CD; Robinson, D; Schnipper, JL; Solomon, DA; Suzuki, J; Weiss, RD | 1 |
| Hulme, J; Sheikh, H; Wiercigroch, D | 1 |
| Banks, ML; Negus, SS; Townsend, EA | 1 |
| Kunzler, NM; Nelson, LS; Wightman, RS | 1 |
| Bergeria, CL; Dunn, KE; Hobelmann, JG; Huhn, AS; Oyler, GA; Strickland, JC; Umbricht, A | 1 |
| Budney, AJ; Marsch, LA; Metcalf, SA; Moore, SK; Saunders, EC; Scherer, E; Walsh, O | 1 |
| Braucht, G; Howell, J; Mericle, A; Miles, J; Sheridan, D | 1 |
| Agus, D; Fingerhood, M; Krawczyk, N; Lyons, BC; Mojtabai, R; Saloner, B; Stuart, EA; Weiner, JP | 1 |
| Babakhanlou-Chase, H; Bernson, D; Land, T; Larochelle, MR; Li, Y; Lodi, S; Walley, AY | 1 |
| Fuehrlein, B; Jaeger, S | 1 |
| Reinecke, BA; Wang, H; Zhang, Y | 1 |
| Hulse, G; Joyce, D; Kelty, E; Preen, DB | 1 |
| Ahmedani, B; Arnsten, JH; Binswanger, IA; Bobb, JF; Boudreau, DM; Braciszewski, JM; Bradley, KA; Campbell, CI; Cunningham, CO; Glass, JE; Hechter, RC; Horigian, VE; Johnson, EA; Lapham, G; Liu, D; Matthews, AG; McCormack, J; Murphy, MT; Rossom, RC; Samet, JH; Saxon, AJ; Schwartz, RP; Szapocznik, J; Yarborough, BJ; Zare, M | 1 |
| Altice, FL; Bromberg, DJ; Nyhan, K; Refsland, BM; Stanojlović, M; Viera, A; Whittaker, S | 1 |
| Akerman, SC; Alam, D; Comer, SD; Douaihy, A; Mannelli, P; Nangia, N; Silverman, BL; Sullivan, MA; Zavod, A | 1 |
| Ding, H; Kiguchi, N; Ko, MC | 1 |
| Gordon, MS; Jalali, A; Jeng, PJ; Murphy, SM; Polsky, D; Poole, SA; Vocci, FJ; Woody, GE | 1 |
| Wakeman, SE | 1 |
| Robinson, CA; Wilson, JD | 1 |
| Ghosh, A; Singh, P | 1 |
| Elman, I; Langleben, DD; Shi, Z; Wang, AL | 1 |
| Andraka-Christou, B; Atkins, D; Madeira, J; Silverman, RD | 1 |
| Fine, M; Herscher, M; Hirt, L; Navalurkar, R; Wang, L | 1 |
| Akerman, SC; Bisaga, A; Krupitsky, E; Nangia, N; Nunes, EV; Silverman, BL; Sullivan, MA | 2 |
| Accetturo, C; Pravetoni, M; Raleigh, MD | 1 |
| Burlew, AK; Campbell, ANC; Haeny, AM; Montgomery, L; Nunes, E; Pavlicova, M; Rotrosen, J; Scodes, J | 1 |
| Burgower, R; Fishman, M; Vo, H; Wenzel, K; Wildberger, J | 1 |
| Dresser, R | 1 |
| Burden, J; Codell, NK; Drexler, K; Dungan, MT; Gordon, AJ; Hagedorn, H; Hawkins, EJ; Mhatre-Owens, A | 1 |
| Joo, H; KuKanich, B; KuKanich, K; Locuson, CW; Rankin, DC | 1 |
| Dionne, R; Fishman, M; Lertch, E; Ludwig, A; Mitchell, SG; Monico, LB; Schwartz, RP | 1 |
| Chalhoub, RM; Kalivas, PW | 1 |
| Aharonovich, E; Akerman, SC; Kosten, T; Lopez-Bresnahan, M; Nangia, N; Sullivan, MA; Zavod, A | 1 |
| Jalali, A; Jeng, PJ; Lee, JD; Leff, JA; McCollister, KE; Murphy, SM; Novo, P; Nunes, EV; Rotrosen, J; Ryan, DA; Schackman, BR | 1 |
| Bachhuber, MA; Barry, CL; Kennedy-Hendricks, A; McGinty, EE; Stone, E | 1 |
| Condon, T; Farabee, D; Hallgren, KA; McCrady, B | 1 |
| Acevedo-Mackey, D; Acharjee, N; Akhtar, K; Al-Buriahi, MS; Amandi, A; An, Y; Anjum, NA; Asgari, Q; Badiei, B; Baez Vasquez, AY; Bagley, GD; Bahreini, MS; Bajelan, S; Baluja, MQ; Barbieri, MA; Batalha, MA; Bettiol, H; Bhattarai, U; Biset, JC; Bjerg, M; Björnsson, BT; Boag, AM; Borthwick, MS; Boukhris, I; Bragança, MLBM; Breves, JP; Britz-McKibbin, P; Broaddus, RR; Burnell, JE; Camargo, CA; Campo, M; Carlsen, KL; Catchpole, B; Cavalli, L; Chai, C; Chanakya, HN; Chang, AYH; Chantada, A; Chen, W; Chen, X; Chen, Y; Cheng, ZL; Chenoweth, DA; Chhetri, S; Coelho, CCNDS; Coker, ES; Cole, MA; Coniglio, A; Connor, TR; Corbishley, A; D'Arienzo, M; da Silva, AAM; Dai, Y; de Oliveira, BR; Dignac, MF; Dong, A; Dottino, JA; Duo, J; Einarsdottir, IE; Ekanayake, EMDNK; El Fels, L; El Hayany, B; El Shahawy, O; Elliott, RJR; Fabrizi, E; Farkas, K; Fellman, B; Fenoglio, D; Ferrario, M; Flögel, F; Fujiogi, M; Gamage, BD; Ganson, KT; Gao, X; Gärtner, S; Gautam, A; Gautam, S; Gaze, WH; Gosse, JA; Graham, DW; Graham, PA; Guastella, G; Guerrero, S; Gul, M; Guo, B; Guo, X; Gupta, VK; Hafidi, M; Halland, A; Han, W; Hardisty, M; Hasegawa, K; Hess, ST; Heydari, R; Hillary, LS; Holm, R; Huang, L; Jaleh, B; Jayasundara, JASB; Ji, X; Jiang, L; Jones, DL; Kac, G; Kebaili, I; Kelley, JB; Kelum, SHP; Kennedy, LJ; Khan, NA; Khazalpour, S; Khuntia, HK; Kinney, MS; Kommedal, Ø; Koomhin, P; Krawczyk, N; Kæstel, T; Lakmal, MAC; Li, H; Li, K; Li, R; Li, S; Li, W; Li, X; Li, Y; Liang, L; Lin, Y; Lippo, E; Liu, B; Liu, F; Liu, J; Liu, X; Liu, Y; Lodha, D; Loose, DS; López-Meza, P; Lu, F; Lu, KH; Lu, Y; Luo, Y; Ma, B; Malham, SK; Masood, A; Matan, N; McCormick, SD; McDonald, JE; McKenzie, LJ; Melendez, BD; Mikaeili, F; Mir, IR; Mirjalili, MH; Moreno, KP; Moura, IB; Müller, S; Nagata, JM; Nasri, A; Nasrollahzadeh, M; Navarro-Jiménez, E; Nie, E; Nielsen, CU; Nielsen, S; Nøhr, MK; Obeng, B; Odetayo, AA; Ortiz-Barrios, M; Ozgen, C; Pan, X; Parisi, ML; Paskavitz, AL; Patel, AK; Pedersen, M; Pontarollo, N; Potts, CM; Price, C; Pu, Y; Quénéa, K; Rahimi Khonakdari, M; Rather, BA; Raut, P; Regish, AM; Reible, DD; Rezadoost, H; Rizzati, M; Roviello, GN; Roviello, V; Rumpel, C; Sang, J; Sangroula, S; Saraiva, MDCP; Sarker, A; Sayyed, MI; Segoshi, A; Sehar, Z; Shao, X; Shaw, D; Shaw, L; Shekhawat, NS; Shim, JK; Shokouhimehr, M; Short, A; Soliman, PT; Songsamoe, S; Springer-Miller, RH; Stenstad, T; Strobl, E; Sun, R; Syme, H; Thai, L; Tian, G; Tofighi, B; Tonguc, B; Tuyiringire, D; Ulaganathan, N; Ulvestad, E; Varacca, A; Vergalli, S; Verma, DK; Villmones, HC; Wang, D; Wang, H; Wang, J; Wang, L; Wang, M; Wang, S; Wang, Y; Wang, Z; Weedon-Fekjær, H; Weller, SR; West, BE; Wilcox, MH; Wu, W; Wufuer, R; Xia, S; Xiang, H; Xu, H; Yan, L; Yang, RK; Yang, Y; Yates, MS; Ye, Q; Yin, H; Yin, Y; Yuan, Y; Yucesan, M; Yue, W; Zeng, W; Zhang, C; Zhang, D; Zhang, H; Zhang, L; Zhang, Q; Zhang, Y; Zhou, B; Zhou, Y; Zhu, Y; Zhu, Z | 1 |
| Ameli, O; Azocar, F; Chaisson, CE; Crown, WH; Larochelle, MR; McPheeters, JT; Sanghavi, DM; Wakeman, SE | 1 |
| Fishman, MA; Kim, PS | 1 |
| Ayers, C; Chan, B; Freeman, M; Kansagara, D; Kondo, K; Korthuis, PT; Paynter, R | 1 |
| Petri, CR; Richards, JB | 1 |
| Friedmann, PD; Min, HS; Pivovarova, E | 1 |
| Fishman, M; Lee, JD; Nunes, E; Pavlicova, M; Rotrosen, J; Scodes, J; Wenzel, K | 1 |
| Andraka-Christou, B; Attermann, J; Beck, AJ; Buche, J; Cupito, A; Haffajee, RL | 1 |
| Oberdick, J; Sadee, W; Wang, Z | 1 |
| Andraka-Christou, B; Atkins, D | 1 |
| Calleo, VJ; Sullivan, RW; Szczesniak, LM | 1 |
| Biondi, BE; Cioe, K; Easly, R; Simard, A; Springer, SA; Zheng, X | 1 |
| Anderson, J; Bourne, D; Mackey, K; Peterson, K; Veazie, S | 1 |
| Bourne, D; Mackey, K; Peterson, K; Veazie, S | 1 |
| Allen, J; Beauchamp, GA; Boateng, N; Burmeister, DB; Esposito, SB; Laubach, LT; Lauber, P; Roth, P; Shaak, S; Yazdanyar, A | 1 |
| Desai, A; Gauthier, P; Greco, P; Meyers-Ohki, S; Rotrosen, J | 1 |
| Bohnert, ASB; Foxman, B; Gicquelais, RE; Thomas, L | 1 |
| Akerman, SC; Bloomgren, G; Desai, A; Fratantonio, J; Jain, P; Liles-Burden, MA; Marino, R; McKinnell, K; Sullivan, MA; Vunnava, P; Wenten, M | 1 |
| Donelan, CJ; Evans, EA; Hayes, E; Potee, RA; Schwartz, L | 1 |
| Fishman, M; Wenzel, K | 1 |
| Blue, TR; Couvillion, K; Danner, ML; Fishman, MJ; Gordon, MS; Jarvis, DK; Maher, K; Mitchell, SG; Murphy, SM; Ryan, D; Vocci, FJ; Wenzel, K | 1 |
| Campbell, A; Díaz, I; Hejazi, NS; Luo, SX; Nunes, EV; Rotrosen, J; Rudolph, KE; Shulman, M; van der Laan, MJ | 1 |
| Choo, TH; Gryczynski, J; Mitchell, MM; Nunes, EV; O'Grady, KE; Pavlicova, M; Rotrosen, J; Schwartz, RP; Stitzer, ML | 1 |
| Crawford, TN; Fischer, KB; Gainer, DM; Wright, MD | 1 |
| Basaraba, C; Bisaga, A; Brooks, DJ; Choi, CJ; Levin, FR; Mahony, AL; Mariani, JJ; Naqvi, N; Pavlicova, M | 1 |
| Board, A; Guy, GP; Jones, CM | 1 |
| Acion, L; Arndt, S; Hedden, S; Lynch, AC; Sabbagh, S; Weber, AN | 1 |
| Baratta, JL; Ferd, P; Patel, N; Schwenk, ES; Torjman, MC; Viscusi, ER | 1 |
| Avery, J; Gang, J; Kocsis, J; Maciejewski, PK; Prigerson, HG | 1 |
| Gault, A; Wahl, G | 1 |
| Bhat, NR; Bierut, LJ; Borodovsky, JT; Grucza, RA; Mintz, CM; Presnall, N; Xu, KY | 1 |
| Cho, P; Fitzgerald, AH; Komp, MS; KuKanich, B; KuKanich, K; Locuson, CW; Rankin, DC | 1 |
| Bergeria, CL; Dunn, KE; Huhn, AS; Nayak, SM; Strain, EC | 1 |
| Costello, E; Novo, P; Nunes, EV; Rotrosen, J; Shulman, M; Weiss, R | 1 |
| Christie, NC | 1 |
| Bystrak, T; De Aquino, JP; Wright, M | 1 |
| Adekoya, P; Gulati, A; Hunter, C; Jones, MR; Kaye, AD; Kaye, AM; Kuppalli, S; Orhurhu, V; Seth, R; Urits, I | 1 |
| Bachireddy, C; Terplan, M | 1 |
| Freeman, PR; Huang, Z; Oser, C; Sohn, M; Talbert, JC | 1 |
| Biondi, BE; Forray, A; Frank, CA; Springer, SA | 1 |
| Gillespie, JC; Ma, H; Mendez, RE; Selley, DE; Wang, H; Zhang, Y | 1 |
| Campbell, ANC; Choo, TH; Haenlein, P; Lee, JD; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M; Tofighi, B; Wai, J | 1 |
| Beckwith, N; Bell, K; Cheng, A; Farabee, D; Goldfeld, K; Groblewski, T; Gryczynski, J; Harding, K; Lee, JD; Malone, M; Marsch, LA; Martin, W; McDonald, RD; Monico, L; Nyaku, A; Reeves, R; Saunders, EC; Schwartz, RP; Springer, SA; Suchocki, A; Talon, K; Torralva, R; Violette, S; Waddell, EN; Wisdom, JP | 1 |
| Jalali, A; Jeng, PJ; Lee, JD; Leff, JA; McCollister, KE; Murphy, SM; Novo, P; Nunes, EV; Rotrosen, J; Schackman, BR; Shulman, M | 1 |
| Ahmed, S; Galbis-Reig, D; Hybki, B; Penders, T; Stanciu, C | 1 |
| Bain, PA; Carrero, ND; Chatterjee, A; Li, R; McLaughlin, MF | 1 |
| Gehlert, DR; Li, K; Medina, JC; Schwartz, N; Youngblood, B | 1 |
| Fishman, M; Lavorato, L; Selby, V; Thomas, J; Wenzel, K; Wildberger, J | 1 |
| Assoumou, SA; Barocas, J; Chatterjee, A; Hadland, SE; Linas, BP; Morgan, JR; Murphy, SM; Walley, AY | 1 |
| Campbell, ANC; Fishman, M; Nunes, E; Pavlicova, M; Rotrosen, J; Scodes, J; Wenzel, K | 1 |
| Adam, GP; Balk, EM; Becker, SJ; Danko, KJ; Helseth, SA; Saldanha, IJ; Scott, K; Steele, DW | 1 |
| Campbell, ANC; Choo, TH; Fishman, M; Greiner, MG; Lee, JD; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Shulman, M | 1 |
| Fishman, MJ; Gryczynski, J; Mitchell, SG; Monico, LB; O'Grady, KE; Schwartz, RP | 1 |
| Dionne, R; Fishman, M; Gryczynski, J; Lertch, E; Ludwig, A; Mitchell, SG; Monico, LB; Schwartz, RP | 1 |
| Campbell, ANC; Montgomery, L; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, J; Twitty, D; Wang, AL; Winhusen, T | 1 |
| Cao, DN; Li, F; Li, J; Wu, N | 1 |
| Carroll, J; Lynch, KG; Poole, S; Woody, GE; Yu, E | 1 |
| Chaisson, CE; Ciemins, E; Larochelle, MR; Morgan, JR; Quinn, EK; Stempniewicz, N; White, LF | 1 |
| Fong, C; Matusow, H; Rosenblum, A | 1 |
| Campbell, ANC; Lee, JD; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Scodes, JM | 1 |
| Bandara, S; Barry, CL; Kennedy-Hendricks, A; Merritt, S; Saloner, B | 1 |
| Nalven, T; Schick, MR; Spillane, NS; Weyandt, LL | 1 |
| Bierut, LJ; Grucza, RA; Hartz, SM; Mintz, CM; Presnall, NJ; Sahrmann, JM; Xu, KY | 1 |
| Ahrens, K; Allen, L; Austin, A; Barnes, AJ; Burns, M; Chang, CH; Clark, S; Cole, E; Crane, D; Cunningham, P; Donohue, JM; Gordon, AJ; Idala, D; Jarlenski, MP; Junker, S; Kennedy, S; Kim, JY; Lanier, P; Mauk, R; McDuffie, MJ; Mohamoud, S; Pauly, N; Sheets, L; Talbert, J; Tang, L; Zivin, K | 1 |
| Beas, I; Bromley, E; Hunter, SB; Hurley, B; Leamon, I; Martinez, J; McCreary, M; McCullough, CM; Montero, A; Ober, AJ; Sheehe, J; Tarn, DM; Watkins, KE | 1 |
| Barbieri, V; Bisaga, A; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Williams, AR | 1 |
| Franchitto, N; Jullian, B; Pelissier, F; Rolland, B; Salles, J | 1 |
| Boku, N; Katakami, N; Nakata, K; Narabayashi, M; Oda, K; Shinozaki, K; Suzuki, Y; Tauchi, K; Yokota, T | 1 |
| Berry, MS; Bigelow, GE; Fingerhood, M; Holtyn, AF; Jarvis, BP; Silverman, K; Subramaniam, S; Umbricht, A | 1 |
| Woody, GE | 1 |
| Boney, TY; Chen, DT; Fishman, MJ; Friedmann, PD; Gordon, M; Hu, MC; Lee, JD; Nunes, EV; O'Brien, CP; Wilson, D | 1 |
| Alexander, E; Johnson, BD; Lincoln, T; McCarthy, P | 1 |
| Gryczynski, J; Kelly, SM; Mitchell, SG; O'Grady, KE; Schwartz, RP; Sharma, A | 1 |
| Clarke, JG; Friedmann, PD; Hoskinson, R; Poshkus, M; Wilson, D | 1 |
| Hulse, G; Kelty, E | 4 |
| Griffin, BL; Stone, RH; Todd, TJ; Tran, TH; Vest, KM | 1 |
| Ali, R; Gowing, L; White, JM | 3 |
| Friedmann, PD; Gordon, M; Lee, JD; Nunes, EV; O'Brien, CP; Rathlev, N; Soares, WE; Wilson, D | 1 |
| Feder, KA; Krawczyk, N; Saloner, B | 1 |
| Hadland, SE; Larochelle, MR; Samet, JH; Schuster, MA; Wharam, JF; Zhang, F | 1 |
| Bigelow, GE; Dunn, KE; Strain, EC; Tompkins, DA | 1 |
| Leff, JA; Linas, BP; Morgan, JR; Schackman, BR; Walley, AY | 1 |
| Bernstein, SL; D'Onofrio, G | 1 |
| Alto, W; Gianutsos, P; Mancl, L; Plawman, A; Rudolf, G; Rudolf, V; Walsh, J | 1 |
| Altice, FL; Dvoriak, S; Filippovych, S; Madden, L; Makarenko, I; Marcus, R; Mazhnaya, A; Polonsky, M; Springer, SA; Zelenev, A | 1 |
| Allen, AA; Boney, TY; Bonnie, RJ; Chen, DT; Friedmann, PD; Gordon, M; Ko, TM; Lee, JD; McDonald, R; Murphy, SM; Nunes, EV; O'Brien, CP; Suratt, CE | 1 |
| Burgower, R; Fishman, M; Rozenberg, I; Vo, HT | 1 |
| Arai, M; Boku, N; Harada, T; Katakami, N; Murata, T; Narabayashi, M; Shinozaki, K; Tada, Y; Tsutsumi, M; Yokota, T | 1 |
| Brown, R; Collier, E; Haram, E; Horst, J; Jacobson, N; Kim, JS; Knudsen, HK; Madden, L; Molfenter, T; Starr, S; Toy, A; Van Etten, M | 1 |
| Friedmann, PD; Suzuki, J | 1 |
| Bouril, A; Elman, I; Fairchild, VP; Gur, RC; Langleben, DD; Lowen, SB; Shi, Z; Wang, AL | 1 |
| Bachrach, K; Bailey, GL; Bhatt, S; Farkas, S; Fishman, M; Gauthier, P; Hodgkins, CC; King, J; Lee, JD; Lindblad, R; Liu, D; Matthews, AG; May, J; Novo, P; Nunes, EV; Peavy, KM; Ross, S; Rotrosen, J; Salazar, D; Schkolnik, P; Shmueli-Blumberg, D; Stablein, D; Subramaniam, G | 1 |
| Lott, DC | 1 |
| Chang, DC; Fairbairn, N; Klimas, J; Wood, E | 1 |
| Abraham, AJ; Andrews, CM; D'Aunno, T; Friedmann, PD; Grogan, CM; Humphreys, K; Pollack, HA | 1 |
| Desai, N; Kelly, MM; Quiñones, T; Reilly, E; Rosenheck, R | 1 |
| Becker, K; Diamant, AL; Ewing, B; Heinzerling, K; Hunter, SB; Lamp, K; Lind, M; Ober, AJ; Osilla, KC; Setodji, CM; Watkins, KE | 1 |
| Dunn, KE; Friedmann, PD; Nunes, EV; O'Brien, CP | 1 |
| Bagley, SM; Carney, BL; Hadland, SE | 1 |
| Atreja, N; Duncan, M; Gore, M; Shah, A; Tai, KS | 1 |
| Altice, FL; Azar, MM; Barbour, R; Biondi, BE; Desabrais, M; Di Paola, A; Lincoln, T; Skiest, DJ; Springer, SA | 1 |
| Bigelow, GE; Holtyn, AF; Jarvis, BP; Oga, EA; Silverman, K; Subramaniam, S; Tompkins, DA | 1 |
| Altice, FL; Bojko, MJ; Dvoriak, S; Filippovych, S; Makarenko, I; Marcus, R; Mazhnaya, A; Springer, SA | 1 |
| Baijnath, S; Gopal, ND; Govender, T; Kruger, HG; Naicker, T; Pamreddy, A; Teklezgi, BG | 1 |
| Alexander-Scott, N; Boss, R; Brinkley-Rubinstein, L; Clarke, J; Green, TC; Marshall, BDL; Rich, JD | 1 |
| Allen, AA; Appelbaum, PS; Boney, TY; Bonnie, RJ; Chen, DT; Friedmann, PD; Gordon, MS; Ko, TM; Lee, JD; McDonald, R; Murphy, SM; Nunes, EV; O'Brien, CP; Suratt, CE; Wilson, D | 1 |
| Brinkley-Rubinstein, L; Cloud, DH; Heise, A; Martino, S; McCauley, E; Seal, D; Zaller, N | 1 |
| Honermann, B; Jones, A; Kutsa, O; Millett, G; Sharp, A; Sherwood, J | 1 |
| Hagemeier, NE; Harirforoosh, S; Salwan, AJ | 1 |
| Akerman, SC; Bisaga, A; Graham, CE; Kosten, TR; Mannelli, P; Nangia, N; Silverman, BL; Sullivan, MA; Tompkins, DA; Yu, M | 1 |
| Azhar, G; Chen, C; Hempel, S; Maglione, MA; Maksabedian, E; Newberry, S; Raaen, L; Shahidinia, N; Shanman, RM; Shen, M | 1 |
| Graham, DP; Kosten, TR; Nielsen, DA | 1 |
| Balhara, YPS; Gupta, R; Sarkar, S; Shah, B | 1 |
| Altice, FL; Azar, MM; Barbour, R; Di Paola, A; Springer, SA | 1 |
| Benth, JŠ; Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Sharma-Haase, K; Solli, KK; Tanum, L | 2 |
| Quaye, AN; Ward, EN; Wilens, TE | 1 |
| Hunter, SB; McCullough, CM; Ober, AJ; Osilla, K; Setodji, CM; Watkins, KE | 1 |
| Candy, B; Jones, L; Larkin, PJ; Stone, P; Vickerstaff, V | 1 |
| Bisaga, A; Campbell, AN; Crystal, S; Friedmann, PD; Johnson, KA; Levin, FR; Nunes, EV; Olfson, M; Pincus, HA; Remien, RH; Williams, AR | 1 |
| Bagley, SM; Bernson, D; Land, T; Larochelle, MR; Liebschutz, JM; Stopka, TJ; Walley, AY; Wang, N; Xuan, Z | 1 |
| Bommagani, SB; Crooks, PA; Dobretsov, M; Fantegrossi, WE; Gannon, BM; Mahelona, RD; Penthala, NR; Wan, A; Yadlapalli, JSK | 1 |
| Bao, YP; Blow, FC; Degenhardt, L; Farrell, M; Ilgen, M; Li, JQ; Liu, MX; Lu, L; Ma, J; Shi, J; Su, MF; Wang, RJ | 1 |
| Childress, AR; Fairchild, VP; Jagannathan, K; Langleben, DD; O'Brien, CP; Shi, Z; Wang, AL | 1 |
| Cutler, SJ; Hemby, SE; Leon, F; McCurdy, CR; McIntosh, S | 1 |
| Akerman, S; Bloomgren, G; Fratantonio, J; Jain, P; Marcopul, K; Silveira, A; Silverman, B; Sullivan, M | 1 |
| Alexander, GC; Saloner, B; Stoller, KB | 1 |
| Rieb, LM | 1 |
| Blackney, KA; Edwards, DA; Kamdar, NV; Liu, CA | 1 |
| Mannelli, P; Swartz, M; Wu, LT | 1 |
| Aschenbrenner, DS | 1 |
| Binswanger, IA; Fazel, S; Hellner, C; Larsson, H; Molero, Y; Zetterqvist, J | 1 |
| Binswanger, IA; Glanz, JM | 1 |
| Aggarwal, AK; Harrison, TK; Kornfeld, H; Lembke, A | 1 |
| Haffajee, RL; Weintraub, E; Yang, YT | 1 |
| Chang, G; Crawford, M; Enggasser, JL; Goodwin, K; Pitts, M; Schein, AZ | 1 |
| Barbosa-Leiker, C; Campbell, ANC; Greenfield, SF; Hatch-Maillette, M; Mennenga, SE; Mitchell, SG; Novo, P; Nunes, EV; Pavlicova, M; Rotrosen, J; Saraiya, T; Scodes, J | 1 |
| Jones, CW; Terplan, M | 1 |
| Clarke, JG; Gresko, SA; Martin, RA; Rich, JD | 1 |
| Bagley, SM; Hadland, SE; Larochelle, MR; Levy, S; Rodean, J; Samet, JH; Silverstein, M; Zima, BT | 1 |
| Broglio, K; Matzo, M | 1 |
| Pixton, GC; Setnik, B; Sommerville, KW; Webster, L | 1 |
| Carroll, KM; DeVito, EE; Frankforter, TL; Kiluk, BD; Nich, C; Sofuoglu, M; Yip, SW | 1 |
| Brewer, C; Streel, E | 2 |
| Bigelow, G; Holtyn, AF; Jarvis, BP; Oga, EA; Silverman, K; Subramaniam, S; Tompkins, DA | 1 |
| Binswanger, IA; Bowe, T; Finlay, AK; Harris, AHS; Smelson, D; Stimmel, MA; Timko, C; Yu, M | 1 |
| Fanelli, A; Ghisi, D; Sorella, MC | 1 |
| Grahan, B | 1 |
| DiPetrillo, L; Ehrich, E; Kelsh, D; Nangia, N; Pathak, S; Puhl, MD; Setnik, B; Stanford, AD; Sun, L; Vince, B | 1 |
| Friedmann, PD; Gordon, MS; Lee, JD; Nunes, EV; O'Brien, CP; Shroff, M; Soares, WE; Wilson, D | 1 |
| Gordon, MS; Gryczynski, J; Jaffe, JH; Kelly, SM; Mitchell, MM; Mitchell, SG; O'Grady, KE; Schwartz, RP | 1 |
| Barocas, JA; Saitz, R | 1 |
| Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Šaltyte Benth, J; Sharma-Haase, K; Solli, KK; Tanum, L | 1 |
| Bowe, TR; Burden, JL; Ellerbe, LS; Finlay, AK; Gupta, S; Harris, AHS; Rubinsky, A; Schmidt, EM; Timko, C; Wong, JJ | 1 |
| Kaplan, L | 1 |
| Ali, R; Hu, L; Marsden, J; Rush, AJ; Tai, B; Volkow, N | 1 |
| Barry, CL; Mauro, C; Mojtabai, R; Olfson, M; Wall, MM | 1 |
| Abraham, AJ; Adams, GB; Bradford, AC; Bradford, WD | 1 |
| Fanucchi, L; Korthuis, PT; Springer, SA | 1 |
| Childress, AR; Fairchild, VP; Jagannathan, K; Langleben, DD; Lynch, KG; Shi, Z; Suh, JJ; Wang, AL | 1 |
| Faraone, S; Johnson, B; Middleton, B; Oaks, Z; Stage, A | 1 |
| Byford, S; Day, E; Hellier, J; Kelleher, M; Marsden, J; Mayet, S; McLennan, B; Murphy, C; Ryan, E; Shearer, J; Strang, J | 1 |
| Katz, JL; Tanda, G; Yue, K; Zanettini, C | 1 |
| Cattaneo, M; Cicero, TJ; Dart, RC; Mardekian, J; Mendoza, M; Park, PW; Polson, M; Roland, CL; Schnoll, SH; Webster, LR | 1 |
| McKee, SA; Moore, KE; Oberleitner, LMS; Reid, HH; Roberts, W; Smith, KMZ | 1 |
| Marsden, J; Neale, J; Strang, J; Tompkins, CNE | 1 |
| Babu, K; Bradley, ES; Brush, DE; Carreiro, SP; Liss, D | 1 |
| Butler, F; Witt, L | 1 |
| Hulse, G; Joyce, D; Kelty, E | 1 |
| Bigelow, GE; DeFulio, A; Fingerhood, M; Holtyn, AF; Jarvis, BP; Koffarnus, MN; Leoutsakos, JS; Silverman, K; Umbricht, A | 1 |
| Barnett, BS; Suzuki, J; Ward, HB | 1 |
| Cami-Kobeci, G; Czoty, PW; DeLoid, HB; Ding, H; Hsu, FC; Husbands, SM; Kiguchi, N; Ko, MC; Sukhtankar, DD; Toll, L | 1 |
| Barry, CL; Gollust, SE; Kennedy-Hendricks, A; Levin, J; McGinty, EE; Stone, E | 1 |
| Barry, CL; Landis, R; Saloner, B; Stein, BD | 1 |
| Law, PY; Loh, HH; Tao, PL; Wang, Y; Yang, PP; Yeh, TK | 1 |
| Landau, R | 1 |
| Banks, ML; Blake, S; Bremer, PT; Faunce, KE; Hwang, CS; Janda, KD; Natori, Y; Townsend, EA; Zhou, B | 1 |
| Dzau, VJ; Leshner, AI | 1 |
| Linas, BP; Morgan, JR; Schackman, BR; Walley, AY; Weinstein, ZM | 1 |
| Duello, A; Green, L; Horn, P; Presnall, N; Rudder, T; Stringfellow, E; Winograd, RP; Wood, C | 1 |
| Allan, GM; Dugré, N; Finley, CR; Garrison, S; Kolber, MR; Korownyk, C; Lindblad, AJ; Perry, D; Thomas, B; Ting, R; Ton, J; Vandermeer, B; Yang, PR | 1 |
| Banken, R; Kumar, VM; Otuonye, IS; Pearson, SD | 1 |
| Choi, S; Healy, S; Neighbors, CJ; Shapoval, L; Sun, T; Yerneni, R | 1 |
| Darke, S; Duflou, J; Farrell, M; Lappin, J; Larance, B | 1 |
| Gaulen, Z; Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Šaltytė Benth, J; Sharma-Haase, K; Solli, KK; Tanum, L | 1 |
| Nelson, R | 1 |
| Carter, G; Jones, H; Miller, M; Saia, K; Shrestha, H; Valle, E; Wachman, EM; Werler, M | 1 |
| Glance, JB; Gopalan, P; Kmiec, J; Spada, M | 1 |
| Bridgeman, PJ; Koehl, JL; Zimmerman, DE | 1 |
| Altice, FL; Dvoriak, S; Filippovich, S; Makarenko, I; Marcus, R; Mazhnaya, A; Pykalo, I; Springer, SA | 1 |
| Klein, AA; Seppala, MD | 1 |
| Katz, E; Towers, CV; Visconti, K; Weitz, B | 1 |
| Hulse, GK; Reece, AS | 1 |
| Israel, JS; Poore, SO | 1 |
| Hahn, JH; Nguyen, TA; Strakowski, SM | 1 |
| Blokhina, E; Burakov, A; Kosten, TR; Krupitsky, E; Masalov, D; Palatkin, V; Romanova, TN; Sinha, R; Tsoy, M; Tyurina, A; Verbitskaya, E; Wahlgren, V; Yaroslavtseva, T; Zvartau, E | 1 |
| Afzali, S; Hassanian-Moghaddam, H; Pooya, A | 1 |
| Gastfriend, DR; Krupitsky, E; Ling, W; Memisoglu, A; Nunes, EV; Silverman, BL | 1 |
| Goli, V; Han, L; Setnik, B; Sommerville, K; Webster, L | 1 |
| Bisaga, A; Comer, SD; Glass, A; Levin, FR; Mariani, JJ; Nunes, EV; Sullivan, MA | 1 |
| Bell, J | 1 |
| Keating, GM; Syed, YY | 1 |
| Chenut, C; Papageorgiou, C; Streel, E; Verbanck, P | 1 |
| Badger, GJ; Brooklyn, JR; Dunn, KE; Heil, SH; Higgins, ST; Patrick, ME; Saulsgiver, K; Sigmon, SC | 1 |
| Pergolizzi, JV; Raffa, RB; Taylor, R | 1 |
| Kunøe, N; Stavseth, LS; Tanum, L | 2 |
| Degenhardt, L; Farrell, M; Gowing, L; Hall, W; Larney, S; Mattick, RP | 1 |
| Hashemian, M; Kolahi, AA; Mohajerani, SA; Mottaghi, K; Safari, F; Salimi, A | 1 |
| Pedersen, E | 1 |
| Ekgren, JS | 1 |
| Mannelli, P; Peindl, KS; Swartz, MS; Woody, GE; Wu, LT | 1 |
| Atayee, RS; Best, BM; Liu, JC; Ma, JD; Morello, CM | 1 |
| Altice, FL; Di Paola, A; Herme, M; Lincoln, T; Skiest, DJ; Springer, SA; Vagenas, P | 1 |
| Ellayah, D; Hulse, G; Jhugroo, A; Norman, A | 1 |
| Bhaw-Luximon, A; Goonoo, N; Hulse, GK; Jhugroo, A; Jhurry, D; Ujoodha, R | 1 |
| Amato, L; Bellisario, C; Davoli, M; Minozzi, S | 1 |
| Chalk, M; Fu, R; Gastfriend, DR; Hartung, DM; McCarty, D; Wiest, K | 1 |
| Aklin, WM; Bigelow, GE; DeFulio, A; Donlin, WD; Dunn, K; Everly, JJ; Fingerhood, M; Leoutsakos, JM; Nuzzo, PA; Silverman, K; Umbricht, A | 1 |
| Bawor, M; Bonner, A; Daiter, J; Dennis, BB; Desai, D; Marsh, DC; Naji, L; Pare, G; Plater, C; Samaan, Z; Thabane, L; Varenbut, M; Worster, A | 1 |
| Altice, FL; Desabrais, M; Di Paola, A; Lincoln, T; Skiest, DJ; Springer, SA | 1 |
| Degenhardt, L; Farrell, M; Hall, W; Kimber, J; Larney, S | 1 |
| Meyer, AC; Miller, ME; Sigmon, SC | 1 |
| Aletraris, L; Bond Edmond, M; Roman, PM | 1 |
| Bisaga, A; Carpenter, KM; Glass, A; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Sullivan, MA | 1 |
| Blokhina, EA; Gastfriend, DR; Krupitsky, EM; Ling, W; Memisoglu, A; Nunes, EV; Silverman, BL | 1 |
| Boney, TY; Bonnie, RJ; Chen, DT; Cornish, JW; Fishman, M; Friedmann, PD; Gordon, M; Hoskinson, RA; Kinlock, TW; Lee, JD; McDonald, R; Nunes, EV; O'Brien, CP | 1 |
| Bixler, EO; Gastfriend, DR; Herschman, PL; Leslie, DL; Meyer, RE; Milchak, W; Velott, DL | 1 |
| Gourevitch, MN; Grossman, E; Laska, E; Lee, JD; McDonald, R; McNeely, J; Rotrosen, J | 1 |
| Chatterjee, D; Jackson, H; Johnson, K; Mandell, K; Vanness, DJ | 1 |
| Biel, SS; Blum, JM; Hilliard, PE; Jutkiewicz, EM | 1 |
| Dakwar, E; Kleber, HD | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Lundy, C; Stringer, M | 1 |
| Bisaga, A; Drill, ES; Khan, NA; Mogali, S; Nunes, E; Pavlicova, M; Sullivan, MA | 1 |
| Chalk, M; Lubran, R; Mark, TL; McCance-Katz, EF; Richardson, J | 1 |
| Ahamad, K; Johnson, C; Kerr, T; Korthuis, TP; Milloy, MJ; Nguyen, P; Uhlmann, S; Wood, E | 1 |
| Donnerstag, N; Lüthi, A; Mehlig, A; Raetz Bravo, A; Schneider, T; Taegtmeyer, A | 1 |
| Willyard, C | 1 |
| Dolgin, E | 1 |
| Maremmani, AG; Maremmani, I; Parrino, MW; Samuels, PN | 1 |
| Barger, J; Cousins, SJ; Crèvecoeur-MacPhail, D; Denering, L; Kim, T; Rawson, RA; Sugita, W; Viernes, J; Weimann, S | 1 |
| Bisaga, A; Carpenter, KM; Glass, A; Haney, M; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Raby, WN; Sullivan, MA | 1 |
| Fitzgerald, TT; Gordon, MS; Kinlock, TW; Memisoglu, A; Silverman, B; Vocci, FJ | 1 |
| Batisse, A; Boucher, A; Chavant, F; Daveluy, A; Diot, C; Donadieu-Rigole, H; Eiden, C; Peyrière, H; Roussin, A | 1 |
| Aguilar, MA; Miñarro, J; Rodríguez-Arias, M | 1 |
| Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S | 1 |
| Cucciare, MA; Garrison-Diehn, C; Schultz, NR; Timko, C; Vittorio, L | 1 |
| Blokhina, EA; Burakov, AM; Bushara, EM; Grininko, AY; Kosten, T; Krupitsky, EM; Masalov, DV; Palatkin, VY; Romanova, TN; Sinha, R; Tiurina, AA; Verbitskaya, VE; Yaroslavtseva, TS; Zvartau, EE | 1 |
| Sudakin, D | 1 |
| Altice, FL; Brown, SE; Di Paola, A; Springer, SA | 1 |
| Alanis-Hirsch, K; Chalk, M; Croff, R; Ford, JH; Johnson, K; McCarty, D; Schmidt, L | 1 |
| Franchitto, N; Nubukpo, P; Pélissier, F; Rougé Bugat, ME | 1 |
| Jiang, GH; Lv, XF; Ma, XF; Qiu, YW; Su, HH; Tian, JZ; Zhuo, FZ | 1 |
| Ang, A; Cousins, SJ; Crèvecoeur-MacPhail, D; Darfler, K; Radfar, SR; Rawson, RA | 1 |
| Binswanger, I; Blue-Howells, J; Clark, S; Finlay, AK; Frayne, SM; Harris, AH; McGuire, J; Oliva, E; Rosenthal, J; Smelson, D; Timko, C | 1 |
| Anderson, BJ; Bailey, GL; Risi, MM; Stein, MD | 1 |
| Krupitsky, E; Woody, GE; Zvartau, E | 1 |
| Ling, W | 1 |
| Boney, TY; Bonnie, RJ; Chen, DT; Cornish, JW; Fishman, M; Friedmann, PD; Gordon, M; Gourevitch, MN; Hoskinson, RA; Kinlock, TW; Lee, JD; McDonald, R; Murphy, SM; Nunes, EV; O'Brien, CP; Rotrosen, J; Wilson, D | 1 |
| Gaulen, Z; Kunøe, N; Latif, ZE; Opheim, A; Sharma-Haase, K; Solli, KK; Tanum, L | 1 |
| Bonilla, W; Flannery, M; Goldfeld, K; Gourevitch, MN; Johnson, CW; Laska, E; Lee, JD; Leibowitz, N; McDonald, RD; Rotrosen, J; Santana-Correa, N; Tofighi, B | 1 |
| Bennett, D; Chandler, RK; Condon, T; Dunlap, LJ; Farabee, D; Finger, MS; Hillhouse, M; Kelly, SM; Laska, E; Lee, JD; McCollister, K; McDonald, RD; Mitchell, SG; O'Grady, KE; Schwartz, RP; Zarkin, GA | 1 |
| Anderson, B; Bailey, G; Herman, D; Stein, M; Uebelacker, LA | 1 |
| Klein, JW | 1 |
| Davis, MP | 1 |
| Condon, T; Farabee, D; Hillhouse, M; Ling, W; McCollister, K; McCrady, B | 1 |
| Barnett, G; Bruner, A; Fishman, M; Sharma, B | 1 |
| Gaulen, Z; Kunøe, N; Latif, ZE; Njå, AM; Opheim, A; Sharma Haase, K; Solli, KK; Tanum, L | 1 |
| Blokhina, E; Burakov, A; Bushara, N; Krupitsky, E; Masalov, D; Palatkin, V; Pecoraro, A; Romanova, T; Tsoy-Podosenin, M; Tyurina, A; Verbitskaya, E; Wahlgren, V; Woody, G; Yaroslavtseva, T; Zvartau, E | 1 |
| Bailey, GL; Brigham, GS; Cohen, AJ; Fishman, M; Lee, JD; Lindblad, R; Ling, W; Liu, D; May, J; Mpa, PN; Nunes, EV; Rotrosen, J; Salazar, D; Shmueli-Blumberg, D; Stablein, D | 1 |
| Bell, RL; Chambers, RA; Engleman, EA; Greene, MS; Sajid, A; Whiteman, A | 1 |
| Bailey, G; Brigham, G; Caplan, A; Farkas, S; Fishman, M; Lee, JD; Novo, P; Nunes, EV; Rotrosen, J; Segal, A; Sisti, D | 1 |
| Crits-Christoph, P; Gallop, R; Gastfriend, DR; Gibbons, MB; Lundy, C; Markell, HM; Stringer, M | 1 |
| Ayanga, D; Kosten, TR; Shorter, D | 1 |
| Blazina, I; Bougatsos, C; Chou, R; Devine, B; Grusing, S; Korthuis, PT; McCarty, D; Weimer, M; Zakher, B | 1 |
| Alagoz, E; Gustafson, DH; Johnson, RA; Kornfield, R; Landucci, G; Mares, ML; McTavish, F; Pe-Romashko, K; Quanbeck, A; Shah, D; Thomas, C; Westergaard, RP | 1 |
| Fitzgerald, TT; Gordon, MS; O'Brien, CP; O'Grady, KE; Vocci, FJ | 1 |
| Ahamad, K; Arenas, V; Ha, D; Korthuis, PT; Kunkel, LE; Lindblad, R; Lum, PJ; Mandler, RN; McCarty, D; Oden, NL; Sorensen, JL; Vergara-Rodriguez, P; Wood, E | 1 |
| Bisaga, A; Carpenter, KM; Choi, CJ; Dakwar, E; Levin, FR; Mariani, JJ; Mishlen, K; Nunes, EV; Pavlicova, M; Sullivan, M | 1 |
| Blokhina, E; Chawarski, M; Desrosiers, A; Krupitsky, E; Schottenfeld, R; Zvartau, E | 1 |
| Bigelow, GE; DeFulio, A; Fingerhood, M; Holtyn, AF; Jarvis, BP; Long, L; Silverman, K; Umbricht, A | 1 |
| Akerman, SC; Silverman, BL | 1 |
| Boney, TY; Bonnie, RJ; Chen, DT; Friedmann, PD; Gordon, M; Hoskinson, R; Lee, JD; Murphy, SM; Nunes, EV; O'Brien, CP; Wilson, D | 1 |
| Correia, M; Deakin, JF; Elliott, R; Ersche, KD; Flechais, RS; Lingford-Hughes, AR; McGonigle, J; Murphy, A; Nutt, DJ; Orban, C; Passamonti, L; Paterson, LM; Reed, LJ; Riccelli, R; Robbins, TW; Sahakian, BJ; Savulich, G; Smith, DG; Suckling, J; Tait, R; Taylor, EM | 1 |
| Robertson, AG; Swartz, MS | 1 |
| Cousins, SJ; Crèvecoeur-MacPhail, D; Kim, T; Rawson, RA | 1 |
| Casadonte, PP; Horton, T; Kolodner, GF; McMurphy, SM | 1 |
| Haile, CN; Kosten, TA; Kosten, TR | 1 |
| O'Brien, CP | 2 |
| Gorelick, DA; Gottheil, E; Mannelli, P; Patkar, AA; Peindl, K; Wu, LT | 1 |
| Becker, GL; France, CP; Gerak, LR; Koek, W | 1 |
| Albanese, M; Herman, J; Khantzian, E; Kueppenbender, K | 1 |
| Kassed, CA; Kranzler, HR; Levit, KR; Mark, TL; Vandivort-Warren, R | 1 |
| Badger, GJ; Dunn, KE; Heil, SH; Higgins, ST; Sigmon, SC | 1 |
| Sharma, B; Singh, SM | 1 |
| Amato, L; Davoli, M; Minozzi, S | 1 |
| Akhtaruzzaman, M; Hoque, MM; Hossain, KJ; Kamal, MM | 1 |
| Reece, AS | 2 |
| Chaplin, TM; Comegys, AD; Dabre, Z; Hong, KI; Hyman, SM; Kimmerling, A; Sinha, R | 1 |
| Frey, R; Gleiss, A; Kasper, S; Naderi, A; Naderi, MM; Naderi-Heiden, A; Rahmani-Didar, F; Salimi, AR | 1 |
| Bramness, J; Gossop, M; Lobmaier, P; Waal, H | 1 |
| Abbott, PJ | 1 |
| Bigelow, GE; Harrison, JA; Lanier, RK; Strain, EC; Tompkins, DA | 1 |
| Gossop, M; Katevoll, T; Kunøe, N; Lobmaier, PP; Waal, H | 1 |
| Gossop, M; Hegstad, S; Hjerkinn, B; Kristensen, O; Kunøe, N; Lobmaier, P; Vederhus, JK; Waal, H | 1 |
| Holt, E | 1 |
| Curran, E; Fishman, MJ; Garrett, S; Subramaniam, G; Winstanley, EL | 1 |
| Gorelick, DA; Mannelli, P; Pae, CU; Patkar, AA; Peindl, K; Wu, LT | 1 |
| Krupitsky, E; Woody, G; Zvartau, E | 1 |
| Gossop, M; Hegstad, S; Hjerkinn, B; Kristensen, Ø; Kunøe, N; Lobmaier, P; Vederhus, JK; Waal, H | 1 |
| Pergolizzi, JV; Raffa, RB | 1 |
| Krupitsky, E; O'Brien, CP; Woody, GE; Zvartau, E | 1 |
| Malek, S; Mottaghi, K; Safari, F; Salimi, A | 1 |
| Amar, R; Casarella, J; Drexler, K; Fareed, A; Vayalapalli, S | 1 |
| Derakhshandeh, K; Fashi, M; Seifoleslami, S | 1 |
| Ekhtiari, H; George, S | 1 |
| Cheng, WY; Mysels, DJ; Nunes, EV; Sullivan, MA | 1 |
| Gastfriend, DR | 1 |
| Aklin, WM; Bigelow, GE; DeFulio, A; Donlin, WD; Everly, JJ; Fingerhood, M; Koffarnus, MN; Leoutsakos, JM; Silverman, K; Umbricht, A | 1 |
| Amato, L; Davoli, M; Kirchmayer, U; Minozzi, S; Vecchi, S; Verster, A | 3 |
| Ambekar, A; Lal, R; Ramdurg, S | 1 |
| Ruan, X | 1 |
| Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Tharwani, HM; Wu, LT | 1 |
| Gastfriend, DR; Illeperuma, A; Krupitsky, E; Ling, W; Nunes, EV; Silverman, BL | 2 |
| Bruce, RD; Carrieri, MP; Dasgupta, N; Newman, R; Wodak, A; Wolfe, D | 1 |
| Gossop, M; Kunøe, N; Lobmaier, PP; Waal, H | 1 |
| Law, F; Melichar, J; O'Shea, J | 1 |
| Bisaga, A; Carpenter, KM; Cheng, WY; Levin, FR; Mariani, JJ; Nunes, EV; Raby, WN; Sullivan, MA | 1 |
| Bihel, F; Bockel, F; Bourguignon, JJ; Elhabazi, K; Maldonado, R; Meziane, H; Mollereau, C; Moulédous, L; Petit-demoulière, B; Schmitt, M; Simonin, F; Trigo, JM; Zajac, JM | 1 |
| Jones, HE; Kirtadze, I; O'Grady, KE; Otiashvili, D | 2 |
| Baser, O; Chalk, M; Fiellin, DA; Gastfriend, DR | 1 |
| Bigelow, GE; DeFulio, A; Everly, JJ; Fingerhood, M; Leoutsakos, JM; Silverman, K; Umbricht, A | 1 |
| Bryant, K; Fiellin, DA; Goulet, JL; Justice, AC; McGinnis, KA; Sullivan, LE; Tate, JP; Tetrault, JM | 1 |
| Metzger, DS; Woody, GE | 1 |
| Bart, G | 2 |
| Rappaport, BA; Roca, R; Temple, R; Throckmorton, DC; Winchell, CJ | 1 |
| Ciric, S; Johnson, FK; Setnik, B; Stauffer, J; Webster, LR | 1 |
| Busch, EL; Elman, I; Langleben, DD; O'Brien, CP | 1 |
| Comer, SD; Eaton, TA; Katz, NP; Revicki, DA; Stauffer, JW; Trudeau, JJ; van Inwegen, RG | 1 |
| Bigelow, GE; Dong, Q; Gastfriend, DR; Preston, KL; Schmittner, J | 1 |
| Greene, WM; Merlo, LJ; Pomm, R | 1 |
| Gorelick, DA; Mannelli, P; Patkar, AA; Peindl, K; Wu, LT | 1 |
| Boney, TY; Clark, CA; Cornish, JW; Coviello, DM; Friedmann, PD; Gordon, MS; Kinlock, TW; Lee, JD; Lynch, KG; Nunes, EV; Nuwayser, ES; O'Brien, CP; Schwartz, RP | 1 |
| Bhatia, KS; Lee, T; Mannelli, P; Peindl, KS; Wu, LT | 1 |
| Bisaga, A; Kosten, T; Nunes, EV; O'Connor, PG; Sigmon, SC; Woody, G | 1 |
| Chisolm, MS; Jansson, LM; Jones, HE; Terplan, M | 2 |
| Blokhina, EA; Krupitskiĭ, EM; Woody, G; Zvartau, EE | 1 |
| Jovanović, T; Lazarević, D; Nikolić, G | 1 |
| Ling, W; Mooney, L; Wu, LT | 1 |
| Bannwarth, B | 1 |
| Blokhina, EA; Gastfriend, DR; Illeperuma, A; Krupitskiĭ, EM; Ling, W; Nunes, EV; Silverman, BL | 1 |
| Degenhardt, L; Farrell, M; Hall, W; Hickman, M | 1 |
| Aklin, WM; Bigelow, GE; Fingerhood, M; Lejuez, CW; Severtson, SG; Silverman, K; Umbricht, A | 1 |
| Memisoglu, A; Mitchell, MC; Silverman, BL | 1 |
| Law, F; Melichar, J; O'Shea, J; Praveen, KT | 1 |
| Schaeffer, T | 1 |
| Hulse, G; Kunøe, N; Lobmaier, P; Ngo, H | 1 |
| Pappagallo, M; Sokolowska, M | 1 |
| Banks, ML; Negus, SS | 1 |
| Hasson, A; Hillhouse, M; Lindblad, R; Ling, W; McCormack, J; Mooney, LJ; Nielsen, S; Saxon, A; Stablein, D; Thomas, C | 1 |
| Aklin, WM; Bigelow, GE; Defulio, A; Donlin, WD; Dunn, KE; Everly, JJ; Fingerhood, M; Leoutsakos, JM; Nuzzo, PA; Silverman, K; Umbricht, A | 1 |
| Chervenak, FA; Coverdale, JH; McCullough, LB | 1 |
| Stitzer, ML | 1 |
| White, J | 1 |
| Clark, N; Verster, A | 1 |
| Bennett, L; Donaldson, LF; Green, A; Kaul, A; Melichar, JK; Mullings, EL; Munafò, MR; Nutt, DJ; O'Shea, J; Sharma, E | 1 |
| de Kan, R; Geerlings, PJ; Kerkhof, BJ; Roozen, HG; van den Brink, W | 1 |
| Liu, JG; Prather, PL | 1 |
| Farren, CK; O'Malley, S | 1 |
| Reece, S | 1 |
| Armstrong, J; Hulse, G; Little, M; Murray, L; O'Neil, G | 1 |
| Modesto-Lowe, V; Van Kirk, J | 1 |
| Baca-García, E; Madoz-Gúrpide, A; Ochoa, E | 1 |
| Schmidt, H; Trosko, O; Zemtsovski, MJ | 1 |
| Church, SH; Collins, E; Kleber, HD; Nunes, EV; Rothenberg, JL; Seracini, A; Sullivan, MA | 1 |
| Allsop, SJ; Bartu, A; Freeman, NC; Gawthorne, GS; Quigley, AJ | 1 |
| Bertschy, G; Besson, J; Bochud Tornay, C; Daeppen, JB; Favrat, B; Monnat, M; Schnyder, C | 1 |
| Compton, M; Ling, W; Rawson, RA | 1 |
| Buonanno, A; De Risio, S; Gottheil, E; Mannelli, P | 1 |
| Chiao, F; Erice, S; Leverone, T; Ma, H; Pearce, S; Quon, R; Tang, J; Wender, RH; White, PF | 1 |
| Hatton, M; Hulse, GK; O'Neil, G; Paech, MJ | 1 |
| Baraban, JM; Reti, IM | 1 |
| Fals-Stewart, W; O'Farrell, TJ | 1 |
| Davoli, M; Kirchmayer, U; Verster, A | 5 |
| Christophersen, AS; Frogopsahl, G; Mørland, J; Olsen, LH; Waal, H | 1 |
| Aamodt, Ø; Olsen, H; Waal, H | 1 |
| Bachs, L; Waal, H | 1 |
| Armstrong, J; Little, M; Murray, L | 1 |
| Raffa, RB; Stagliano, GW; Umeda, S | 1 |
| Carr, M; Johnson, TS | 1 |
| Bilsky, EJ; Kieffer, BL; Lin, ET; Lowery, JJ; Raehal, KM; Sadée, W; Wang, D | 1 |
| Warhaft, N | 1 |
| Koutsogiannis, Z; Kronborg, I; Lubman, D | 1 |
| Alvarez, CE; Bascarán, MT; Bobes, J; Carreño, JE; Díaz, M; Narciso, GI | 1 |
| Digiusto, E; Mattick, RP; O'Brien, S; Ritter, A; Shakeshaft, A | 1 |
| Golden, SA; Sakhrani, DL | 1 |
| Christophersen, AS; Frogopsahl, G; Mørland, J; Olsen, L; Waal, H | 2 |
| Blum, K; Braverman, ER; Chen, TJ; Hopper, D; Payte, JT; Schoolfield, J; Stanford, M | 1 |
| Ball, SA; Carroll, KM; Eagan, D; Nich, C; Rounsaville, BJ | 1 |
| Hagan, JJ; Heidbreder, CA | 1 |
| Bhamidipati, CM; Bilsky, EJ; Blair, JR; Lowery, JJ; Paolino, RM; Raehal, KM; Sadée, W; Wang, D | 1 |
| Horspool, M; Keen, J; Oliver, P | 1 |
| Arnold-Reed, D; Comer, SD; Hulse, GK; Jacobs, IG; Sullivan, MA; Tait, RJ | 1 |
| Chaudry, S; Daiter, J; Herman, S; Raz, B; Teplin, D; Varenbut, M; Whang, P; Yung, M; Zachos, CT | 1 |
| Ambrosino, F; Avolio, A; Capuano, A; D'Ambra, C; Del Franco, F; Mazzeo, F; Stella, L | 1 |
| Burns, LH; Olmstead, MC | 1 |
| O'Connor, PG | 1 |
| De Jong, CJ | 2 |
| de Jong, CA; de Waart, R; Kerkhof, AJ; Roozen, HG; van den Brink, W; van der Windt, DA | 1 |
| de Jong, CJ; Krabbe, PF; Laheij, RJ; van Cauter Victory, RM | 1 |
| Fantoma, A; Gerra, G; Zaimovic, A | 1 |
| Badaras, R; Ivaskevicius, J; Jovaisa, T; Laurinenas, G; Sipylaite, J; Vosylius, S | 1 |
| Arfken, CL; Koch, AL; Schuster, CR | 1 |
| Jolly, A; Vickers, AP | 1 |
| Heading, CE | 1 |
| Ali, R; Gowing, L; White, J | 1 |
| Contreras, JA | 1 |
| Jaffe, JH | 1 |
| Berglund, M; Johansson, BA; Lindgren, A | 1 |
| Freye, E; Latasch, L; Levy, JV | 1 |
| Cubells, JF; Tang, YL; Zhao, C; Zhao, D | 1 |
| Ott, J | 1 |
| Gottheil, E; Mannelli, P; Van Bockstaele, EJ | 1 |
| Ng, BY; Peh, LH | 1 |
| Bush, KR; Calsyn, DA; Davis Correale, TM; Davison, JW; Kivlahan, DR; Reoux, JP; Sloan, KL; Sweeney, ML | 1 |
| Carpenter, KM; Kleber, HD; Nunes, EV; Rothenberg, JL; Sullivan, MA | 1 |
| Doebrick, C; Kimmerling, A; Kosten, TR; Sinha, R | 1 |
| Adi, Y; Bayliss, S; Burls, A; Day, E; Frew, E; Jowett, S; Juarez-Garcia, A; Roberts, T; Wang, D | 1 |
| Cottone, P; Sabino, V; Steardo, L; Zorrilla, EP | 1 |
| Doebrick, C; Fox, H; Hong, KI; Hyman, SM; Sinha, R | 1 |
| Brady, KT | 1 |
| Garnick, DW; Hodgkin, D; Horgan, CM; Merrick, EL; Reif, S | 1 |
| Bluschke, SM; De Jong, CA; Dijkstra, BA; Krabbe, PF; van der Staak, CP | 1 |
| Degenhardt, LJ; Gibson, AE | 1 |
| Comer, SD; Hulse, GK; Sullivan, MA | 1 |
| Hubbard, R; Mannelli, P; Murray, HW; Patkar, AA; Peindl, K; Wu, LT | 1 |
| Gardner, TJ; Kosten, TR | 1 |
| Degenhardt, L; Gibson, A; Hall, W; Mattick, RP | 1 |
| McCann, DJ | 1 |
| Bjørndal, A; Kornør, H; Kunøe, N; Lobmaier, P | 1 |
| Boyce, D; Carr, DB; McNicol, ED; Schumann, R | 1 |
| Ali, R; Henry, D; Sansom, L; Wodak, AD | 1 |
| Gold, MS; Pottash, AC; Washton, AM | 2 |
| Ginzburg, HM; Glass, WJ | 1 |
| Rawson, RA; Resnick, RB; Tennant, FS; Washton, AM | 1 |
| Extein, I; Gold, MS; Kleber, HD; Pottash, AL | 2 |
| Resnick, RB; Washton, AM | 4 |
| Schecter, A | 1 |
| Extein, I; Gold, MS; Kleber, HD; Martin, D; Pottash, AC | 1 |
| Gold, MS; Rea, WS | 1 |
| Childress, AR; Ehrman, RN; McLellan, AT; O'Brien, CP; Ternes, J | 1 |
| Dackis, CA; Gold, MS; Washton, AM | 1 |
| Evans, BD; Greenstein, RA; McLellan, AT; O'Brien, CP | 2 |
| Arndt, R; Evans, B; Greenstein, RA; O'Brien, CP; Woody, GE | 1 |
| Arndt, I; McLellan, AT; O'Brien, CP | 1 |
| Childress, AR; McLellan, AT; O'Brien, CP | 1 |
| Arndt, IC; Evans, B; Greenstein, RA; McLellan, AT; O'Brien, CP | 1 |
| Kleber, HD; Kosten, TR | 2 |
| Cohen, AJ; Mann, A; Rawson, RA; Tennant, FS | 1 |
| Ling, W; Wesson, DR | 2 |
| Brahen, LS; Capone, T; Henderson, RK; Kordal, N | 1 |
| Bigelow, GE; Sherman, MF; Singleton, EG | 1 |
| Hogan, I; Jalali, B; Kleber, HD; Kosten, TR | 1 |
| Ginzburg, HM | 1 |
| Resnick, RB; Stone-Washton, N; Washton, AM | 1 |
| Verebey, K | 1 |
| Sharon, AC; Wise, DL | 1 |
| Krivoy, W; McLellan, AT; O'Brien, CP; Terenius, L; Wahlström, A | 1 |
| Herling, S; Woods, JH; Young, AM | 1 |
| Crits-Christoph, K; Kleber, H; Rounsaville, BJ; Weissman, MM; Wilber, C | 1 |
| Braverman, P; Charney, DS; Heninger, GR; Kleber, HD; Murburg, M; Redmond, DE; Riordan, CE; Sternberg, DE | 1 |
| Coyle-Perkins, G; Grabowski, J; Greenstein, RA; Long, M; McLellan, AT; O'Brien, CP; Vittor, A; Woody, GE | 1 |
| Goldstein, A; Himmelberger, DU; Judson, BA | 2 |
| Carroll, KM; Diagkogiannis, IA; O'Connor, PG; Rounsaville, BJ; Schottenfeld, RS; Waugh, ME | 1 |
| Azatian, A; Joseph, H; Papiasvilli, A | 1 |
| Gallino, G; Liffredo, C | 1 |
| Gelkopf, M; Lerner, AG; Sigal, M | 1 |
| Ho, IK; Hoskins, B; Jaw, SP | 1 |
| Cutler, R; Fishbain, DA; Rosomoff, HL | 1 |
| Gold, MS | 1 |
| Ciervo, U; Coccoli, M; Giannini, P; Rocchi, R; Rugolo, AP | 1 |
| Chami, TN; Cheskin, LJ; Jaffe, JH; Johnson, RE | 1 |
| Bigelow, GE; Eissenberg, T; Greenwald, MK; Johnson, RE; Liebson, IA; Stitzer, ML | 1 |
| Basbaum, AI; Detweiler, DJ; Rohde, DS | 1 |
| Rounsaville, BJ | 1 |
| Litten, RZ | 1 |
| Simon, DL | 1 |
| Stephenson, J | 1 |
| Ehrenreich, H; Poser, W | 1 |
| Blansfield, HN | 1 |
| Ho, ST; Lee, SC; Tao, PL; Wang, JJ | 1 |
| Easterling, KW; Holtzman, SG | 1 |
| Frosch, D; Ling, W; McCann, MJ; Miotto, K; Rawson, RA | 1 |
| Yeo, BK | 1 |
| Cohen, H; Kotler, M; Rabinowitz, J; Tarrasch, R | 1 |
| Kosten, TR; O'Connor, PG | 1 |
| Brewer, C; Carreño Rendueles, E; Garcia, JB; Williams, J | 1 |
| Lerner, AG; Oyffe, I; Sigal, M | 1 |
| Deden, AL; Kerkhof, AJ; Roozen, HG; van den Brink, W; Vorsteveld, JP | 1 |
| Büchele, W; Burkhardt, D; Bussello-Spieth, B; Reiss, J; Tretter, F; Walcher, S | 1 |
| Dworkin, SI; Martin, TJ; Smith, JE | 1 |
| Cohen, H; Kotler, M; Rabinowitz, J | 1 |
| Gooberman, LL | 1 |
| Brewer, C; Gastfriend, DR | 1 |
| Auerbach, SB; Ma, Z; Tao, R | 1 |
| Berkowitz, R; Hass, F; Hoffman, WE; McDonald, T | 1 |
| Compton, P | 1 |
| Collins, PD; Cook, TM | 1 |
| Hudson, S | 1 |
| Hall, W; Mattick, RP; Ward, J | 1 |
| Hirtl, C; Pfab, R; Zilker, T | 1 |
| Berkowitz, R; Cooke, B; Cunningham, F; Hoffman, WE; McDonald, T | 1 |
| Cullen, DJ; Dwyer, MJ; Gold, CG; Gonzales, S; Houtmeyers, D | 1 |
| Gaughwin, MD | 1 |
| Latt, NC | 1 |
| Taylor, LK; Thackway, SV; Ward, PL | 1 |
| Bickel, WK; Petry, NM | 1 |
| Irvine, RJ; White, JM | 1 |
| Hensel, M; Kox, WJ | 1 |
| Hensel, M; Kox, WJ; Wolter, S | 1 |
| Easterling, KW; Holtzman, SG; Plovnick, RM | 1 |
| Abels, I; Albanese, AP; Eustace, JC; Field, JM; Gevirtz, C; Oppenheim, B | 1 |
| Conte, G; De Risio, S; Pozzi, G | 1 |
| Fudala, PJ; Heishman, SJ; Henningfield, JE; Johnson, RE; Jones, HE | 1 |
| Bearn, J; Buntwal, N; Gossop, M; Strang, J | 1 |
| Iakovchuk, Am; Mishnaevakiĭ, AL; Savchenkov, VA; Sivolap, IuP | 1 |
| Iakovchuk, AM; Kaludzherovich, LV; Mishnaevskiĭ, AL; Mustafin, KhKh; Parfenov, DA; Rasulov, MM; Savchenkov, VA; Sivolap, IuP | 1 |
| Breiter, H; D'Ambra, MN; Elman, I; Gastfriend, DR; Kane, M; Krause, S; Morris, R; Tuffy, L | 1 |
| Barr, GA; Jones, KL | 1 |
| Yui, K | 1 |
| Brown, R; Lo, R | 1 |
| Ball, SA; Carroll, KM; Eagan, DA; Frankforter, TL; Nich, C; O'Connor, PG; Rounsaville, BJ; Shi, J; Triffleman, EG | 1 |
| van Brussel, GH | 1 |
| Bornstein, G; Church, SH; Nunes, EV; Rothenberg, JL; Sullivan, MA | 1 |
| Crain, SM; Shen, KF | 1 |
| Stimmel, B | 1 |
| Hamilton, RJ; Hoffman, RS; Howland, MA; Hung, OL; Lewin, NL; Nelson, LS; Olmedo, RE; Perrone, J; Shah, S | 1 |
| Friedland, G; Jatlow, P; Kosten, TR; McCance-Katz, EF; Rainey, PM | 1 |
| Moss, J; Yuan, CS | 1 |
| Babuscio, T; Carroll, KM; Nich, C; Rounsaville, BJ; Sinha, R | 1 |
| Atias, S; Cohen, H; Rabinowitz, J | 1 |
| Heilig, M | 1 |
| Alvarez, CE; Bascarán, MT; Bobes, J; Brewer, C; Carreño, JE; San Narciso, GI; Sánchez del Río, J | 1 |
| France, CP; Sell, SL | 1 |
| Grabowski, J; Jordan-Hayes, J; O'Brien, CP; Ternes, JW; Wellerstein, H | 1 |
| Rawson, RA; Resnick, RB; Washton, AM | 1 |
| Brahen, LS; Capone, T; Wojak, JC | 1 |
| Kleber, HD; Kosten, TR; Morgan, C | 2 |
| Bacalu, A; Burganski, I; Gelkopf, M; Lerner, A; Shiff, R; Sigal, M | 1 |
| Aghajanian, GK; Kogan, JH; Nestler, EJ | 1 |
| Kosten, TA; Kosten, TR | 1 |
| Kehoe, P; Shoemaker, W | 1 |
| Lenz, K; Loimer, N; Presslich, O; Schmid, R | 1 |
| Caballero, L; Iruela, LM; Oliveros, SC | 1 |
| Ladewig, D | 1 |
| Fraser, AD | 1 |
| Jepsen, PW | 1 |
| Sinclair, JD | 1 |
| Bickel, WK; Bigelow, GE; Jasinski, DR; Johnson, RE; Liebson, IA; Stitzer, ML | 1 |
| Bronson, ME; Sparber, SB | 1 |
| Woody, G | 1 |
| Chaumont, AJ; Kintz, P; Lugnier, AA; Mangin, P | 1 |
| Charney, DS; Kleber, HD; Kosten, TR; Krystal, JH; Morgan, CH; Price, LH | 1 |
| Cornish, J; Druley, P; McLellan, AT; Metzger, DS; O'Brien, CP; Woody, GE | 1 |
| Bedate, J; Cami, J; Forteza-Rei, J; García-Alonso, F; Gutierrez, M; López-Alvarez, M; Palop, R; Pérez de los Cobos, JC; Rodríguez-Artalejo, F; San, L | 1 |
| Santos, EF | 1 |
| Fram, DH; Holden, R; Marmo, J | 1 |
| Croughan, J; Sanders, K | 1 |
| DeLander, GE; Portoghese, PS; Takemori, AE | 1 |
| Brogden, RN; Gonzalez, JP | 1 |
| Peachey, JE | 1 |
| Adams, M; Cushman, P; Dewey, W; Morris, D | 1 |
| Eisenberg, RM | 1 |
| Crowley, TJ; Macdonald, M; Wagner, JE; Zerbe, G | 1 |
| Zagon, IS | 1 |
| Kleber, HD | 1 |
| Mello, NK; Mendelson, JH | 2 |
| France, CP; Woods, JH | 1 |
| Gabel, T; Malcolm, R; Morton, A | 1 |
| Wells, B | 1 |
| San Molina, L | 1 |
| Kleber, HD; Kosten, TR; Rounsaville, BJ | 1 |
| Jalali, B; Kleber, HD; Kosten, TR; Steidl, JH | 1 |
| Hogan, I; Jalali, B; Kleber, HD; Kosten, TR; Steidl, J | 1 |
| Brahen, L; Capone, T; Condren, R; Kordal, N; Melchionda, R; Peterson, M | 1 |
| Grey, C; Osborn, E; Reznikoff, M | 2 |
156 review(s) available for naltrexone and Addiction, Opioid
| Article | Year |
|---|---|
Prevention of Opioid Abuse and Treatment of Opioid Addiction: Current Status and Future Possibilities.
Topics: Abuse-Deterrent Formulations; Analgesics, Opioid; Device Approval; Dosage Forms; Drug Approval; Drug Compounding; Drug Delivery Systems; Drug Labeling; Humans; Naltrexone; Opioid-Related Disorders; Pain; Pain Management; Prescription Drug Misuse; Prescription Drugs; United States; United States Food and Drug Administration | 2019 |
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Ethnicity; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Disease Management; Drug Overdose; Female; Fentanyl; Harm Reduction; Humans; Male; Mental Disorders; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Practice Guidelines as Topic; Prevalence | 2022 |
Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Female; Health Services Accessibility; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2022 |
An overview of buprenorphine prescribing for the advanced practice psychiatric nurse.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Review of medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; COVID-19; COVID-19 Drug Treatment; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Morphine; Naltrexone; Network Meta-Analysis; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2022 |
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Topics: Analgesics, Opioid; Antiemetics; Benzodiazepines; Buprenorphine; Hospitals; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; United States | 2022 |
Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.
Topics: Analgesia; Analgesics, Opioid; Humans; Ligands; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Receptors, Opioid, mu | 2022 |
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Opioid Use Disorder Treatments: An Evidence Map.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.
Topics: Alcoholism; Analgesics, Opioid; Depressive Disorder, Major; Humans; Naltrexone; Narcotic Antagonists; Opioid Peptides; Opioid-Related Disorders | 2023 |
Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Craving; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2023 |
The Growing Epidemic of Opioid Use Disorder in the Elderly and Its Treatment: A Review of the Literature.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Drug-Related Side Effects and Adverse Reactions; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Treatment of Acute Pain in Patients on Naltrexone: A Narrative Review.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain, Postoperative | 2023 |
Medication Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Medications for Maintenance Treatment of Opioid Use Disorder in Adolescents: A Narrative Review and Assessment of Clinical Benefits and Potential Risks.
Topics: Adolescent; Adolescent Behavior; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Medication-Assisted Treatment for Opioid-Use Disorder.
Topics: Algorithms; Buprenorphine; Decision Trees; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Opioid Use Disorder: Medical Treatment Options.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Evidence-Based Medicine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
Adjunctive memantine for opioid use disorder treatment: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Humans; Memantine; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Outcome Assessment, Health Care; Substance Withdrawal Syndrome | 2019 |
Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
Topics: Adult; Criminals; Delayed-Action Preparations; Drug Overdose; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Secondary Prevention; Treatment Outcome | 2020 |
Medications Development for Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Drug Development; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome | 2021 |
Opioid Withdrawal Precipitated by Long-Acting Antagonists.
Topics: Drug Combinations; Emergency Service, Hospital; Humans; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2020 |
Buprenorphine initiation to treat opioid use disorder in emergency rooms.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2020 |
Impact of Pharmacological Treatments for Opioid Use Disorder on Mortality.
Topics: Analgesics, Opioid; Buprenorphine; Drug Administration Schedule; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Management | 2020 |
Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults.
Topics: Adolescent; Buprenorphine; Child; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2020 |
Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Topics: Analgesics, Opioid; Animals; Isoquinolines; Naltrexone; Opioid Peptides; Opioid-Related Disorders; Pain; Phenylpropionates; Receptors, Opioid | 2022 |
Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients.
Topics: Analgesics, Opioid; Buprenorphine; Harm Reduction; Hospitalization; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic | 2020 |
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Brain; Buprenorphine; Disease Models, Animal; Endocannabinoids; Glutamic Acid; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Orexins; Reward; Secondary Prevention; Signal Transduction; Treatment Outcome | 2020 |
Topics: Acyclic Monoterpenes; Adipose Tissue; Adolescent; Adult; Aged; Aged, 80 and over; Air Pollutants; Air Pollutants, Occupational; Amino Acid Transport Systems; Analgesics, Opioid; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Arthrobacter; Bacteria; Bacteriological Techniques; Benzaldehydes; Biodegradation, Environmental; Biofilms; Biological Transport; Biomarkers; Biomass; Bioreactors; Body Composition; Body Mass Index; Brassica; Brazil; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Caco-2 Cells; Cadmium; Calcium; Calcium Carbonate; Calcium Channels; Catalysis; Cell Degranulation; Cell Line; Cell Membrane; Chitosan; Chromatography, High Pressure Liquid; Chromium; Cobalt; Cohort Studies; Colony Count, Microbial; Composting; Copper; COVID-19; Cross-Sectional Studies; Cytoplasm; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Diethylhexyl Phthalate; Dose-Response Relationship, Drug; Drug Implants; Drug Stability; Drug Synergism; Electroplating; Endometrial Neoplasms; Endometrium; Environmental Monitoring; Environmental Restoration and Remediation; Estradiol; Estrogens; Feces; Female; Food Microbiology; Food Preservation; Fruit and Vegetable Juices; Gasotransmitters; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gene Expression Regulation, Developmental; Genetic Predisposition to Disease; Glutathione; Gold; Graphite; Growth Hormone; Harm Reduction; Hot Temperature; Humans; Hydrocortisone; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydrogen-Ion Concentration; Ileum; Imidazoles; Injections, Intraperitoneal; Insecticides; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor I; Intestinal Absorption; Light; Lignin; Liver; Magnetics; Male; Manganese; Mast Cells; Melanoma; Membrane Potentials; Metals; Methadone; Microbial Viability; Microplastics; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Middle Aged; Mitochondrial Swelling; Molecular Dynamics Simulation; Monophenol Monooxygenase; Morocco; Naloxone; Naltrexone; Nanocomposites; Nanomedicine; Nanoparticles; Narcotic Antagonists; Neonicotinoids; Nitric Oxide; Nitro Compounds; Nitrogen; Nitrogen Compounds; Obesity; Obesity, Abdominal; Occupational Exposure; Ontario; Opiate Substitution Treatment; Opioid-Related Disorders; Oryza; Overweight; Oxidative Stress; Oxides; Oxygen; Perception; Photoelectron Spectroscopy; Plants; Plastics; Point Mutation; Polychlorinated Biphenyls; Polycyclic Aromatic Hydrocarbons; Potassium; Premenopause; Prodrugs; Prospective Studies; Protons; Pyrolysis; Qualitative Research; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Resins, Synthetic; Rhodamines; Risk Factors; ROC Curve; Salmo salar; SARS-CoV-2; Seawater; Severity of Illness Index; Sewage; Social Media; Soil; Soil Microbiology; Soil Pollutants; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Staining and Labeling; Stainless Steel; Steel; Stress, Physiological; Substance Abuse Treatment Centers; Symporters; T-Lymphocytes; Toluene; Triclosan; Ultraviolet Rays; Waist Circumference; Waste Disposal, Fluid; Wastewater; Water Purification; Welding; X-Ray Diffraction; Young Adult | 2020 |
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Topics: Chronic Pain; Fibromyalgia; Humans; Multiple Sclerosis; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.
Topics: Analgesics, Opioid; Antidepressive Agents; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Female; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Humans; Ligands; Macaca mulatta; Mice; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Pain Management; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome | 2020 |
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Managing Acute Pain in Patients Taking Medication for Opioid Use Disorder: a Rapid Review.
Topics: Acute Pain; Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies | 2020 |
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Naltrexone; Narcotic Antagonists; Nitrosamines; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Recent Advances in the Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Implants; Humans; Injections, Intramuscular; Methadone; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Receptors, G-Protein-Coupled; Receptors, Opioid, mu; Secologanin Tryptamine Alkaloids; Thiophenes; Urea; Vaccines | 2021 |
Pharmacotherapy for Management of 'Kratom Use Disorder': A Systematic Literature Review With Survey of Experts.
Topics: Buprenorphine; Humans; Methadone; Mitragyna; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Opioid use disorder treatment for people experiencing homelessness: A scoping review.
Topics: Buprenorphine; Health Services Accessibility; Health Services Misuse; Humans; Ill-Housed Persons; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Effectiveness of medication for opioid use disorders in transition-age youth: A systematic review.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States; Young Adult | 2022 |
Insights into the mechanisms underlying opioid use disorder and potential treatment strategies.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2021 |
Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Child; Cross-Sectional Studies; Female; Humans; Male; Medicaid; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; United States; Young Adult | 2021 |
Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
Topics: Alcoholism; Analgesics, Opioid; Animals; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Substance Withdrawal Syndrome | 2017 |
Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2017 |
A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Drug Implants; Female; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies | 2017 |
Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Treatment Outcome | 2017 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Non-Randomized Controlled Trials as Topic; Opioid-Related Disorders; Prospective Studies; Randomized Controlled Trials as Topic; Severity of Illness Index; Substance Withdrawal Syndrome | 2017 |
Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care | 2018 |
Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Overdose; Humans; Injections, Intramuscular; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2018 |
Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
Topics: Abuse-Deterrent Formulations; Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Compounding; Humans; Naltrexone; Opioid-Related Disorders; United States; United States Food and Drug Administration | 2018 |
Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Opioid Use Disorders: Perioperative Management of a Special Population.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Drug Tolerance; Humans; Interdisciplinary Communication; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Patient Discharge; Patient-Centered Care; Perioperative Care | 2018 |
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Topics: Constipation; Defecation; Female; Gastrointestinal Agents; Humans; Intestinal Diseases; Male; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Related Disorders; Oxycodone; Palliative Care; Piperidines; Quaternary Ammonium Compounds; Randomized Controlled Trials as Topic; Receptors, Opioid, mu | 2018 |
Developing an opioid use disorder treatment cascade: A review of quality measures.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2018 |
Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk | 2019 |
Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain Management; Perioperative Care | 2018 |
CE: Acute Pain Management for People with Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Management; Palliative Care; Substance Withdrawal Syndrome | 2018 |
Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
Topics: Abuse-Deterrent Formulations; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Humans; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prescription Drug Misuse | 2018 |
Pharmacotherapy for opioid addiction in community corrections.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons | 2018 |
Medications for Treatment of Opioid Use Disorder among Persons Living with HIV.
Topics: Buprenorphine; HIV Infections; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Treatment Outcome | 2019 |
Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Randomized Controlled Trials as Topic; Recidivism; Risk-Taking | 2019 |
Potential uses of naltrexone in emergency department patients with opioid use disorder.
Topics: Analgesics, Opioid; Drug Overdose; Emergency Service, Hospital; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2019 |
Post-cesarean delivery pain. Management of the opioid-dependent patient before, during and after cesarean delivery.
Topics: Analgesia, Patient-Controlled; Buprenorphine; Cesarean Section; Female; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain, Postoperative; Pregnancy; Pregnancy Complications | 2019 |
Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews.
Topics: Analgesics, Opioid; Buprenorphine; Counseling; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Randomized Controlled Trials as Topic; Systematic Reviews as Topic | 2019 |
A Summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
Topics: Analgesics, Opioid; Buprenorphine; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Methadone; Models, Economic; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Policy; Treatment Outcome; United States | 2019 |
Consideration of opioid agonist treatment in a pregnant adolescent: A case report and literature review.
Topics: Adolescent; Ambulatory Care; Analgesics, Opioid; Buprenorphine; Child, Foster; Female; Humans; Lost to Follow-Up; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Pregnancy in Adolescence | 2020 |
Medications for management of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2019 |
Pharmacotherapies for treating opioid use disorder.
Topics: Age Factors; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; United States | 2013 |
Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Topics: Adult; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention | 2013 |
Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
Topics: Analgesics, Opioid; Delayed-Action Preparations; Humans; Illicit Drugs; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone | 2014 |
A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.
Topics: Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2014 |
Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
Topics: Alcoholism; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Humans; Micelles; Naltrexone; Nanoparticles; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
Detoxification treatments for opiate dependent adolescents.
Topics: Adolescent; Buprenorphine; Clonidine; Humans; Maintenance Chemotherapy; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Dropouts; Randomized Controlled Trials as Topic | 2014 |
Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Topics: Alcoholism; Delayed-Action Preparations; Health Care Costs; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
Abuse-deterrent opioid formulations.
Topics: Analgesics, Opioid; Animals; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Humans; Morphine; Naltrexone; Opioid-Related Disorders | 2015 |
Therapies in early development for the treatment of opiate addiction.
Topics: Analgesics, Opioid; Animals; Buprenorphine; Drug Design; Humans; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2015 |
Retention in medication-assisted treatment for opiate dependence: A systematic review.
Topics: Behavior Therapy; Buprenorphine; Heroin; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Naltrexone: Not Just for Opioids Anymore.
Topics: Alcoholism; Animals; Behavior, Addictive; Delayed-Action Preparations; Drug Compounding; Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Treatment Outcome | 2016 |
Antagonist Models for Relapse Prevention and Reducing HIV Risk.
Topics: HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid, mu; Risk Factors; Russia; Secondary Prevention | 2016 |
A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2016 |
Pharmacotherapy for Substance Use Disorders.
Topics: Age Factors; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Buprenorphine; Bupropion; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Substance Withdrawal Syndrome; Substance-Related Disorders; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2016 |
Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Humans; Low Back Pain; Naltrexone; Opioid-Related Disorders; Oxycodone; Practice Guidelines as Topic | 2016 |
Opioid Use Disorders.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2016 |
Medication-Assisted Treatment of Adolescents With Opioid Use Disorders.
Topics: Adolescent; Buprenorphine; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2016 |
Update on pharmacotherapy for treatment of opioid use disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clonidine; Combined Modality Therapy; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome | 2016 |
Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review.
Topics: Buprenorphine; Combined Modality Therapy; Education, Medical, Continuing; Health Education; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Psychotherapy | 2017 |
Pharmacogenetic treatments for drug addiction: alcohol and opiates.
Topics: Alcoholism; beta-Endorphin; Buprenorphine; Cytochrome P-450 CYP2D6; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Polymorphism, Single Nucleotide; Predictive Value of Tests; Receptors, Opioid, mu | 2008 |
Unintentional rapid opioid detoxification: case report.
Topics: Adult; Consciousness Disorders; Critical Care; Diazepam; Drug Interactions; Emergency Service, Hospital; Epilepsy, Generalized; Humans; Illicit Drugs; Infusions, Intravenous; Male; Naltrexone; Narcotic Antagonists; Narcotics; Neurologic Examination; Opioid-Related Disorders; Private Practice; Substance Abuse Detection; Substance Withdrawal Syndrome | 2009 |
Detoxification treatments for opiate dependent adolescents.
Topics: Adolescent; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2009 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clinical Trials as Topic; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2009 |
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.
Topics: Anesthetics; Humans; Hypnotics and Sedatives; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2010 |
The pharmacological treatment of opioid addiction--a clinical perspective.
Topics: Adrenergic Agonists; Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Social Support; Substance Withdrawal Syndrome | 2010 |
A review of the community reinforcement approach in the treatment of opioid dependence.
Topics: Adult; Female; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Psychotherapy; Reinforcement, Psychology; Therapy, Computer-Assisted | 2009 |
Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.
Topics: Clinical Trials as Topic; Humans; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Russia; Secondary Prevention | 2010 |
Opioid formulations designed to resist/deter abuse.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Combinations; Humans; Morphine; Naltrexone; Niacin; Opioid-Related Disorders; Oxycodone; Pain; United States | 2010 |
Heroin anticraving medications: a systematic review.
Topics: Buprenorphine; Heroin; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2010 |
Naltrexone in the treatment of opioid dependence.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention | 2010 |
Intramuscular extended-release naltrexone: current evidence.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2011 |
Oral naltrexone maintenance treatment for opioid dependence.
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2011 |
Oral naltrexone maintenance treatment for opioid dependence.
Topics: Administration, Oral; Benzodiazepines; Buprenorphine; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2011 |
Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
Topics: Alcoholism; Delayed-Action Preparations; Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2011 |
Opioid dependence.
Topics: Analgesics, Opioid; Buprenorphine; Evidence-Based Medicine; Heroin Dependence; Humans; Incidence; Methadone; Naltrexone; Opioid-Related Disorders | 2009 |
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
Topics: Biological Availability; Buprenorphine; Chemistry, Pharmaceutical; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
Topics: Adrenergic alpha-2 Receptor Agonists; Buprenorphine; Clinical Protocols; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research.
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Maintenance medication for opiate addiction: the foundation of recovery.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Long-Term Care; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2012 |
Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
Topics: Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Combinations; Drug Discovery; Drug Overdose; Drug Prescriptions; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Pain | 2012 |
Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.
Topics: Analgesics, Opioid; Buprenorphine; Chemistry, Pharmaceutical; Dextroamphetamine; Humans; Lisdexamfetamine Dimesylate; Morphine; Naltrexone; Opioid-Related Disorders; Pain; Prescription Drug Misuse; United States; United States Food and Drug Administration | 2012 |
Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
Topics: Delayed-Action Preparations; Drug Implants; Female; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Prisoners; Time Factors | 2014 |
Medications development for opioid abuse.
Topics: Analgesics, Opioid; Buprenorphine; Choice Behavior; Endocannabinoids; Evidence-Based Medicine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neuroglia; Opioid-Related Disorders; Receptors, Opioid, mu; Reinforcement, Psychology; Self Administration; Substance Withdrawal Syndrome; Treatment Outcome | 2013 |
Clinical uses of naltrexone: a review of the evidence.
Topics: Alcoholism; Animals; Behavior, Addictive; Cocaine-Related Disorders; Feeding and Eating Disorders; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Opioid-Related Disorders; Schizophrenia; Self-Injurious Behavior; Substance-Related Disorders; Tobacco Use Disorder | 2002 |
[A review of naltrexone maintenance programs: effectiveness, predictors and profile].
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Evaluation | 2002 |
[Opioid detoxication under general anesthesia].
Topics: Anesthesia, General; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Infusions, Intravenous; Monitoring, Physiologic; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2002 |
Naltrexone maintenance treatment for opioid dependence.
Topics: Controlled Clinical Trials as Topic; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.
Topics: Alcoholism; Clinical Trials as Topic; Cocaine-Related Disorders; Humans; Naltrexone; Narcotic Antagonists; Nicotine; Opioid-Related Disorders; Structure-Activity Relationship; Substance-Related Disorders; Tobacco Use Disorder | 2005 |
A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence.
Topics: Alcoholism; Clinical Trials as Topic; Humans; Long-Term Care; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychotherapy; Research Design | 2006 |
Vivitrex (Alkermes/Cephalon).
Topics: Alcoholism; Animals; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2006 |
Oral naltrexone maintenance treatment for opioid dependence.
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2006 |
Opioid antagonists with minimal sedation for opioid withdrawal.
Topics: Adrenergic alpha-Agonists; Clinical Trials as Topic; Clonidine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2006 |
Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.
Topics: Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychotherapy; Randomized Controlled Trials as Topic | 2006 |
Opiate addiction in China: current situation and treatments.
Topics: Buprenorphine; China; Clonidine; Drugs, Chinese Herbal; HIV Infections; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse, Intravenous; Substance Withdrawal Syndrome; Sympatholytics | 2006 |
Antagonist treatment of opioid withdrawal translational low dose approach.
Topics: Animals; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2006 |
Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.
Topics: Cost-Benefit Analysis; Counseling; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk; Secondary Prevention; Time Factors | 2007 |
Sustained-release naltrexone: novel treatment for opioid dependence.
Topics: Animals; Delayed-Action Preparations; Humans; Naltrexone; Opioid-Related Disorders | 2007 |
Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
Topics: Buprenorphine; Comorbidity; Delayed-Action Preparations; Drug Administration Schedule; Drug Design; Drug Therapy, Combination; Humans; Mental Disorders; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2008 |
Sustained-release naltrexone for opioid dependence.
Topics: Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2008 |
Mu-opioid antagonists for opioid-induced bowel dysfunction.
Topics: Constipation; Defecation; Gastrointestinal Agents; Humans; Intestinal Diseases; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Piperidines; Quaternary Ammonium Compounds; Receptors, Opioid, mu | 2008 |
The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Topics: Clinical Trials as Topic; Double-Blind Method; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
The role of endorphins in opiate addiction, opiate withdrawal, and recovery.
Topics: Alcoholism; Brain; Endorphins; Humans; Hypothalamo-Hypophyseal System; Locus Coeruleus; Naltrexone; Norepinephrine; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
The sequential use of clonidine and naltrexone in the treatment of opiate addicts.
Topics: Adult; Baclofen; Clonidine; Drug Therapy, Combination; Electric Stimulation Therapy; Endorphins; Ethanol; Female; Humans; Locus Coeruleus; Male; Methyldopa; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1984 |
[Naltrexone in the therapeutic relation in cases of opioid abuse and dependence].
Topics: Humans; Naltrexone; Narcotics; Opioid-Related Disorders; Physician-Patient Relations; Substance-Related Disorders | 1993 |
Opiate detoxification protocols. A clinical manual.
Topics: Administration, Cutaneous; Clinical Protocols; Clonidine; Codeine; Female; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Psychiatric Status Rating Scales; Receptors, Opioid; Substance Withdrawal Syndrome | 1993 |
Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.
Topics: Animals; Buprenorphine; Clonidine; Humans; Locus Coeruleus; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1993 |
[Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
Topics: Alcoholism; Delayed-Action Preparations; Follow-Up Studies; Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Treatment Outcome | 1996 |
Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study.
Topics: Anesthesia, General; Clonidine; Follow-Up Studies; Humans; Israel; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Recurrence; Substance Withdrawal Syndrome; Treatment Outcome | 1997 |
Rapid and ultrarapid opioid detoxification techniques.
Topics: Clinical Trials as Topic; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Research Design; Substance Withdrawal Syndrome | 1998 |
Role of maintenance treatment in opioid dependence.
Topics: Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disorders | 1999 |
Mechanisms of fatal opioid overdose.
Topics: Drug Interactions; Drug Overdose; Drug Tolerance; Humans; Naltrexone; Narcotics; Neurotransmitter Agents; Opioid-Related Disorders; Respiration; Respiratory Insufficiency | 1999 |
Naltrexone maintenance treatment for opioid dependence.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2000 |
Naltrexone maintenance treatment for opioid dependence.
Topics: Controlled Clinical Trials as Topic; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2000 |
The physical and psychosocial consequences of opioid addiction: an overview of changes in opioid treatment.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2000 |
[Limited role of naltrexone in the treatment of opiate addiction].
Topics: Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention | 2001 |
Naltrexone maintenance treatment for opioid dependence.
Topics: Controlled Clinical Trials as Topic; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2001 |
Naltrexone maintenance treatment for opioid dependence.
Topics: Controlled Clinical Trials as Topic; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2002 |
Pharmacological blocking agents for treating substance abuse.
Topics: Alcoholism; Animals; Behavior Therapy; Disulfiram; Drug Antagonism; Drug Design; Humans; Naltrexone; Narcotic Antagonists; Neurosciences; Opioid-Related Disorders; Rats; Substance-Related Disorders | 1991 |
[Clonidine-naltrexone: a new technic for the detoxification of opiate addicts].
Topics: Clonidine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1990 |
Drugs of abuse--opiates.
Topics: Central Nervous System; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotics; Opioid-Related Disorders; Primary Health Care; Receptors, Opioid | 1990 |
Clinical toxicology of drugs used in the treatment of opiate dependency.
Topics: Buprenorphine; Clonidine; Humans; Methadone; Methadyl Acetate; Naltrexone; Opioid-Related Disorders | 1990 |
[Naltrexone. An opioid antagonist to support the drug-free state in previous opioid addicts having stopped the habit].
Topics: Humans; Inactivation, Metabolic; Naltrexone; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 1990 |
Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.
Topics: Animals; Heroin; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid | 1988 |
Opioids and development: new lessons from old problems.
Topics: Animals; Brain; Child Behavior; Child Development; Dose-Response Relationship, Drug; Female; Fetus; Humans; Naltrexone; Narcotics; Opioid-Related Disorders; Pregnancy; Rats; Receptors, Opioid; Substance Withdrawal Syndrome | 1985 |
Clinical investigations of drug effects in women.
Topics: Buprenorphine; Cocaine; Desipramine; Female; Heroin Dependence; Humans; Male; Naltrexone; Opioid-Related Disorders; Sex Factors; Substance-Related Disorders | 1986 |
Behavioral pharmacology of buprenorphine.
Topics: Adult; Animals; Buprenorphine; Conditioning, Operant; Eating; Heroin Dependence; Humans; Macaca; Male; Methadone; Morphinans; Naltrexone; Opioid-Related Disorders; Reinforcement, Psychology; Self Administration | 1985 |
173 trial(s) available for naltrexone and Addiction, Opioid
| Article | Year |
|---|---|
A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.
Topics: Administration, Oral; Adult; Behavior Therapy; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Treatment Outcome | 2019 |
Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.
Topics: Adult; Cost-Benefit Analysis; Criminal Law; Criminals; Female; Humans; Male; Naltrexone; Narcotic Antagonists; New England; Opioid-Related Disorders; Recurrence; Secondary Prevention; Treatment Outcome | 2017 |
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2021 |
Optimizing opioid use disorder treatment with naltrexone or buprenorphine.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse.
Topics: Adult; Analgesics, Opioid; Delayed-Action Preparations; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Treatment Adherence and Compliance | 2022 |
Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.
Topics: Buprenorphine; Delayed-Action Preparations; Fentanyl; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Prescribers' satisfaction with delivering medications for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Personal Satisfaction | 2021 |
Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder.
Topics: Buprenorphine; Humans; Naltrexone; Opioid-Related Disorders; Quality of Life; Randomized Controlled Trials as Topic; Referral and Consultation | 2021 |
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up.
Topics: Delayed-Action Preparations; Follow-Up Studies; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Personal Satisfaction | 2022 |
Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
Topics: Buprenorphine, Naloxone Drug Combination; Chronic Pain; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prospective Studies | 2022 |
HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine; Cocaine-Related Disorders; Delayed-Action Preparations; Enkephalins; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Protein Precursors | 2022 |
Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Humans; Hypnotics and Sedatives; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prevalence; Recurrence; Treatment Outcome | 2022 |
Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
Topics: Adult; Analgesics, Opioid; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Young Adult | 2022 |
Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
Topics: Analgesics, Opioid; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners; Prisons | 2022 |
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Hepatitis C; HIV Infections; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA; Social Justice | 2022 |
Enhancing Use of Medications for Opioid Use Disorder Through External Coaching.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration.
Topics: Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Quality of Life | 2023 |
Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine-naloxone (BUP-NX) or extended-release naltrexone (XR-NTX) for opioid use disorder.
Topics: Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Treatment Outcome | 2023 |
18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Injections, Subcutaneous; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial.
Topics: Case Management; Female; HIV Infections; Humans; Male; Naltrexone; Opioid-Related Disorders; Russia; Standard of Care; Viral Load | 2023 |
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2023 |
Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Administration, Oral; Adolescent; Adult; Chemoprevention; Clonidine; Craving; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Pilot Projects; Recurrence; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2019 |
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2019 |
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Drug Substitution; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2020 |
Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Acceptance of Health Care; Prisoners; Prisons; Quality of Life; Treatment Outcome | 2020 |
Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Cigarette Smoking; Craving; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Retrospective Studies; Tobacco Products; Young Adult | 2020 |
Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
Topics: Adult; Black or African American; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
A pilot randomized controlled trial of assertive treatment including family involvement and home delivery of medication for young adults with opioid use disorder.
Topics: Adolescent; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Young Adult | 2021 |
Pharmacokinetics and pharmacodynamics of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Fluconazole; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
Opioid overdose experiences in a sample of US adolescents and young adults: a thematic analysis.
Topics: Adolescent; Analgesics, Opioid; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Opiate Overdose; Opioid-Related Disorders; United States; Young Adult | 2021 |
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial.
Topics: Buprenorphine; Cognition; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life | 2020 |
A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
Topics: Adult; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Navigation; Prisoners | 2020 |
Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders.
Topics: Adult; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Quality of Life | 2021 |
Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
Topics: Aftercare; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Discharge | 2021 |
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
Topics: Adult; Buprenorphine; Clinical Protocols; Delayed-Action Preparations; Humans; Injections, Intramuscular; Jails; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2021 |
Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
Topics: Adult; Delayed-Action Preparations; Humans; Injections, Intramuscular; Mediation Analysis; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 2021 |
An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Topics: Administration, Sublingual; Adult; Ambulatory Care; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Topics: Adult; Animals; Benzazepines; Buprenorphine; Delayed-Action Preparations; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Swine | 2021 |
Naltrexone treatment for prolonged grief disorder: study protocol for a randomized, triple-blinded, placebo-controlled trial.
Topics: Comorbidity; Grief; Humans; Naltrexone; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Research Design | 2021 |
Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.
Topics: Criminal Law; Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Sex Factors | 2021 |
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; United States | 2021 |
Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.
Topics: Aged; Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2021 |
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Topics: Adult; Analgesics, Opioid; Delayed-Action Preparations; Follow-Up Studies; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; United States | 2021 |
Extended-release naltrexone for youth with opioid use disorder.
Topics: Adolescent; Adult; Aftercare; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Discharge; Young Adult | 2021 |
Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Tobacco Use | 2021 |
Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners; Prisons | 2021 |
Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
Topics: Administration, Sublingual; Adult; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2021 |
Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Constipation; Defecation; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Related Disorders | 2017 |
Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
Topics: Adult; Delayed-Action Preparations; Female; Heroin; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Detection; Substance Abuse, Intravenous; Unemployment | 2018 |
Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Prisoners; Recurrence | 2018 |
Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Topics: Adult; Analgesics; Analgesics, Opioid; Buprenorphine; Clonidine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome; Tramadol; Treatment Outcome; Young Adult | 2017 |
Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision.
Topics: Adult; Clinical Trials as Topic; Criminals; Humans; Informed Consent; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Selection; Secondary Prevention | 2017 |
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Topics: Adult; Aged; Analgesics, Opioid; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Naltrexone; Neoplasms; Opioid-Related Disorders; Pain Management; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2017 |
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Topics: Buprenorphine; Capacity Building; Family Practice; Health Personnel; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Organizational Innovation; Psychiatry; Research Design; Staff Development; Telemedicine; United States; Workflow | 2017 |
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Topics: Administration, Oral; Adult; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Research Design | 2018 |
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Topics: Adult; Criminal Law; Delayed-Action Preparations; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Injections, Intramuscular; Male; Middle Aged; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners; Prospective Studies; Research Design; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2018 |
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Topics: Adult; Ambulatory Care; Buprenorphine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Patient Transfer; Substance Withdrawal Syndrome | 2018 |
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Alcohol Deterrents; Alcoholism; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Prisoners; RNA, Viral; Viral Load | 2018 |
Patient predictors of substance use disorder treatment initiation in primary care.
Topics: Adult; Age Factors; Alcoholism; Buprenorphine, Naloxone Drug Combination; Cognitive Behavioral Therapy; Cooperative Behavior; Female; Health Services Accessibility; Humans; Logistic Models; Male; Middle Aged; Motivational Interviewing; Multivariate Analysis; Naltrexone; Opioid-Related Disorders; Primary Health Care; Psychotherapy, Brief; Sex Factors | 2018 |
Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
Topics: Adult; Craving; Cues; Delayed-Action Preparations; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroimaging; Nucleus Accumbens; Opioid-Related Disorders; Photic Stimulation; Prefrontal Cortex; Substance Withdrawal Syndrome; Young Adult | 2018 |
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Outpatients; Severity of Illness Index; Substance Withdrawal Syndrome; Symptom Assessment | 2018 |
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial.
Topics: Adult; Buprenorphine; Comorbidity; Demography; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk-Taking; Sex Factors | 2018 |
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.
Topics: Administration, Oral; Adult; Anhedonia; Anxiety; Depression; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Treatment Outcome | 2018 |
Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual.
Topics: Adult; Criminal Law; Criminals; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recidivism | 2019 |
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Topics: Administration, Oral; Adolescent; Adult; Anxiety; Buprenorphine, Naloxone Drug Combination; Comorbidity; Delayed-Action Preparations; Depression; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Sleep Initiation and Maintenance Disorders; Young Adult | 2019 |
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Chronic Pain; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Norway; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Measurement | 2019 |
Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.
Topics: Administration, Oral; Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Naltrexone; Opioid-Related Disorders; Placebos; United Kingdom | 2019 |
Factors influencing recruitment to a randomised placebo-controlled trial of oral naltrexone and extended release implant naltrexone: Qualitative study.
Topics: Adult; Delayed-Action Preparations; Female; Health Personnel; Humans; Injections, Intramuscular; Interviews as Topic; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Qualitative Research; Research Personnel; Time Factors | 2019 |
The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
Topics: Adult; Black or African American; Cocaine; Delayed-Action Preparations; Female; Heroin; Humans; Injections; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Detection; Workplace | 2019 |
Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Topics: Adult; Ambulatory Care; Delayed-Action Preparations; Double-Blind Method; Duration of Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Russia; Survival Analysis; Treatment Outcome | 2020 |
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Acceptance of Health Care; Young Adult | 2019 |
Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Guanfacine; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Russia; Secondary Prevention; Young Adult | 2013 |
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Self Report | 2013 |
Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreation
Topics: Analgesics, Opioid; Area Under Curve; Body Mass Index; Cross-Over Studies; Delayed-Action Preparations; Discrimination, Psychological; Double-Blind Method; Endpoint Determination; Ethnicity; Female; Follow-Up Studies; Humans; Male; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pupil; Tablets; Young Adult | 2013 |
Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Topics: Adolescent; Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Proportional Hazards Models | 2013 |
A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Topics: Adult; Buprenorphine; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome; Young Adult | 2013 |
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Topics: Adult; Buprenorphine; Craving; Delayed-Action Preparations; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Substance Withdrawal Syndrome; Young Adult | 2014 |
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Delayed-Action Preparations; Female; gamma-Glutamyltransferase; HIV Infections; Humans; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners | 2014 |
Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.
Topics: Adult; Cocaine-Related Disorders; Drug Users; Employment; Female; Follow-Up Studies; Humans; Injections; Male; Medication Adherence; Middle Aged; Naltrexone; Opioid-Related Disorders; Reinforcement, Psychology; Secondary Prevention; Treatment Outcome; Unemployment | 2015 |
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Topics: Communication; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Prisoners; Research Design; Risk-Taking; Time Factors | 2014 |
Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.
Topics: Adult; Behavior Therapy; Buprenorphine; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Misuse | 2015 |
Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
Topics: Administration, Oral; Adult; Behavior Therapy; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Patient Dropouts | 2015 |
[Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
Topics: Adult; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2014 |
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Topics: Adult; Criminal Law; Criminals; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention | 2015 |
Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.
Topics: Adult; Cohort Studies; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pennsylvania; Rehabilitation Centers; Withholding Treatment; Young Adult | 2015 |
Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Topics: Adult; Delayed-Action Preparations; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; New York City; Opioid-Related Disorders; Pilot Projects; Prisoners; Recurrence; Treatment Outcome | 2015 |
Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.
Topics: Administration, Oral; Adult; Buprenorphine; Drug Administration Schedule; Feasibility Studies; Female; Humans; Injections; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2015 |
Baseline characteristics of patients predicting suitability for rapid naltrexone induction.
Topics: Administration, Oral; Adult; Buprenorphine; Clonidine; Delayed-Action Preparations; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Selection; Prognosis | 2015 |
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Topics: Adult; Cannabinoids; Delayed-Action Preparations; Double-Blind Method; Dronabinol; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Substance Withdrawal Syndrome; Young Adult | 2015 |
[A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence].
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Analgesics, Opioid; Double-Blind Method; Drug Therapy, Combination; Female; Guanfacine; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Secondary Prevention; Treatment Outcome; Young Adult | 2015 |
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
Topics: Adult; Criminals; Delayed-Action Preparations; Double-Blind Method; Female; HIV Infections; Humans; Injections; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Transitional Care | 2015 |
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Topics: Adult; Community Health Services; Counseling; Criminals; Delayed-Action Preparations; Drug Overdose; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Substance Abuse, Intravenous | 2016 |
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Norway; Opioid-Related Disorders | 2016 |
Extended-release naltrexone opioid treatment at jail reentry (XOR).
Topics: Analgesics, Opioid; Cause of Death; Delayed-Action Preparations; Drug Overdose; Humans; Injections, Intramuscular; Methadone; Mortality; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Participation; Prisons; Secondary Prevention | 2016 |
The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Topics: Analgesics, Opioid; Cooperative Behavior; Criminal Law; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; National Institute on Drug Abuse (U.S.); Opiate Substitution Treatment; Opioid-Related Disorders; Patient Navigation; Prisoners; Prisons; Treatment Outcome; United States | 2016 |
Injectable pharmacotherapy for opioid use disorders (IPOD).
Topics: Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Navigation; Prisoners; Prisons | 2016 |
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Topics: Administration, Oral; Adult; Anhedonia; Anxiety; Craving; Delayed-Action Preparations; Depression; Double-Blind Method; Drug Implants; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2016 |
NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Topics: Buprenorphine, Naloxone Drug Combination; Comparative Effectiveness Research; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; National Institute on Drug Abuse (U.S.); Opioid-Related Disorders; Socioeconomic Factors; United States | 2016 |
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
Topics: Adaptation, Psychological; Analgesics, Opioid; Buprenorphine; Clinical Protocols; Combined Modality Therapy; Drug Users; Health Services Accessibility; Humans; Methadone; Mobile Applications; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life; Recurrence; Research Design; Smartphone; Telemedicine; Time Factors; Treatment Outcome; Wisconsin | 2016 |
Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
Topics: Crime; Delayed-Action Preparations; Delivery of Health Care; Female; HIV Infections; Humans; Injections, Intramuscular; Male; Medication Adherence; Mobile Health Units; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisoners; Prisons; Recurrence; Risk-Taking; Substance Abuse Treatment Centers; United States | 2017 |
Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Topics: Alcoholism; British Columbia; Chicago; Delayed-Action Preparations; Feasibility Studies; Female; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Treatment Outcome | 2017 |
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Behavior Therapy; Buprenorphine; Clonidine; Combined Modality Therapy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Remission Induction; Secondary Prevention; Young Adult | 2017 |
Psychiatric symptoms, quality of life, and HIV status among people using opioids in Saint Petersburg, Russia.
Topics: Adult; Female; HIV Seropositivity; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychiatric Status Rating Scales; Quality of Life; Russia; Substance Abuse, Intravenous; Young Adult | 2017 |
Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
Topics: Adult; Alcoholic Intoxication; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Quality of Life; Secondary Prevention; Time Factors | 2018 |
Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.
Topics: Adult; Adult Survivors of Child Adverse Events; Alcoholism; Amygdala; Brain; Case-Control Studies; Cocaine-Related Disorders; Cross-Over Studies; Cues; Double-Blind Method; Female; Functional Neuroimaging; Gyrus Cinguli; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neural Pathways; Opioid-Related Disorders; Prefrontal Cortex; Substance-Related Disorders; Young Adult | 2017 |
Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.
Topics: Adult; Analgesics, Opioid; Community Mental Health Services; Disruptive, Impulse Control, and Conduct Disorders; Double-Blind Method; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Development; Substance Withdrawal Syndrome | 2009 |
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Behavior, Addictive; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Oxycodone; Placebos | 2010 |
Naltrexone implants compared to methadone: outcomes six months after prison release.
Topics: Adult; Crime; Drug Implants; Female; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Prisons; Secondary Prevention | 2010 |
Challenges to antagonist blockade during sustained-release naltrexone treatment.
Topics: Adult; Crime; Delayed-Action Preparations; Depression; Drug Implants; Drug Overdose; Euphoria; Female; Hair; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Compliance; Psychiatric Status Rating Scales; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2010 |
The association between naltrexone treatment and symptoms of depression in opioid-dependent patients.
Topics: Adult; Affect; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2011 |
Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Cocaine; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Employment; Female; Humans; Injections, Subcutaneous; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Reinforcement, Psychology; Salaries and Fringe Benefits; Young Adult | 2011 |
Problem drinking and low-dose naltrexone-assisted opioid detoxification.
Topics: Adult; Alcohol Drinking; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Severity of Illness Index; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2011 |
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; HIV Seropositivity; Humans; Injections; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Detection | 2011 |
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.
Topics: Adult; Disease Progression; Dopamine Agents; Double-Blind Method; Female; Humans; Male; Medication Adherence; Memantine; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Young Adult | 2011 |
Drug use and HIV risk outcomes in opioid-injecting men in the Republic of Georgia: behavioral treatment + naltrexone compared to usual care.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Counseling; Directive Counseling; Female; Georgia (Republic); HIV Infections; Humans; Male; Naltrexone; Opioid-Related Disorders; Patient Education as Topic; Risk-Taking; Substance Abuse, Intravenous; Treatment Outcome | 2012 |
Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
Topics: Adult; Delayed-Action Preparations; Employment; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Reinforcement, Psychology; Workplace | 2012 |
Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Topics: Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Drug Combinations; Drug Interactions; Euphoria; Humans; Injections, Intravenous; Male; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Pain Measurement; Substance-Related Disorders; Young Adult | 2011 |
Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence.
Topics: Adult; Analysis of Variance; Cues; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Reward; Substance Abuse, Intravenous; Sucrose; Taste Perception | 2012 |
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.
Topics: Adult; Blood Pressure; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Hydromorphone; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Oxygen; Pupil; Respiratory Rate; Skin Temperature; Time Factors | 2012 |
Behavioral treatment + naltrexone reduces drug use and legal problems in the Republic of Georgia.
Topics: Adult; Behavior Therapy; Georgia (Republic); Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse, Intravenous; Treatment Outcome | 2012 |
The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adult; Clonidine; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome | 2012 |
Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence.
Topics: Administration, Oral; Adult; Baltimore; Cocaine-Related Disorders; Conditioning, Operant; Female; Heroin Dependence; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Opioid-Related Disorders; Patient Acceptance of Health Care; Personality Assessment; Psychometrics; Rehabilitation, Vocational; Risk-Taking; Sheltered Workshops; Substance Abuse Detection; Substance Abuse, Intravenous | 2012 |
Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
Topics: Adult; Delayed-Action Preparations; Double-Blind Method; Female; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Intramuscular; Liver Function Tests; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2012 |
Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2013 |
Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cocaine-Related Disorders; Employment; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Reinforcement, Psychology; Substance Abuse, Intravenous; Substance-Related Disorders; Workplace | 2013 |
Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cross-Over Studies; Dietary Sucrose; Double-Blind Method; England; Female; Food Preferences; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Osmolar Concentration; Sodium Chloride, Dietary; Taste Perception; Taste Threshold; Young Adult | 2013 |
A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Use of very low-dose naltrexone during opiate detoxification.
Topics: Adult; Drug Administration Schedule; Female; Humans; Inactivation, Metabolic; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2003 |
Behavioral family counseling and naltrexone for male opioid-dependent patients.
Topics: Adult; Behavior Therapy; Counseling; Diagnostic and Statistical Manual of Mental Disorders; Family Therapy; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.
Topics: Adult; Ambulatory Care; Biological Availability; Combined Modality Therapy; Comorbidity; Delayed-Action Preparations; Drug Administration Schedule; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Mental Disorders; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Premedication; Psychotherapy; Spain; Treatment Outcome | 2003 |
Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.
Topics: Adult; Aged; Amino Acids; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neprilysin; Opioid-Related Disorders; Patient Compliance; Phenylalanine; Pilot Projects; Secondary Prevention; Texas; Treatment Outcome | 2004 |
Millon Clinical Multiaxial Inventory-III subtypes of opioid dependence: validity and matching to behavioral therapies.
Topics: Adult; Behavior Therapy; Counseling; Female; Humans; Male; Naltrexone; Narcotics; Opioid-Related Disorders; Personality Disorders; Predictive Value of Tests; Prevalence; Reproducibility of Results; Surveys and Questionnaires | 2004 |
Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients.
Topics: Adult; Anti-Anxiety Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Prazepam; Secondary Prevention; Substance Abuse Detection | 2005 |
[Safety and effectiveness of opiate antagonist detoxification under general anesthesia].
Topics: Adolescent; Adult; Anesthesia, General; Antidotes; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Inactivation, Metabolic; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Placebos; Prospective Studies; Receptors, Opioid; Safety; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2005 |
Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?
Topics: Behavior Therapy; Combined Modality Therapy; Heroin Dependence; Humans; Inpatients; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Treatment Outcome | 2006 |
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
Topics: Adult; Behavior, Addictive; Clonidine; Cues; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Stress, Psychological; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome | 2007 |
Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.
Topics: Adult; Anxiety; Behavior, Addictive; Blood Pressure; Cues; Emotions; Female; Heart Rate; Humans; Imagery, Psychotherapy; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Stress, Psychological | 2007 |
Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
Topics: Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Psychotherapy; Substance Withdrawal Syndrome; Treatment Refusal | 2007 |
The role of the National Institute on Drug Abuse in the development of naltrexone.
Topics: Aftercare; Animals; Carcinogens; Clinical Trials as Topic; Clonidine; Drug Administration Schedule; Drug and Narcotic Control; Drug Evaluation; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Motivation; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Rats; United States; United States Substance Abuse and Mental Health Services Administration | 1984 |
Clonidine versus methadone for opiate detoxification.
Topics: Clinical Trials as Topic; Clonidine; Humans; Inactivation, Metabolic; Methadone; Naltrexone; Opioid-Related Disorders | 1980 |
The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
Topics: Clinical Trials as Topic; Double-Blind Method; Endorphins; Humans; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
Clonidine and naltrexone. A safe, effective, and rapid treatment of abrupt withdrawal from methadone therapy.
Topics: Adult; Blood Pressure; Clonidine; Double-Blind Method; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
Primary care-based ambulatory opioid detoxification: the results of a clinical trial.
Topics: Adolescent; Adult; Ambulatory Care; Chi-Square Distribution; Clonidine; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Pilot Projects; Primary Health Care; Prospective Studies; Treatment Outcome | 1995 |
Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
Topics: Adult; Arousal; Autonomic Nervous System; Constipation; Dose-Response Relationship, Drug; Gastrointestinal Motility; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1995 |
Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.
Topics: Adult; Depressive Disorder; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Psychiatric Status Rating Scales; Psychotherapy; Suicide, Attempted | 1997 |
Pain tolerance in opioid addicts on and off naltrexone pharmacotherapy: a pilot study.
Topics: Adolescent; Adult; Cold Temperature; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Pressure | 1998 |
Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure.
Topics: Acute Kidney Injury; Adult; Anesthesia; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Respiratory Insufficiency; Substance Withdrawal Syndrome; Thyroid Hormones | 1999 |
Rapid opioid detoxification during general anesthesia: a review of 20 patients.
Topics: Adult; Anesthesia, General; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1999 |
EEG controlled rapid opioid withdrawal under general anaesthesia.
Topics: Anesthesia, General; Anesthetics, Intravenous; Electroencephalography; Female; Humans; Male; Monitoring, Physiologic; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Propofol; Substance Withdrawal Syndrome | 2000 |
Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).
Topics: Adolescent; Adult; Aftercare; Anesthesia, General; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Recurrence; Retreatment; Substance Withdrawal Syndrome | 2000 |
Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Analysis of Variance; Clonidine; Drug Therapy, Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Substance Withdrawal Syndrome; Trazodone | 2000 |
Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Humans; Injections, Intravenous; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Pupil | 2000 |
Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.
Topics: Adult; Blood Pressure; Clonidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome | 2000 |
Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Family Therapy; Female; Humans; Interpersonal Relations; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Reward; Substance Abuse Detection; Treatment Outcome; Treatment Refusal | 2001 |
Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude.
Topics: Adult; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Risk-Taking; Social Behavior; Treatment Outcome | 2002 |
24-Hour opiate detoxification and antagonist induction at home--the 'Asturian method': a report on 1368 procedures.
Topics: Administration, Oral; Adult; Aftercare; Anti-Anxiety Agents; Benzodiazepines; Clonidine; Drug Implants; Female; Follow-Up Studies; Heroin Dependence; Home Care Services, Hospital-Based; Humans; Male; Methadone; Naltrexone; Octreotide; Opioid-Related Disorders; Patient Admission; Substance Withdrawal Syndrome; Time Factors | 2002 |
The double-blind crossover trial design: how good is it for psychoactive drugs?
Topics: Adult; Cyclazocine; Double-Blind Method; Humans; Male; Naloxone; Naltrexone; Opioid-Related Disorders | 1979 |
Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone.
Topics: Adult; Blood Pressure; Buprenorphine; Double-Blind Method; Female; Humans; Male; Methadone; Methoxyhydroxyphenylglycol; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1992 |
A naltrexone double blind placebo controlled study in Israel.
Topics: Adult; Ambulatory Care; Double-Blind Method; Family; Female; Follow-Up Studies; Humans; Israel; Male; Naltrexone; Opioid-Related Disorders; Placebos; Psychotherapy; Social Adjustment; Social Support | 1992 |
[Naltrexone--an effective aid in the psychosocial rehabilitation process of former opiate dependent patients].
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Psychiatric Department, Hospital; Psychotherapy; Randomized Controlled Trials as Topic | 1990 |
[Naltrexone. An opioid antagonist to support the drug-free state in previous opioid addicts having stopped the habit].
Topics: Humans; Inactivation, Metabolic; Naltrexone; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 1990 |
Rapid detoxification from opioid dependence.
Topics: Buprenorphine; Clinical Trials as Topic; Double-Blind Method; Humans; Naloxone; Naltrexone; Opioid-Related Disorders; Placebos; Substance Withdrawal Syndrome | 1989 |
Naltrexone in federal probationers.
Topics: Follow-Up Studies; Humans; Naltrexone; Opioid-Related Disorders; Prisoners; Randomized Controlled Trials as Topic | 1989 |
Naltrexone-induced dysphoria in former opioid addicts.
Topics: Adult; Affective Symptoms; Ejaculation; Emotions; Humans; Libido; Male; Motor Activity; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1985 |
479 other study(ies) available for naltrexone and Addiction, Opioid
| Article | Year |
|---|---|
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Topics: Animals; Aorta, Thoracic; Cocaine; Cyclic AMP; Electric Stimulation; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Male; Mice; Muscle, Smooth; Opioid-Related Disorders; Rats; Receptors, Dopamine; Receptors, Opioid; Receptors, Serotonin; Substance-Related Disorders | 1998 |
Racial‒Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid.
Topics: Analgesics, Opioid; Buprenorphine; Ethnicity; Humans; Medicaid; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Topics: Adolescent; Adult; Craving; Educational Status; Employment; Female; Humans; Male; Mental Health; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries; Time Factors; Treatment Outcome; United States; Young Adult | 2018 |
Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence.
Topics: Adult; Cause of Death; Delayed-Action Preparations; Drug Overdose; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Time Factors; Young Adult | 2018 |
Severe opioid withdrawal precipitated by Vivitrol®.
Topics: Adult; Emergency Medical Services; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2018 |
Managing unplanned severe opiate withdrawal after Vivitrol.
Topics: Humans; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2019 |
A history of opioid abuse: Why buprenorphine is superior for the management of opioid use disorder and pain.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain | 2021 |
Multivariate pattern analysis links drug use severity to distributed cortical hypoactivity during emotional inhibitory control in opioid use disorder.
Topics: Delayed-Action Preparations; Emotions; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Comparison of naltrexone implant and oral buprenorphine-naloxone in the treatment of opiate use disorder.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opiate Alkaloids; Opioid-Related Disorders; Prospective Studies; Retrospective Studies | 2022 |
Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methamphetamine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2021 |
Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011-2017.
Topics: Analgesics, Opioid; Buprenorphine; Health Expenditures; Humans; Naltrexone; Opioid-Related Disorders; Prescriptions; United States | 2022 |
Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Hospital Mortality; Humans; Length of Stay; Logistic Models; Male; Methadone; Middle Aged; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; Prospective Studies | 2022 |
Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
Topics: Delayed-Action Preparations; Female; HIV Infections; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
Extended-release buprenorphine outcomes among treatment resistant veterans.
Topics: Buprenorphine; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Veterans | 2022 |
Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retention in Care; Retrospective Studies | 2022 |
Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.
Topics: Aged; Buprenorphine; Cross-Sectional Studies; Dental Care; Humans; Male; Massachusetts; Medicare; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
Topics: Analgesics, Opioid; Buprenorphine; Clinical Studies as Topic; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Qualitative Research | 2022 |
Post-residential treatment outpatient care preferences: Perspectives of youth with opioid use disorder.
Topics: Adolescent; Ambulatory Care; Humans; Naltrexone; Opioid-Related Disorders; Patient Discharge; Residential Treatment | 2022 |
Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Female; Humans; Medicaid; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Quality of Life; United States; Young Adult | 2022 |
Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Buprenorphine; Cohort Studies; Cost Sharing; Female; Health Expenditures; Humans; Insurance, Health; Male; Medication Adherence; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States; Young Adult | 2022 |
Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.
Topics: Adult; Analgesics, Opioid; Buprenorphine; COVID-19; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pandemics; Pharmacy; SARS-CoV-2; United States; Young Adult | 2022 |
Perioperative Management of Patients on Maintenance Medication for Addiction Treatment: The Development of an Institutional Guideline.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Heroin; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2022 |
Understanding and co-managing medication treatment options for opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.
Topics: Analgesics, Opioid; Arrhythmias, Cardiac; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2022 |
Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Medicaid; Naltrexone; North Carolina; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2022 |
Opioid-like adverse effects of tianeptine in male rats and mice.
Topics: Analgesics, Opioid; Animals; Male; Mice; Mice, Inbred ICR; Naltrexone; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Respiratory Insufficiency; Self Stimulation; Thiazepines | 2022 |
Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.
Topics: Analgesics, Opioid; Buprenorphine; Housing; Humans; Methadone; Missouri; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pain; Prospective Studies | 2022 |
Provider perspectives on emergency department initiation of medication assisted treatment for alcohol use disorder.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Naltrexone; Opioid-Related Disorders | 2022 |
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; COVID-19 Drug Treatment; Cross-Sectional Studies; Health Services Accessibility; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2022 |
Opioid Antagonist Nanodrugs Successfully Attenuate the Severity of Ischemic Stroke.
Topics: Analgesics, Opioid; Animals; Ischemic Stroke; Mice; Morphine; Naloxone; Naltrexone; Nanoparticles; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Stroke; Tight Junction Proteins | 2022 |
Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Surveys and Questionnaires | 2022 |
Gender differences among persons entering medication treatment for opioid use disorder in the community.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality of Life; Sex Factors | 2022 |
Medication prescribing for alcohol use disorders during alcohol-related encounters in a Colorado regional healthcare system.
Topics: Adult; Alcoholism; Colorado; Delivery of Health Care; Ethanol; Female; Humans; Naltrexone; Opioid-Related Disorders | 2022 |
Association of Bupropion, Naltrexone, and Opioid Agonist Treatment With Stimulant-Related Admissions Among People With Opioid Use Disorder: A Case-Crossover Analysis.
Topics: Analgesics, Opioid; Buprenorphine; Bupropion; Central Nervous System Stimulants; Cross-Over Studies; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2022 |
Emergency department utilization by individuals with opioid use disorder who were recently incarcerated.
Topics: Analgesics, Opioid; Buprenorphine; Emergency Service, Hospital; Humans; Infant, Newborn; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners; Retrospective Studies | 2022 |
Effects of methadone, buprenorphine, and naltrexone on actigraphy-based sleep-like parameters in male rhesus monkeys.
Topics: Actigraphy; Analgesics, Opioid; Animals; Buprenorphine; Humans; Macaca mulatta; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Sleep | 2022 |
Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
Topics: Adult; Buprenorphine; Cohort Studies; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retention in Care; Retrospective Studies | 2022 |
Use of long-acting injectable buprenorphine in the correctional setting.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisons; Retrospective Studies | 2022 |
Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related Disorders; Physician Assistants | 2022 |
Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Topics: Analgesics, Opioid; Buprenorphine; Child; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Treatment Outcome | 2022 |
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Topics: Aged; Analgesics, Opioid; Buprenorphine; COVID-19; Drug Overdose; Female; Humans; Longitudinal Studies; Male; Medicare; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pandemics; Telemedicine; United States | 2022 |
Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone.
Topics: Adult; Analgesics, Opioid; Delayed-Action Preparations; Humans; Impulsive Behavior; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2022 |
Sensitivity of a fentanyl-vs.-social interaction choice procedure to environmental and pharmacological manipulations.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Male; Naltrexone; Opioid-Related Disorders; Rats; Self Administration; Social Interaction | 2022 |
Health care use and spending for Medicaid patients diagnosed with opioid use disorder receiving primary care in Federally Qualified Health Centers and other primary care settings.
Topics: Analgesics, Opioid; Benzodiazepines; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Cross-Sectional Studies; Delivery of Health Care; Humans; Medicaid; Methadone; Naltrexone; Opioid-Related Disorders; Primary Health Care; United States | 2022 |
Extended-release naltrexone for people with alcohol use disorder on therapeutic anticoagulation: A case series.
Topics: Alcoholism; Anticoagulants; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2022 |
Optimally Choosing Medication Type for Patients With Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Depression; Humans; Naltrexone; Opioid-Related Disorders | 2023 |
Evidence for Endogenous Opioid Dependence Related to Latent Sensitization in a Rat Model of Chronic Inflammatory Pain.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Disease Models, Animal; Drug Inverse Agonism; Hyperalgesia; Inflammation; Mice; Naltrexone; Opioid Peptides; Opioid-Related Disorders; Rats; Rats, Wistar | 2023 |
Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference.
Topics: Analgesics, Opioid; Animals; Humans; Mice; Mice, Inbred C57BL; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid, delta; Receptors, Opioid, mu | 2023 |
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder.
Topics: Buprenorphine; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Social ecological factors and medication treatment for opioid use disorder among justice-involved rural and urban persons: the
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Overdose; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Observational Studies as Topic; Opioid-Related Disorders; Recurrence; Reproducibility of Results | 2023 |
Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine.
Topics: Administration, Sublingual; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Topics: Analgesics, Opioid; Buprenorphine; Drug Overdose; Humans; Massachusetts; Naltrexone; Opioid-Related Disorders | 2023 |
Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder.
Topics: Analgesics, Opioid; Cues; Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2023 |
Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
Topics: Buprenorphine; Criminal Law; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2023 |
Augmenting project ECHO for opioid use disorder with data-informed quality improvement.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opiate Overdose; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improvement; Surveys and Questionnaires | 2023 |
Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.
Topics: Analgesics, Opioid; Animals; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Naltrexone; Opioid-Related Disorders; Oxycodone; Receptors, Dopamine D3; Self Administration | 2023 |
In brief: Over-the-counter Narcan nasal spray.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Nasal Sprays; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Racial Inequality in Receipt of Medications for Opioid Use Disorder.
Topics: Aged; Analgesics, Opioid; Benzodiazepines; Black or African American; Buprenorphine; Healthcare Disparities; Hispanic or Latino; Humans; Medicare; Naloxone; Naltrexone; Narcotic Antagonists; Opiate Overdose; Opioid-Related Disorders; United States; White | 2023 |
Impact of Medication-Based Treatment on Health Care Utilization Among Individuals With Opioid Use Disorder.
Topics: Ambulatory Care; Analgesics, Opioid; Behavior, Addictive; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care | 2023 |
On the Social Determinants of Health and Extended-Release Naltrexone.
Topics: Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Social Determinants of Health | 2023 |
The Utilization of Low Dose Naltrexone for Chronic Pain.
Topics: Analgesics, Opioid; Chronic Disease; Chronic Pain; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 2023 |
Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder.
Topics: Buprenorphine; Humans; Long QT Syndrome; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions; Retrospective Studies; United States | 2023 |
Risks of returning to opioid use at treatment entry and early in opioid use disorder treatment: Role of non-opioid substances.
Topics: Analgesics, Opioid; Buprenorphine; Cocaine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2023 |
Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Female; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2023 |
Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
Topics: Addiction Medicine; Adult; Aged; Analgesics, Opioid; Buprenorphine; Humans; Medicare; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; United States | 2024 |
Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Buprenorphine; Female; Humans; Leadership; Male; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2023 |
US ED Opioid-Related Visits Increase, While Use of Medication for Opioid Use Disorder Undetectable, 2011-2016.
Topics: Buprenorphine; Drug Overdose; Emergency Service, Hospital; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Retrospective Studies; United States | 2020 |
Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Health Services Accessibility; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; Young Adult | 2019 |
Optimising opioid substitution therapy in the prison environment.
Topics: Age Factors; Buprenorphine; Comorbidity; Continuity of Patient Care; Delayed-Action Preparations; Drug Administration Schedule; England; Hepatitis C; HIV Infections; Humans; Mental Disorders; Methadone; Naltrexone; Narcotics; Needle Sharing; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Quality Improvement; Social Work; Wales | 2019 |
Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.
Topics: Adolescent; Adult; Attitude; Buprenorphine, Naloxone Drug Combination; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prevalence; United States; Young Adult | 2020 |
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Continuity of Patient Care; Delayed-Action Preparations; Female; Health Services Accessibility; Humans; Interviews as Topic; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Satisfaction; Prisoners; Qualitative Research; Socioeconomic Factors | 2019 |
Hide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests.
Topics: Analgesics, Opioid; Animals; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Detection | 2019 |
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
Topics: Adolescent; Adult; Age Distribution; Analgesics, Opioid; Buprenorphine; Databases, Factual; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Time-to-Treatment; Young Adult | 2020 |
Predictors of availability of long-acting medication for opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Female; Forecasting; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Surveys and Questionnaires; United States | 2019 |
Characteristics and current clinical practices of opioid treatment programs in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse Treatment Centers; Surveys and Questionnaires; Telemedicine; United States | 2019 |
Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment.
Topics: Analgesics, Opioid; Clinical Protocols; Cross-Sectional Studies; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Rhode Island; Risk Assessment; Risk Factors; Social Work; Stakeholder Participation; Substance-Related Disorders; United States | 2019 |
Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial.
Topics: Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Female; Health Services Accessibility; HIV Infections; Humans; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Patient Selection; Prospective Studies; Qualitative Research; Young Adult | 2019 |
Commentary on Nunes et al. (2020): Blocked opioid use in antagonist treatment-time for cognitive and user-centered perspectives.
Topics: Cognition; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
Medications for opioid use disorders: clinical and pharmacological considerations.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2020 |
An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
Topics: Analgesics, Opioid; Beneficence; Buprenorphine; Correctional Facilities; Evidence-Based Practice; Health Services Accessibility; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Personal Autonomy; Prisoners; Public Health; Social Justice | 2020 |
Discrimination learning in oxycodone-treated nonhuman primates.
Topics: Analgesics, Opioid; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Primates; Saimiri; Self Administration; Substance Withdrawal Syndrome | 2020 |
Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Topics: Aged; Analgesics, Opioid; Buprenorphine; Humans; Medicare; Methadone; Naltrexone; Opioid-Related Disorders; United States | 2020 |
A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Feasibility Studies; Female; Heroin Dependence; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Recurrence; Substance Withdrawal Syndrome; Young Adult | 2020 |
Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.
Topics: Adolescent; Adult; Behavior Therapy; Buprenorphine; Decision Making; Female; Humans; Male; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care; Patient Education as Topic; Prisoners; Prisons; Proportional Hazards Models; Retrospective Studies; Young Adult | 2020 |
Naltrexone use in pregnancy: a time for change.
Topics: Female; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pregnancy | 2020 |
Individual and county-level variation in outcomes following non-fatal opioid-involved overdose.
Topics: Adult; Analgesics, Opioid; Black or African American; Black People; Cohort Studies; Emergency Medical Services; Ethnicity; Female; Humans; Indiana; Local Government; Male; Middle Aged; Multilevel Analysis; Naltrexone; Narcotic Antagonists; Opiate Overdose; Opioid-Related Disorders; White People | 2020 |
Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Endocarditis; Female; Humans; Injections; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Odds Ratio; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Patient Discharge; Retrospective Studies; Treatment Refusal | 2020 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergency Service, Hospital; Female; Gabapentin; Humans; Male; Middle Aged; Naltrexone; Ontario; Opioid-Related Disorders; Patient Acceptance of Health Care; Primary Health Care; Referral and Consultation; Socioeconomic Factors; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Young Adult | 2020 |
Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Health Services Accessibility; Humans; Medicaid; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Residential Treatment; Substance Abuse Treatment Centers; United States | 2020 |
Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
Topics: Adult; Buprenorphine; Humans; Naltrexone; Opioid-Related Disorders; Perception; Pharmaceutical Preparations; United States | 2020 |
Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.
Topics: Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid Epidemic; Opioid-Related Disorders; Residential Treatment; Social Stigma; Social Support | 2020 |
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Cause of Death; Cohort Studies; Drug Overdose; Female; Humans; Male; Maryland; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Time Factors; United States; Young Adult | 2020 |
Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Residential Treatment; Retrospective Studies; Substance Withdrawal Syndrome; Young Adult | 2020 |
Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
Topics: Allosteric Regulation; Humans; Isoquinolines; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Protein Conformation; Receptors, Opioid, mu | 2020 |
Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.
Topics: Buprenorphine; Cross-Sectional Studies; Female; Humans; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Primary Health Care; United States | 2020 |
Diagnosis and Treatment of Opioid Use Disorder in 2020.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Drug and Narcotic Control; Harm Reduction; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Psychotherapy; Sensitivity and Specificity | 2020 |
Management of Opioid Misuse and Opioid Use Disorders Among Youth.
Topics: Adolescent; Adolescent Medicine; Behavior Therapy; Buprenorphine; Cause of Death; Combined Modality Therapy; Cross-Sectional Studies; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Pediatrics; Self-Help Groups; Substance Abuse, Intravenous; United States; Young Adult | 2020 |
Extinction as the behavioral mechanism of the naltrexone-extended release for opioid dependence: could there be an alternative explanation?
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: A preliminary study of Florida criminal problem-solving and dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Criminals; Cross-Sectional Studies; Drug Industry; Florida; Humans; Judicial Role; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Problem Solving | 2020 |
Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2020 |
Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
Topics: Analgesics, Opioid; Animals; Brain; Delayed-Action Preparations; Hemocyanins; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Rats; Vaccines | 2020 |
Precommitment Devices: A Defensible Treatment for Opioid Addiction?
Topics: Drug Implants; Human Experimentation; Humans; Informed Consent; Mental Competency; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Therapies, Investigational; Withholding Treatment | 2020 |
Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Topics: Ambulatory Care Facilities; Analgesics, Opioid; Buprenorphine; Delivery of Health Care; Health Services Accessibility; Hospitals, Veterans; Humans; Implementation Science; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pain Clinics; Primary Health Care; Teacher Training; United States; United States Department of Veterans Affairs; Veterans Health Services | 2020 |
Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians.
Topics: Buprenorphine; Drug Prescriptions; Female; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Physicians, Primary Care; Primary Health Care; Surveys and Questionnaires; United States | 2020 |
Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Behavior Therapy; Buprenorphine; Cohort Studies; Female; Health Care Costs; Hospitalization; Humans; Male; Medicare; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2020 |
Management of Sedation and Analgesia in Critically Ill Patients Receiving Long-Acting Naltrexone Therapy for Opioid Use Disorder.
Topics: Analgesia; Analgesics, Opioid; Critical Illness; Humans; Hypnotics and Sedatives; Naltrexone; Opioid-Related Disorders | 2020 |
Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder.
Topics: Adolescent; Adult; Aged; Buprenorphine, Naloxone Drug Combination; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Young Adult | 2020 |
A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Topics: Analgesics, Opioid; Attitude of Health Personnel; Buprenorphine; Delayed-Action Preparations; Drug and Narcotic Control; Female; Humans; Insurance Coverage; Insurance, Health; Male; Mental Disorders; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Specialization; United States | 2020 |
Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
Topics: Analgesics, Opioid; Buprenorphine; Case Managers; Counselors; Criminal Law; Criminals; Cross-Sectional Studies; Female; Florida; Health Knowledge, Attitudes, Practice; Humans; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2020 |
Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2020 |
Implementation of a Medication for Addiction Treatment (MAT) and Linkage Program by Leveraging Community Partnerships and Medical Toxicology Expertise.
Topics: Adult; Buprenorphine; Female; Humans; Interprofessional Relations; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Care Team; United States | 2021 |
Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment.
Topics: Adult; Analgesics, Opioid; Bacteria; Bacteroides; Bilophila; Buprenorphine; Feces; Female; Gastrointestinal Microbiome; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Population Dynamics; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Young Adult | 2020 |
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Tolerance; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opiate Overdose; Opioid-Related Disorders | 2021 |
COVID-19 and treating incarcerated populations for opioid use disorder.
Topics: Buprenorphine; COVID-19; Humans; Massachusetts; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisoners; Prisons; Public Health; Telemedicine | 2021 |
Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency.
Topics: Buprenorphine; COVID-19; Delayed-Action Preparations; Humans; Mobile Health Units; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2021 |
The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Health Questionnaire | 2021 |
Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020.
Topics: Analgesics, Opioid; Angiotensin Receptor Antagonists; Antidepressive Agents; Benzodiazepines; Buprenorphine; COVID-19; Drug Utilization; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Naloxone; Naltrexone; Opiate Overdose; Opioid-Related Disorders; Pandemics; SARS-CoV-2; United States | 2021 |
Three-month outcomes from a patient-centered program to treat opioid use disorder in Iowa, USA.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Iowa; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient-Centered Care | 2021 |
An anesthesiologist-led inpatient buprenorphine initiative.
Topics: Analgesics, Opioid; Anesthesiologists; Buprenorphine; Humans; Inpatients; Methadone; Naltrexone; Opioid-Related Disorders | 2021 |
Medication for Adolescents and Young Adults With Opioid Use Disorder.
Topics: Adolescent; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Young Adult | 2021 |
Reversal of ingested fentanyl patch toxicity with oral naltrexone in remote Australia: case report.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Australia; Fentanyl; Humans; Male; Naltrexone; Opioid-Related Disorders; Out-of-Hospital Cardiac Arrest; Rural Population; Transdermal Patch; Treatment Outcome | 2021 |
Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Topics: Accidental Falls; Adult; Alcohol-Related Disorders; Alcoholism; Analgesics, Opioid; Buprenorphine; Central Nervous System Depressants; Drug Overdose; Ethanol; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Protective Factors; Wounds and Injuries; Young Adult | 2021 |
Multiple-dose pharmacokinetics and opioid effects of a novel analgesic with a deterrent to human opioid abuse (methadone-fluconazole-naltrexone) after oral administration in dogs.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Animals; Dog Diseases; Dogs; Fluconazole; Humans; Methadone; Naltrexone; Opioid-Related Disorders | 2021 |
Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Family; Female; Goals; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Perception; Professional-Family Relations; Treatment Outcome | 2021 |
The role of social isolation in opioid addiction.
Topics: Analgesics, Opioid; Animals; Naltrexone; Narcotic Antagonists; Object Attachment; Opioid-Related Disorders; Social Isolation | 2021 |
Case report: Increasing the frequency of intramuscular naltrexone administration in a high risk patient with opioid use disorder.
Topics: Delayed-Action Preparations; Humans; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 2021 |
Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
Topics: Ambulatory Care; Buprenorphine; COVID-19; Health Services Accessibility; Humans; Insurance, Health, Reimbursement; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Telemedicine; United States | 2021 |
Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Chronic Pain; Cross-Sectional Studies; Drug Monitoring; Female; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; United States; Young Adult | 2021 |
Exploring naltrexamine derivatives featuring azaindole moiety via nitrogen-walk approach to investigate their in vitro pharmacological profiles at the mu opioid receptor.
Topics: Binding Sites; Humans; Ligands; Models, Molecular; Molecular Docking Simulation; Naltrexone; Nitrogen; Opioid-Related Disorders; Protein Conformation; Receptors, Opioid, mu | 2021 |
Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Injections, Intramuscular; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2021 |
A Novel Maintenance Therapeutic for Opioid Use Disorder.
Topics: Buprenorphine; Naltrexone; Opioid-Related Disorders | 2021 |
Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Young Adult | 2021 |
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; United States | 2021 |
Drug and sexual HIV-risk behaviors among adolescents and young adults with opioid use disorder.
Topics: Adolescent; Delayed-Action Preparations; Female; HIV Infections; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk-Taking; Young Adult | 2021 |
Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prescriptions; Retrospective Studies | 2022 |
Online Medication Assisted Treatment Education for Court Professionals: Need, Opportunities and Challenges.
Topics: Buprenorphine; Criminal Law; Humans; Naltrexone; Narcotic Antagonists; Ohio; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
Topics: Analgesics, Opioid; Buprenorphine; Health Services Accessibility; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
Topics: Alcoholism; Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders | 2021 |
Opioid Use Disorder Among Clients of Community Mental Health Clinics: Prevalence, Characteristics, and Treatment Willingness.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Heroin; Humans; Male; Mental Health; Naltrexone; Opioid-Related Disorders; Prevalence | 2022 |
Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
Topics: Adolescent; Adult; Delayed-Action Preparations; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Young Adult | 2017 |
Current Progress in Opioid Treatment.
Topics: Buprenorphine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2017 |
Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.
Topics: Adult; Female; Humans; Injections, Intramuscular; Inpatients; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Randomized Controlled Trials as Topic; Recurrence; Substance Withdrawal Syndrome | 2018 |
Extended-release naltrexone for opioid use disorder started during or following incarceration.
Topics: Adult; Ambulatory Care; Delayed-Action Preparations; Drug Overdose; Female; Humans; Injections, Intramuscular; Male; Massachusetts; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prisons; Prospective Studies | 2018 |
A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
Topics: Adult; Australia; Buprenorphine; Drug Administration Routes; Female; Humans; Incidence; Infant, Newborn; Male; Methadone; Naltrexone; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Retrospective Studies | 2017 |
Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Topics: Adult; Criminal Law; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Acceptance of Health Care; Patient Admission; Randomized Controlled Trials as Topic; Retrospective Studies; United States | 2018 |
Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
Topics: Adult; Buprenorphine; Cohort Studies; Drug Implants; Drug Overdose; Female; Humans; Male; Methadone; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Risk Factors; Western Australia; Young Adult | 2017 |
Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder.
Topics: Adolescent; Adult; Buprenorphine; Diagnostic Tests, Routine; Humans; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2017 |
Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Topics: Adolescent; Buprenorphine; Cohort Studies; Female; Humans; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Acceptance of Health Care; Prevalence; Retrospective Studies; United States; Young Adult | 2017 |
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Topics: Adult; Age Factors; Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Administration Routes; Female; Humans; Insurance Claim Review; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Practice Patterns, Physicians'; Prevalence; Sex Factors; United States | 2018 |
Screening, treatment initiation, and referral for substance use disorders.
Topics: Alcoholism; Buprenorphine; Emergency Service, Hospital; Humans; Mass Screening; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Tobacco Use Disorder | 2017 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxyzine; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2018 |
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.
Topics: Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Preference; Ukraine | 2017 |
Home-based delivery of XR-NTX in youth with opioid addiction.
Topics: Adult; Community Networks; Delayed-Action Preparations; Female; Home Care Services; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Secondary Prevention; Young Adult | 2018 |
More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic.
Topics: Continuity of Patient Care; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Abuse Treatment Centers | 2017 |
Sustained opioid antagonism modulates striatal sensitivity to baby schema in opioid use disorder.
Topics: Adult; Brain; Delayed-Action Preparations; Facial Recognition; Female; Humans; Magnetic Resonance Imaging; Maternal Behavior; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Reward | 2018 |
Extended-release naltrexone: good but not a panacea.
Topics: Delayed-Action Preparations; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2018 |
Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Therapy, Combination; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2018 |
State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
Topics: Adult; Buprenorphine; Government Programs; Health Policy; Humans; Longitudinal Studies; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; State Government; United States | 2018 |
Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Comorbidity; Cross-Sectional Studies; Female; Humans; Injections, Intramuscular; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans; Veterans Health | 2018 |
Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.
Topics: Adult; Alcohol-Related Disorders; Attitude of Health Personnel; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Delivery of Health Care; Feasibility Studies; Female; Financing, Government; Humans; Los Angeles; Male; Middle Aged; Motivational Interviewing; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Primary Health Care; United States | 2017 |
Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.
Topics: Delayed-Action Preparations; Humans; Injections, Intramuscular; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 2018 |
Healthcare utilization and costs associated with treatment for opioid dependence.
Topics: Adult; Age Factors; Buprenorphine; Comorbidity; Counseling; Delayed-Action Preparations; Health Expenditures; Health Resources; Humans; Male; Methadone; Middle Aged; Models, Econometric; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies | 2018 |
A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
Topics: Adult; Delayed-Action Preparations; Female; Focus Groups; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Preference; Ukraine | 2018 |
Time-dependent regional brain distribution of methadone and naltrexone in the treatment of opioid addiction.
Topics: Animals; Brain; Caudate Nucleus; Cerebral Cortex; Hippocampus; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Putamen; Rats, Sprague-Dawley | 2019 |
Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System.
Topics: Adolescent; Adult; Buprenorphine; Cause of Death; Drug Overdose; Female; Fentanyl; Health Plan Implementation; Humans; Male; Methadone; Middle Aged; Naltrexone; Odds Ratio; Opioid-Related Disorders; Patient Discharge; Prisoners; Prisons; Retrospective Studies; Rhode Island; Transitional Care; Young Adult | 2018 |
Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision.
Topics: Adult; Criminal Law; Criminals; Female; Humans; Informed Consent; Injections; Male; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Compliance; Patient Preference | 2018 |
Criminal justice continuum for opioid users at risk of overdose.
Topics: Analgesics, Opioid; Criminal Law; Delayed-Action Preparations; Drug Overdose; Humans; Judicial Role; Law Enforcement; Mass Screening; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Risk Assessment; United States | 2018 |
Impact of Medicaid Expansion on Access to Opioid Analgesic Medications and Medication-Assisted Treatment.
Topics: Analgesics, Opioid; Buprenorphine; Drug Prescriptions; Eligibility Determination; Humans; Medicaid; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States | 2018 |
Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury.
Topics: Analgesics, Opioid; Brain Injuries, Traumatic; Buprenorphine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Receptors, Opioid, mu | 2018 |
Injection Butorphanol dependence: A case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Butorphanol; GABA Modulators; Humans; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; Nitrazepam; Opiate Substitution Treatment; Opioid-Related Disorders | 2018 |
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Topics: Adult; Buprenorphine, Naloxone Drug Combination; Cohort Studies; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Injections, Intramuscular; Male; Naltrexone; Narcotic Antagonists; Norway; Opioid-Related Disorders; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Drug Overdose; Female; Humans; Male; Massachusetts; Methadone; Middle Aged; Mortality; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Proportional Hazards Models; Retrospective Studies; Young Adult | 2018 |
Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-
Topics: Analgesics, Opioid; Animals; Conditioning, Operant; Discrimination Learning; Drug Tolerance; Male; Morphine Derivatives; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome | 2018 |
Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Mitragyna; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Receptors, Opioid, delta; Receptors, Opioid, mu; Secologanin Tryptamine Alkaloids; Self Administration | 2019 |
Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence".
Topics: Delayed-Action Preparations; Humans; Naltrexone; Opioid-Related Disorders | 2018 |
Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence".
Topics: Delayed-Action Preparations; Humans; Naltrexone; Opioid-Related Disorders | 2018 |
Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment.
Topics: Buprenorphine; Drug Approval; Drug Overdose; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Primary Health Care; United States; United States Food and Drug Administration | 2018 |
Extended-release naltrexone overlooked in opioid use disorders guideline.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2018 |
Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report.
Topics: Analgesics, Opioid; Colonic Pseudo-Obstruction; Constipation; Decompression, Surgical; Humans; Hydromorphone; Intestinal Perforation; Low Back Pain; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Postoperative Complications; Quaternary Ammonium Compounds; Spinal Stenosis | 2019 |
Overview of Drugs Used to Treat Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Nurse's Role; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Education as Topic | 2018 |
Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime.
Topics: Acamprosate; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Cohort Studies; Crime; Drug Overdose; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Risk Factors; Suicidal Ideation; Young Adult | 2018 |
Potential Risk Window for Opioid Overdose Related to Treatment with Extended-Release Injectable Naltrexone.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Overdose; Humans; Naltrexone; Opioid-Related Disorders | 2018 |
Telemedicine's Role in Addressing the Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Epidemics; Health Policy; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Telemedicine; United States | 2018 |
Adherence to extended release naltrexone: Patient and treatment characteristics.
Topics: Adult; Alcoholism; Delayed-Action Preparations; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Retrospective Studies; United States; Veterans; Veterans Health | 2018 |
Pregnancy and Naltrexone Pharmacotherapy.
Topics: Adult; Delivery, Obstetric; Female; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain, Postoperative; Pregnancy; Pregnancy Complications | 2018 |
The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System.
Topics: Buprenorphine; Female; Humans; Male; Mass Screening; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Rhode Island; United States | 2018 |
Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Topics: Adolescent; Behavior Therapy; Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Retention in Care; Retrospective Studies; Time Factors; United States; Young Adult | 2018 |
Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users.
Topics: Adult; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Female; Humans; Male; Middle Aged; Morphine; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2019 |
Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2019 |
Extended-release injectable naltrexone (XR-NTX): a response to clinical issues raised by Brewer & Streel.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2019 |
Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.
Topics: Buprenorphine; Hospitals, Veterans; Humans; Implementation Science; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Quality Improvement; Quality Indicators, Health Care; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Tackling addiction in primary care.
Topics: Alcoholism; Buprenorphine; Drug Combinations; Humans; Illicit Drugs; Interdisciplinary Communication; Intersectoral Collaboration; Mass Screening; Minnesota; Naloxone; Naltrexone; Opioid-Related Disorders; Prescription Drugs; Primary Health Care; Referral and Consultation; Substance-Related Disorders | 2017 |
Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Topics: Adult; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pentazocine; Placebos | 2019 |
Being Explicit About Decisions: Prescribe Medications for Opioid Use Disorder on the Basis of Proven Effectiveness, Not Beliefs.
Topics: Analgesics, Opioid; Buprenorphine, Naloxone Drug Combination; Cost-Benefit Analysis; Humans; Naltrexone; Opioid-Related Disorders; Recurrence | 2019 |
Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Topics: Analgesics, Opioid; Buprenorphine; Cohort Studies; Female; Hospitals, Veterans; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Residential Treatment; United States; United States Department of Veterans Affairs; Veterans | 2018 |
Medication-assisted treatment for opioid use disorder.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Nurse Practitioners; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Nurses'; United States | 2019 |
Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?
Topics: Analgesics, Opioid; Buprenorphine; Diagnostic and Statistical Manual of Mental Disorders; Evidence-Based Medicine; Humans; International Classification of Diseases; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Reported Outcome Measures; Remission Induction | 2019 |
Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
Topics: Buprenorphine; Drug Overdose; Health Services Accessibility; Humans; Insurance, Health; Medicaid; Medicare; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Treatment Centers; United States | 2019 |
County-level access to opioid use disorder medications in medicare Part D (2010-2015).
Topics: Buprenorphine; Health Services Accessibility; Humans; Logistic Models; Medicare Part D; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Patterns, Physicians'; Residence Characteristics; Socioeconomic Factors; United States | 2019 |
Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder.
Topics: Adolescent; Adult; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Magnetic Resonance Imaging; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Opioid-Related Disorders; Photic Stimulation; Predictive Value of Tests; Psychomotor Performance; Treatment Outcome; Young Adult | 2019 |
Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Dose-Response Relationship, Drug; Female; Fibromyalgia; Humans; Hyperalgesia; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Pain Management; Pain Measurement; Pain Threshold; Predictive Value of Tests; Retrospective Studies; Young Adult | 2018 |
A further assessment of a role for Toll-like receptor 4 in the reinforcing and reinstating effects of opioids.
Topics: Analgesics, Opioid; Animals; Conditioning, Operant; Heroin; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Self Administration; Toll-Like Receptor 4 | 2020 |
Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
Topics: Adolescent; Adult; Analgesics, Opioid; Cohort Studies; Delayed-Action Preparations; Female; Humans; Male; Medicaid; Middle Aged; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Acceptance of Health Care; Prescription Drug Misuse; Retrospective Studies; United States; Young Adult | 2019 |
Prescription Drug and Alcohol Use Disorders: Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Female; Humans; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy | 2019 |
A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine.
Topics: Buprenorphine; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies | 2019 |
Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
Topics: Adult; Antidiarrheals; Antiemetics; Antipruritics; Buprenorphine; Clonidine; Deprescriptions; Drug Substitution; Female; Humans; Loperamide; Methadone; Methocarbamol; Muscle Relaxants, Central; Naltrexone; Narcotic Antagonists; Ondansetron; Opiate Substitution Treatment; Opioid-Related Disorders; Promethazine; Substance Withdrawal Syndrome; Sympatholytics | 2019 |
BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.
Topics: Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Tolerance; Hyperalgesia; Injections, Spinal; Isoquinolines; Macaca mulatta; Male; Naltrexone; Nociception; Opioid-Related Disorders; Pain Threshold; Phenylpropionates | 2019 |
News Media Reporting On Medication Treatment For Opioid Use Disorder Amid The Opioid Epidemic.
Topics: Analgesics, Opioid; Buprenorphine; Female; Health Education; Health Information Management; Humans; Information Dissemination; Male; Mass Media; Medical Informatics; Methadone; Naltrexone; Needs Assessment; Opiate Substitution Treatment; Opioid Epidemic; Opioid-Related Disorders; Public Health; Retrospective Studies; Risk Assessment; United States | 2019 |
The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia.
Topics: Buprenorphine; Databases, Factual; Drug Overdose; Female; Humans; Insurance Claim Review; Male; Medicaid; Naltrexone; Narcotic Antagonists; Opioid Epidemic; Opioid-Related Disorders; Patient Protection and Affordable Care Act; Prevalence; Retrospective Studies; Risk Assessment; Survival Analysis; United States; West Virginia | 2019 |
Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice.
Topics: Analgesics; Animals; Constipation; Drug Tolerance; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Receptors, Opioid, delta; Respiratory Insufficiency | 2019 |
Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Animals; Behavior, Animal; Choice Behavior; Clonidine; Drug-Seeking Behavior; Feeding Behavior; Female; Fentanyl; Food; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Reinforcement, Psychology; Self Administration; Substance Withdrawal Syndrome; Tetanus Toxoid; Vaccines, Conjugate | 2019 |
Medication-Based Treatment to Address Opioid Use Disorder.
Topics: Analgesics, Opioid; Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Stereotyping | 2019 |
Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
Topics: Adult; Buprenorphine; Cohort Studies; Delayed-Action Preparations; Drug Overdose; Female; Follow-Up Studies; Humans; Insurance, Health; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; United States; Young Adult | 2019 |
The case for a medication first approach to the treatment of opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Certification; Health Plan Implementation; Health Services Accessibility; Humans; Methadone; Missouri; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; State Government | 2019 |
Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Topics: Adolescent; Adult; Age Factors; Buprenorphine; Drug Utilization; Female; Humans; Male; Medicaid; Methadone; Middle Aged; Naltrexone; New York; Opiate Substitution Treatment; Opioid-Related Disorders; United States; Young Adult | 2019 |
Circumstances of death of opioid users being treated with naltrexone.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Australia; Cause of Death; Drug Implants; Drug Overdose; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Suicide; Young Adult | 2019 |
The Opioid Crisis: Treatment Efforts Exclude Inmates.
Topics: Adult; Analgesics, Opioid; Female; Humans; Male; Middle Aged; Naltrexone; Opioid Epidemic; Opioid-Related Disorders; Prisoners; United States | 2019 |
Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Infant, Newborn; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pilot Projects; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Retrospective Studies; Treatment Outcome | 2019 |
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes.
Topics: Adult; Delayed-Action Preparations; Feasibility Studies; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Patient Compliance; Quality of Life; Ukraine | 2019 |
Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
Topics: Adult; Ambulatory Care; Behavior Therapy; Buprenorphine, Naloxone Drug Combination; Combined Modality Therapy; Day Care, Medical; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Outcome Assessment, Health Care; Patient Compliance; Prospective Studies; Residential Treatment | 2019 |
Use of naltrexone in treating opioid use disorder in pregnancy.
Topics: Abortion, Spontaneous; Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Prospective Studies; Stillbirth; Young Adult | 2020 |
Impact of opioid pharmacotherapy on arterial stiffness and vascular ageing: cross-sectional and longitudinal studies.
Topics: Adult; Aging; Blood Vessels; Buprenorphine; Cross-Sectional Studies; Endothelium, Vascular; Female; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Phenotype; Pulse Wave Analysis; Regression Analysis; Vascular Stiffness | 2013 |
The clinical conundrum of perioperative pain management in patients with opioid dependence: lessons from two cases.
Topics: Adult; Buprenorphine; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain Management; Pain, Postoperative | 2013 |
Withdrawal syndrome caused by naltrexone in opioid abusers.
Topics: Adolescent; Adult; Aged; Cross-Sectional Studies; Female; Humans; Iran; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Severity of Illness Index; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Young Adult | 2014 |
Commentary on Krupitsky et al.(2013): Refuge from the streets--parked on methadone, or seeking shelter of a depot?
Topics: Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2013 |
DSM IV axis II traits can influence compliance to treatment with oral naltrexone: a preliminary study on 30 opiate dependent patients.
Topics: Administration, Oral; Adult; Female; Humans; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Personality; Personality Assessment; Personality Disorders; Recurrence | 2014 |
[Long-acting naltrexone--a new way out of opiate addiction?].
Topics: Delayed-Action Preparations; Drug Overdose; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2013 |
Long-term relapse of ultra-rapid opioid detoxification.
Topics: Adolescent; Adult; Anesthesia, General; Employment; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Recurrence; Regression Analysis; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2014 |
[Registered opiate addicts in Norway].
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
[Violation of the Helsinki Declaration].
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
[L.S. Stavseth and colleagues reply].
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2014 |
Naltrexone metabolism and concomitant drug concentrations in chronic pain patients.
Topics: Age Factors; Analgesics, Opioid; Chronic Pain; Creatinine; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Humans; Limit of Detection; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Sex Factors | 2014 |
Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
Topics: Adult; Buprenorphine; Drug Implants; Humans; Mauritius; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2014 |
The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.
Topics: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Heroin; Humans; Methadone; Naloxone; Naltrexone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Research Design; Systematic Reviews as Topic | 2014 |
Excess mortality among opioid-using patients treated with oral naltrexone in Australia.
Topics: Administration, Oral; Australia; Cohort Studies; Humans; Methadone; Naltrexone; Narcotic Antagonists; New South Wales; Opiate Substitution Treatment; Opioid-Related Disorders; Washington | 2015 |
Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
Topics: Alcohol-Related Disorders; Humans; Naltrexone; Opioid-Related Disorders; Substance Abuse Treatment Centers; United States | 2015 |
Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
Topics: Adolescent; Adult; Aged; Buprenorphine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Humans; Injections; Male; Markov Chains; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Young Adult | 2015 |
Preoperative ultra-rapid opiate detoxification for the treatment of post-operative surgical pain.
Topics: Analgesics, Opioid; Humans; Models, Biological; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain, Postoperative; Preoperative Care; Receptors, Opioid | 2015 |
Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.
Topics: Adult; Alcohol-Related Disorders; Criminals; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care | 2015 |
Medicaid coverage of medications to treat alcohol and opioid dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Buprenorphine, Naloxone Drug Combination; Humans; Insurance Coverage; Medicaid; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Taurine; United States | 2015 |
Factors associated with willingness to take extended release naltrexone among injection drug users.
Topics: Adult; Canada; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Acceptance of Health Care; Socioeconomic Factors; Substance Abuse, Intravenous | 2015 |
Severe opioid withdrawal syndrome after a single dose of nalmefene.
Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2015 |
Pharmacotherapy: Quest for the quitting pill.
Topics: Animals; Behavior, Addictive; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Clinical Trials as Topic; Cocaine-Related Disorders; Counseling; Dopamine; Drug Discovery; Drug Industry; Humans; Ibogaine; Lobeline; Molecular Targeted Therapy; Naloxone; Naltrexone; Oligopeptides; Opioid-Related Disorders; Pleasure; Rats; Receptors, Nicotinic; Reward; Substance-Related Disorders; Tobacco Use Disorder; Vaccines; Vesicular Monoamine Transport Proteins | 2015 |
Technology: Barriers to misuse.
Topics: Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Combinations; Drug Overdose; Drug Users; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone; Prodrugs | 2015 |
Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Topics: Behavior, Addictive; Buprenorphine; Global Health; Health Services Accessibility; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prescription Drug Misuse; United States | 2015 |
A demonstration project implementing extended-release naltrexone in Los Angeles County.
Topics: Adult; Delayed-Action Preparations; Female; Health Services Accessibility; Humans; Los Angeles; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Development; Young Adult | 2016 |
A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
Topics: Adult; Delayed-Action Preparations; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Prisoners; Treatment Outcome | 2015 |
Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene: unrecognized interaction.
Topics: Analgesics, Opioid; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2015 |
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome | 2015 |
Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use.
Topics: Alcohol-Related Disorders; Delayed-Action Preparations; Humans; Insurance, Health, Reimbursement; Interviews as Topic; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Qualitative Research; United States | 2016 |
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Buprenorphine; Drug Interactions; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2016 |
Short-term UROD treatment on cerebral function in codeine-containing cough syrups dependent male individuals.
Topics: Adult; Anesthesia, General; Antitussive Agents; Brain; Brain Mapping; Codeine; Humans; Magnetic Resonance Imaging; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Prospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2016 |
Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
Topics: Adult; Craving; Delayed-Action Preparations; Female; Heroin Dependence; Humans; Los Angeles; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse, Intravenous | 2016 |
Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Female; Humans; Logistic Models; Male; Methadone; Middle Aged; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Prisons; Retrospective Studies; Social Justice; United States; United States Department of Veterans Affairs; Veterans | 2016 |
Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification.
Topics: Adult; Continuity of Patient Care; Female; Humans; Injections, Intramuscular; Inpatients; Male; Massachusetts; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries; Substance Abuse Treatment Centers | 2016 |
Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Topics: Adult; Buprenorphine; Delayed-Action Preparations; Female; Humans; Interviews as Topic; Male; Methadone; Naltrexone; Opiate Substitution Treatment; Opioid-Related Disorders; Patient Preference; Substance Withdrawal Syndrome; Young Adult | 2016 |
Interest in Extended Release Naltrexone among Opioid Users.
Topics: Adult; Aged; Delayed-Action Preparations; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Surveys and Questionnaires; Young Adult | 2016 |
Prescription drug monitoring program data tracking of opioid addiction treatment outcomes in integrated dual diagnosis care involving injectable naltrexone.
Topics: Adult; Alcohol-Related Disorders; Analgesics, Opioid; Diagnosis, Dual (Psychiatry); Female; Humans; Injections, Intravenous; Longitudinal Studies; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prescription Drug Monitoring Programs; Substance Abuse Detection; Treatment Outcome | 2016 |
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
Topics: Administration, Sublingual; Buprenorphine, Naloxone Drug Combination; Comparative Effectiveness Research; Counseling; Delayed-Action Preparations; Ethics, Research; Humans; Informed Consent; Injections, Intramuscular; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Preference; Patient Safety; Prisoners; Randomized Controlled Trials as Topic; Vulnerable Populations | 2016 |
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Missouri; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outcome Assessment, Health Care; Psychotherapy; Taurine | 2016 |
Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.
Topics: Adult; Behavior, Addictive; Cocaine; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opiate Alkaloids; Opioid-Related Disorders; Pilot Projects; Randomized Controlled Trials as Topic | 2018 |
Antagonist Treatment for Opioid Use Disorder.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2017 |
Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment.
Topics: Delayed-Action Preparations; Evidence-Based Medicine; Humans; Injections, Intramuscular; Jurisprudence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recidivism | 2018 |
The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).
Topics: Adult; Delayed-Action Preparations; Female; Health Services Accessibility; Humans; Los Angeles; Male; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Program Development; Quality of Life; Substance-Related Disorders | 2018 |
Community treatment programs take up buprenorphine.
Topics: Buprenorphine; Humans; Mental Health Services; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Selection; Substance Abuse Treatment Centers | 2004 |
Response to Degenhardt et al.: 'depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy'.
Topics: Australia; Drug Implants; Humans; Legislation, Drug; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2008 |
A 50-year-old woman addicted to heroin: review of treatment of heroin addiction.
Topics: Buprenorphine; Drug Therapy, Combination; Female; Heroin Dependence; History, 19th Century; History, 20th Century; Humans; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Recurrence; Self-Help Groups; United States | 2008 |
Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.
Topics: Animals; Behavior, Animal; Body Temperature; Circadian Rhythm; Conditioning, Operant; Discrimination Learning; Drug Administration Schedule; Female; Heart Rate; Humans; Injections, Subcutaneous; Macaca mulatta; Morphine; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Sodium Chloride; Stereotyped Behavior; Substance Withdrawal Syndrome; Time Factors | 2008 |
"Narcotics helped, I thought." Recurrent traumatization and recovery from drug dependence.
Topics: Adaptation, Psychological; Adult; Alcoholism; Anxiety Disorders; Behavior Therapy; Child; Child Abuse; Child Abuse, Sexual; Combined Modality Therapy; Comorbidity; Countertransference; Diagnosis, Dual (Psychiatry); Family Therapy; Female; Humans; Life Change Events; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Physician-Patient Relations; Psychotherapy; Psychotherapy, Group; Reactive Attachment Disorder; Recurrence; Spouse Abuse | 2008 |
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Buprenorphine; Delayed-Action Preparations; Disulfiram; Drug Costs; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osteopathic Medicine; Physicians; Physicians, Family; Psychiatry; Taurine; United States | 2009 |
Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.
Topics: Adult; Behavior Therapy; Buprenorphine; Epidemiologic Methods; Feasibility Studies; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prescription Drugs; Substance Abuse Detection; Time Factors | 2009 |
Naltrexone in drug addiction: significance in the prevention of relapse.
Topics: Adolescent; Adult; Child; Female; Health Surveys; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Topics: Administration, Sublingual; Adult; Australia; Buprenorphine; Drug Implants; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries; Substance Abuse Treatment Centers; Time Factors; Treatment Outcome | 2009 |
A stress-coping profile of opioid dependent individuals entering naltrexone treatment: a comparison with healthy controls.
Topics: Adaptation, Psychological; Adolescent; Adult; Analysis of Variance; Chi-Square Distribution; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Selection; Personality Inventory; Regression Analysis; Self Concept; Social Support; Stress, Psychological; Surveys and Questionnaires | 2009 |
Ultra-rapid opiate detoxification followed by nine months of naltrexone maintenance therapy in Iran.
Topics: Adult; Anesthesia, General; Follow-Up Studies; Humans; Iran; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Severity of Illness Index; Substance Withdrawal Syndrome; Young Adult | 2010 |
Favorable mortality profile of naltrexone implants for opiate addiction.
Topics: Administration, Oral; Adult; Age Factors; Australia; Buprenorphine; Dosage Forms; Drug Implants; Female; Follow-Up Studies; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries; Risk Factors; Sex Factors; Treatment Outcome | 2010 |
Retention in naltrexone implant treatment for opioid dependence.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Treatment Outcome | 2010 |
Russian injected drug use soars in face of political inertia.
Topics: Drug Implants; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Politics; Russia; Substance Abuse, Intravenous | 2010 |
Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
Topics: Adolescent; Adult; Buprenorphine; Delayed-Action Preparations; Drug Administration Schedule; Feasibility Studies; Female; Humans; Injections, Subcutaneous; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Parents; Patient Satisfaction; Retrospective Studies; Secondary Prevention; Substance Abuse Detection; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2010 |
Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.
Topics: Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Logistic Models; Marijuana Abuse; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic | 2010 |
Addiction treatment in Russia.
Topics: Behavior, Addictive; Buprenorphine; Delayed-Action Preparations; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Russia; Substance Abuse, Intravenous; Suicide Prevention | 2010 |
Effect of ultra-rapid opiate detoxification on withdrawal syndrome.
Topics: Adult; Anesthesia, General; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2010 |
Thermosensitive Pluronic hydrogel: prolonged injectable formulation for drug abuse.
Topics: beta-Cyclodextrins; Calorimetry, Differential Scanning; Delayed-Action Preparations; Excipients; Hydrogels; Hydrogen-Ion Concentration; Injections, Subcutaneous; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Poloxamer; Temperature | 2010 |
Recent developments in naltrexone implants and depot injections for opiate abuse: the new kid on the block is approaching adulthood.
Topics: Delayed-Action Preparations; Drug Implants; Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2010 |
Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence.
Topics: Adult; Buprenorphine; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Sexual Dysfunction, Physiological; Surveys and Questionnaires | 2012 |
Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Dosage Forms; Drug Combinations; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Pain | 2011 |
Concerns about injectable naltrexone for opioid dependence.
Topics: Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2011 |
Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments.
Topics: Adamantane; Analgesics, Opioid; Animals; Behavior, Animal; Conditioning, Classical; Dipeptides; Drug Tolerance; Fentanyl; Hot Temperature; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Receptors, Neuropeptide; Substance Withdrawal Syndrome | 2012 |
Cost and utilization outcomes of opioid-dependence treatments.
Topics: Adult; Chi-Square Distribution; Female; Health Care Costs; Health Services; Humans; Inpatients; Insurance Claim Review; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Outpatients; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome; United States | 2011 |
Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.
Topics: Adult; Aged; Alanine Transaminase; Alcoholism; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Databases, Factual; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; RNA, Viral; Veterans | 2012 |
Injectable extended-release naltrexone for opioid dependence.
Topics: Administration, Oral; Delayed-Action Preparations; Drug Implants; Humans; Injections; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Russia | 2011 |
Promise of extended-release naltrexone is a red herring.
Topics: Buprenorphine; Delayed-Action Preparations; Humans; Injections; Methadone; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Russia | 2011 |
Injectable extended-release naltrexone for opioid dependence.
Topics: Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders | 2011 |
Injectable extended-release naltrexone for opioid dependence.
Topics: Delayed-Action Preparations; Drug Approval; Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States; United States Food and Drug Administration | 2011 |
Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations.
Topics: Analgesics, Opioid; Heroin; Humans; Naltrexone; Opioid-Related Disorders | 2012 |
Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice.
Topics: Adult; Anesthesiology; Contracts; Drug Evaluation, Preclinical; Female; Florida; Follow-Up Studies; Humans; Internship and Residency; Male; Mandatory Programs; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Physician Impairment; Rehabilitation, Vocational; Secondary Prevention | 2011 |
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
Topics: Adult; Delayed-Action Preparations; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections; Injections, Subcutaneous; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pilot Projects; Prisoners; Young Adult | 2012 |
Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Analgesics, Opioid; Cause of Death; Drug Implants; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Sex Distribution; Survival Rate; Western Australia; Young Adult | 2012 |
A 'miracle cure' misunderstood.
Topics: Administration, Oral; Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2012 |
[The use of different forms of naltrexone in the treatment of opioid dependence].
Topics: Administration, Oral; Drug Implants; Humans; Injections; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Russia | 2011 |
[Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].
Topics: Adult; Depression; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Young Adult | 2012 |
Advances in opioid antagonist treatment for opioid addiction.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Delayed-Action Preparations; Drug Therapy, Combination; GABA Agonists; Humans; Injections, Intramuscular; Medication Adherence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2012 |
Commentary on Kelty & Hulse (2012): is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?
Topics: Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2012 |
Opioid dependence.
Topics: Buprenorphine; Clonidine; Evidence-Based Medicine; Humans; Inactivation, Metabolic; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Prognosis; Risk Factors; Substance Withdrawal Syndrome; Time Factors | 2012 |
The implications of tamper-resistant formulations for opioid rotation.
Topics: Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Drug Tolerance; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone; Oxymorphone; Patient Selection | 2012 |
An ethical framework for conducting research on pregnant, opioid-dependent women.
Topics: Ethics, Medical; Female; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Research Design | 2013 |
Dual dilemma-should naltrexone be used in the treatment of opioid-dependent pregnant women?
Topics: Buprenorphine; Female; Humans; Infant, Newborn; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Neonatal Abstinence Syndrome; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Risk Assessment; Treatment Outcome | 2013 |
Blocking endogenous opioids during development--do we understand the consequences?
Topics: Animals; Brain; Buprenorphine; Female; Fetal Development; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Treatment Outcome | 2013 |
Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research.
Topics: Buprenorphine; Female; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Randomized Controlled Trials as Topic; Research Design; Substance Withdrawal Syndrome | 2013 |
Naltrexone in the treatment of opioid-dependent pregnant women: common ground.
Topics: Animals; Brain; Buprenorphine; Ethics, Medical; Female; Fetal Development; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Pregnancy; Pregnancy Complications; Research Design | 2013 |
Dangers involved in rapid opioid detoxification while using opioid antagonists: dehydration and renal failure.
Topics: Acute Kidney Injury; Adult; Dehydration; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2002 |
Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Topics: Adenylyl Cyclases; Analgesics, Opioid; Animals; Cell Line; Cell Membrane; Drug Tolerance; Enkephalin, D-Penicillamine (2,5)-; Guanosine 5'-O-(3-Thiotriphosphate); Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Receptors, Opioid, delta; Receptors, Opioid, mu | 2002 |
Rapid opioid detoxification in Australia.
Topics: Cause of Death; Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Safety Management; Substance Abuse Treatment Centers; Time Factors; Western Australia | 2002 |
Rapid opioid detoxification in Australia.
Topics: Australia; Cause of Death; Dehydration; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid; Risk Factors; Safety Management; Substance Abuse Treatment Centers; Time Factors | 2002 |
Combining naltrexone and behavior therapy.
Topics: Alcoholism; Behavior Therapy; Combined Modality Therapy; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2002 |
Behavioral naltrexone therapy: an integrated treatment for opiate dependence.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Compliance; Time Factors; Treatment Outcome | 2002 |
Characteristics, retention and readmissions of opioid-dependent clients treated with oral naltrexone.
Topics: Administration, Oral; Adult; Female; Humans; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Patient Compliance; Patient Readmission; Retrospective Studies; Substance Abuse Treatment Centers | 2002 |
Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results.
Topics: Adult; Buprenorphine; Conscious Sedation; Family Practice; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Premedication; Recurrence; Substance Withdrawal Syndrome; Time Factors; Vomiting | 2003 |
Clinical treatment of opioid addiction and dependence.
Topics: Administration, Oral; Administration, Sublingual; Buprenorphine; Humans; Inactivation, Metabolic; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
The effect of clonidine on gastrointestinal side effects associated with ultra-rapid opioid detoxification.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Diarrhea; Female; Gastrointestinal Diseases; Humans; Hypnotics and Sedatives; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Nausea; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Vomiting | 2003 |
Use of oral and implantable naltrexone in the management of the opioid impaired physician.
Topics: Administration, Oral; Drug Implants; Humans; Naltrexone; Opioid-Related Disorders; Patient Compliance; Physician Impairment; Treatment Outcome | 2003 |
Opiate withdrawal induces Narp in the extended amygdala.
Topics: Amygdala; Analgesics; Animals; C-Reactive Protein; Cell Count; Clonidine; Dose-Response Relationship, Drug; Immunohistochemistry; Male; Naloxone; Naltrexone; Narcotic Antagonists; Nerve Tissue Proteins; Nucleus Accumbens; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Septal Nuclei; Substance Withdrawal Syndrome | 2003 |
[Naltrexone implants--a pilot project].
Topics: Adult; Capsules; Drug Implants; Drug Monitoring; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Satisfaction; Pilot Projects | 2003 |
[Use of naltrexone in the treatment of young drug addicts].
Topics: Adult; Chemotherapy, Adjuvant; Drug Monitoring; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
[Naltrexone in the treatment of addiction].
Topics: Adult; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2003 |
Emergency department presentations of naltrexone-accelerated detoxification.
Topics: Adolescent; Adult; Cohort Studies; Emergency Service, Hospital; Female; Hospital Mortality; Humans; Inactivation, Metabolic; Male; Middle Aged; Morbidity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome | 2003 |
kappa-Opioid withdrawal in Planaria.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adaptation, Physiological; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hydrogen-Ion Concentration; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Osmolar Concentration; Planarians; Reaction Time; Receptors, Opioid, kappa; Substance Withdrawal Syndrome | 2003 |
Naltrexone-mediated opiate detoxification: a matter of terminology!
Topics: Humans; Inactivation, Metabolic; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Terminology as Topic | 2003 |
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Topics: Adenylyl Cyclases; Animals; Brain; Disease Models, Animal; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred ICR; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome; Sulfur Radioisotopes | 2004 |
Naltrexone implants.
Topics: Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Physician Impairment; Treatment Outcome | 2003 |
Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users.
Topics: Adult; Buprenorphine; Emergency Medical Services; Female; Humans; Inactivation, Metabolic; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Severity of Illness Index; Substance Abuse, Intravenous; Substance Withdrawal Syndrome | 2003 |
Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Topics: Adult; Analgesics, Opioid; Australia; Buprenorphine; Drug Overdose; Female; Humans; Male; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2004 |
Unexpected delirium during Rapid Opioid Detoxification (ROD).
Topics: Adult; Alcohol Withdrawal Delirium; Clonidine; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Inactivation, Metabolic; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2004 |
Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.
Topics: Adult; Drug Implants; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2004 |
In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Topics: Animals; Benzylidene Compounds; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred ICR; Morphine; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2005 |
Fatal opiate overdose following regimen changes in naltrexone treatment.
Topics: Drug Implants; Drug Overdose; Fatal Outcome; Humans; Infusion Pumps, Implantable; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2005 |
Treating opiate addiction, Part II: alternatives to maintenance.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychotherapy | 2005 |
Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants.
Topics: Adult; Cohort Studies; Drug Implants; Drug Overdose; Emergency Service, Hospital; Female; Heroin Dependence; Hospitalization; Humans; Male; Medical Record Linkage; Naltrexone; Narcotics; Opioid-Related Disorders; Patient Admission; Prospective Studies | 2005 |
Measurement of symptom withdrawal severity in a 24-hour period after the anesthesia-assisted rapid opiate detoxification procedure.
Topics: Adult; Anesthetics, Intravenous; Clinical Protocols; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Inactivation, Metabolic; Injections, Subcutaneous; Male; Naltrexone; Narcotics; Opioid-Related Disorders; Propofol; Retrospective Studies; Severity of Illness Index; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2005 |
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.
Topics: Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Morphine Dependence; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Orientation; Oxycodone; Rats; Rats, Sprague-Dawley; Reward; Substance Withdrawal Syndrome | 2005 |
Methods of detoxification and their role in treating patients with opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Failure | 2005 |
Adolescent opioid abuse.
Topics: Adolescent; Adolescent Behavior; Behavior Therapy; Buprenorphine; Humans; Hydrocodone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Substance Withdrawal Syndrome; Treatment Outcome; United States | 2005 |
General anaesthesia is patient-friendly in opioid antagonist detoxification treatment.
Topics: Anesthesia, General; Anxiety; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2005 |
De Jong, Krabbe, Laheij & Van Cauter refuted: evidence-based non-effectiveness can hardly be patient-friendly.
Topics: Anesthesia, General; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2005 |
Naltrexone and buprenorphine combination in the treatment of opioid dependence.
Topics: Adult; Affect; Buprenorphine; Cocaine; Cocaine-Related Disorders; Female; Heroin Dependence; Humans; Liver; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychiatric Status Rating Scales; Substance Abuse Detection; Survival Analysis | 2006 |
Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Topics: Buprenorphine; Data Collection; Drug Approval; Humans; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Substance Abuse Treatment Centers; Technology Transfer; United States; United States Food and Drug Administration | 2006 |
Naltrexone and problems in pain management.
Topics: Administration, Oral; Analgesics, Opioid; Contraindications; Drug Resistance; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain; Patient Selection; Risk Factors | 2006 |
Detoxification and treating opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2006 |
Detoxification and treating opioid dependence.
Topics: Anesthesia, General; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2006 |
Do antagonists have a role in the treatment of opioid dependence?
Topics: Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2006 |
S(+)-ketamine attenuates increase in electroencephalograph activity and amplitude height of sensory-evoked potentials during rapid opioid detoxification.
Topics: Adult; Electroencephalography; Evoked Potentials, Somatosensory; Female; Humans; Ketamine; Male; Middle Aged; Naltrexone; Opioid-Related Disorders | 2006 |
Obviation of opioid withdrawal syndrome by concomitant administration of naltrexone in microgram doses: two psychonautic bioassays.
Topics: Codeine; Half-Life; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Naltrexone implants -- duration, tolerability and clinical usefulness. A pilot study.
Topics: Drug Implants; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Satisfaction; Pilot Projects; Psychometrics | 2006 |
Medicalising the treatment of opioid dependence.
Topics: Buprenorphine; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 2006 |
Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification.
Topics: Aftercare; Ambulatory Care; Follow-Up Studies; Hospitalization; Humans; Inactivation, Metabolic; Length of Stay; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Psychotherapy, Group; Time Factors; Treatment Outcome; Veterans | 2006 |
Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food.
Topics: Adiposity; Animals; Anxiety; Behavior, Animal; Body Weight; Eating; Feeding Behavior; Female; Food; Food Preferences; Ghrelin; Growth Hormone; Leptin; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Wistar | 2008 |
Medical treatment of opiate dependence: expanding treatment options.
Topics: Administration, Sublingual; Ambulatory Care; Buprenorphine; Drug Combinations; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Randomized Controlled Trials as Topic; Substance Abuse Detection; Treatment Outcome | 2007 |
Availability of addiction medications in private health plans.
Topics: Alcohol Deterrents; Alcoholism; Buprenorphine; Cost Sharing; Data Collection; Disulfiram; Drugs, Generic; Formularies as Topic; Health Services Accessibility; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 2008 |
Does naltrexone affect craving in abstinent opioid-dependent patients?
Topics: Adult; Female; Heroin; Heroin Dependence; Humans; Longitudinal Studies; Male; Methadone; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2007 |
Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
Topics: Australia; Buprenorphine; Drug Prescriptions; Drug Therapy; Episode of Care; Humans; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Registries | 2007 |
Pharmacotherapeutic environments for substance use disorders.
Topics: Ambulatory Care; Buprenorphine; Cognitive Behavioral Therapy; Delayed-Action Preparations; Family Practice; Heroin Dependence; Hospitalization; Humans; Methadone; Naltrexone; Office Visits; Opioid-Related Disorders; Secondary Prevention; Substance-Related Disorders | 2007 |
Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
Topics: Australia; Drug Implants; Ethics, Medical; Humans; Legislation, Medical; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2008 |
Ensuring the safety of new medications and devices: are naltrexone implants safe?
Topics: Australia; Capsules; Drug Implants; Drug Monitoring; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Satisfaction | 2008 |
Naltrexone in addicted business executives and physicians.
Topics: Administrative Personnel; Adult; Aftercare; Ambulatory Care; Clonidine; Commerce; Female; Hospitalization; Humans; Male; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Physician Impairment | 1984 |
Clonidine hydrochloride detoxification from methadone treatment--the value of naltrexone aftercare.
Topics: Adult; Aftercare; Attitude to Health; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1984 |
Anti-endorphin effects of methadone.
Topics: Endorphins; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid | 1980 |
Clonidine and opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
Methadone-induced endorphin dysfunction in addicts.
Topics: Adrenocorticotropic Hormone; Brain; Endorphins; Humans; Hydrocortisone; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Receptors, Opioid; Substance Withdrawal Syndrome | 1982 |
Use of naltrexone to extinguish opioid-conditioned responses.
Topics: Adult; Combined Modality Therapy; Conditioning, Classical; Extinction, Psychological; Heroin Dependence; Humans; Male; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Recurrence; Relaxation Therapy | 1984 |
Predictors of favorable outcome following naltrexone treatment.
Topics: Employment; Humans; Morphine; Naloxone; Naltrexone; Opioid-Related Disorders; Time Factors | 1983 |
Recent advances in opiate detoxification: clonidine and lofexidine.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1983 |
Opioid antagonists: do they have a role in treatment programs?
Topics: Buprenorphine; Drug Tolerance; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence | 1983 |
Abstinence treatments for opiate addicts: therapeutic community or naltrexone?
Topics: Follow-Up Studies; Humans; Male; Naloxone; Naltrexone; Opioid-Related Disorders; Substance-Related Disorders; Therapeutic Community | 1984 |
Naltrexone in addicted physicians and business executives.
Topics: Clonidine; Commerce; Humans; Naltrexone; Opioid-Related Disorders; Physicians; Socioeconomic Factors; Time Factors | 1984 |
Assessment and extinction of conditioned withdrawal-like responses in an integrated treatment for opiate dependence.
Topics: Adult; Conditioning, Classical; Emotions; Extinction, Psychological; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Skin Temperature; Substance Withdrawal Syndrome; Time Factors | 1984 |
Naltrexone: a clinical perspective.
Topics: Adult; Alcohol Drinking; Ambulatory Care; Follow-Up Studies; Heroin Dependence; Hospitalization; Humans; Middle Aged; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Dropouts; Social Support; Substance Withdrawal Syndrome | 1984 |
Naltrexone induction: psychologic and pharmacologic strategies.
Topics: Ambulatory Care; Behavior Therapy; Clonidine; Counseling; Drug Administration Schedule; Drug Therapy, Combination; Family Therapy; Hospitalization; Humans; Illicit Drugs; Injections, Intramuscular; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Dropouts; Research Design | 1984 |
Clinical experience with naltrexone in suburban opioid addicts.
Topics: Adult; Ambulatory Care; Combined Modality Therapy; Female; Guanabenz; Heroin Dependence; Humans; Male; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Dropouts; Psychotherapy; Suburban Population; Time Factors | 1984 |
Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience.
Topics: Adult; Age Factors; Aged; Female; Health Occupations; Humans; Male; Middle Aged; Naloxone; Naltrexone; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Physician Impairment; Private Practice; Time Factors | 1984 |
Naltrexone treatment in a jail work-release program.
Topics: Adolescent; Adult; Ambulatory Care; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; New York; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Prisoners; Psychological Tests; Psychotherapy | 1984 |
The index of choice: indications of methadone patients' selection of naltrexone treatment.
Topics: Adult; Attitude; Humans; Internal-External Control; Male; Methadone; Motivation; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Acceptance of Health Care; Prospective Studies; Self Concept; Social Environment | 1984 |
Strategies to improve compliance with narcotic antagonists.
Topics: Combined Modality Therapy; Humans; Life Style; Methadone; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Compliance; Patient Dropouts; Research; Social Support; Substance Withdrawal Syndrome | 1984 |
Family denial as a prognostic factor in opiate addict treatment outcome.
Topics: Adult; Attitude to Health; Denial, Psychological; Family; Family Therapy; Female; Housing; Humans; Male; Marriage; Naltrexone; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Parent-Child Relations; Prognosis | 1983 |
Naltrexone and clonidine: alternatives to methadone.
Topics: Clonidine; Humans; Naloxone; Naltrexone; Opioid-Related Disorders | 1983 |
Predictors of favorable outcome following naltrexone treatment.
Topics: Employment; Follow-Up Studies; Humans; Male; Marriage; Naloxone; Naltrexone; Opioid-Related Disorders; Patient Acceptance of Health Care; Regression Analysis; Social Support; Time Factors | 1983 |
Psychotherapy and naltrexone in opioid dependence.
Topics: Adult; Humans; Naloxone; Naltrexone; Opioid-Related Disorders; Opium; Psychotherapy; Time Factors | 1981 |
The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
Topics: Animals; Biotransformation; Feces; Humans; Naloxone; Naltrexone; Opioid-Related Disorders; Time Factors; Tissue Distribution | 1981 |
Development of drug delivery systems for use in treatment of narcotic addiction.
Topics: Animals; Delayed-Action Preparations; Drug Compounding; Drug Implants; Haplorhini; Humans; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; United States | 1981 |
Endorphin levels in opioid-dependent human subjects: a longitudinal study.
Topics: Adult; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
Classification of narcotics on the basis of their reinforcing, discriminative, and antagonist effects in rhesus monkeys.
Topics: Animals; Behavior, Animal; Conditioning, Operant; Cyclazocine; Discrimination, Psychological; Ethylketocyclazocine; Humans; Macaca; Macaca mulatta; Morphine; Naloxone; Naltrexone; Narcotics; Opioid-Related Disorders; Reinforcement, Psychology; Self Administration | 1982 |
Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome.
Topics: Adult; Depressive Disorder; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Therapeutic Community | 1982 |
Outpatient opiate detoxification with clonidine.
Topics: Ambulatory Care; Clonidine; Double-Blind Method; Drug Therapy, Combination; Heroin Dependence; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1982 |
The clinical use of clonidine in outpatient detoxification from opiates.
Topics: Clonidine; Dose-Response Relationship, Drug; Heroin Dependence; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Self Administration; Substance Withdrawal Syndrome | 1981 |
Naltrexone: a short-term treatment for opiate dependence.
Topics: Adult; Employment; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Opioid-Related Disorders; Outcome and Process Assessment, Health Care; Patient Dropouts; Substance Withdrawal Syndrome; Time Factors | 1981 |
The naloxone test for opiate dependence.
Topics: Humans; Injections, Intramuscular; Injections, Intravenous; Methadyl Acetate; Naloxone; Naltrexone; Narcotics; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1980 |
A study of the use of clonidine and naltrexone in the treatment of opioid addiction in the former USSR.
Topics: Adult; Clonidine; Cross-Cultural Comparison; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heroin Dependence; Humans; Male; Naltrexone; Neurologic Examination; Opioid-Related Disorders; Patient Dropouts; Recurrence; Treatment Outcome; USSR | 1994 |
Naltrexone abuse and risk of suicide.
Topics: Ambulatory Care; Humans; Naltrexone; Opioid-Related Disorders; Recurrence; Risk Factors; Self Medication; Suicide | 1993 |
Opioid antagonists and butorphanol dependence.
Topics: Animals; Behavior, Animal; Butorphanol; Indoles; Injections, Intraventricular; Male; Morphinans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Substance Withdrawal Syndrome | 1993 |
[Naltrexone therapy. Experience with "Telephone Assistance" in Rome].
Topics: Adult; Hotlines; Humans; Italy; Naltrexone; Opioid-Related Disorders; Recurrence | 1993 |
Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1996 |
Spinal cord mechanisms of opioid tolerance and dependence: Fos-like immunoreactivity increases in subpopulations of spinal cord neurons during withdrawal [corrected].
Topics: Analgesics, Opioid; Animals; Drug Implants; Drug Tolerance; Male; Morphine; Naltrexone; Narcotic Antagonists; Neurons; Opioid-Related Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Spinal Cord; Substance Withdrawal Syndrome | 1996 |
Can psychotherapy rescue naltrexone treatment of opioid addiction?
Topics: Combined Modality Therapy; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Psychotherapy | 1995 |
International update: new findings on promising medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States | 1996 |
The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
Topics: Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 1996 |
Experts debate merits of 1-day opiate detoxification under anesthesia.
Topics: Anesthesia, General; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Treatment Centers; Substance Withdrawal Syndrome | 1997 |
Methadone vs naltrexone.
Topics: Connecticut; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 1997 |
Nalbuphine coadministered with morphine prevents tolerance and dependence.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Male; Morphine; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pyrrolidines; Rats; Rats, Sprague-Dawley | 1997 |
Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with mu opioid agonists.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Electric Stimulation; Male; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, mu; Self Stimulation | 1997 |
What you need to know: addiction--prescribing naltrexone.
Topics: Alcoholism; Heroin Dependence; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1997 |
Unethical promotion of rapid opiate detoxification under anaesthesia (RODA)
Topics: Advertising; Anesthesia, General; Ethics, Institutional; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Spain; Substance Abuse Treatment Centers; United Kingdom | 1998 |
Naltrexone-induced reduction of tobacco intake.
Topics: Adult; Ambulatory Care; Animals; Comorbidity; Humans; Male; Naltrexone; Opioid-Related Disorders; Smoking; Smoking Cessation; Smoking Prevention | 1998 |
[Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy].
Topics: Adrenergic alpha-Agonists; Adult; Behavior Therapy; Clonidine; Combined Modality Therapy; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pilot Projects; Substance Abuse Treatment Centers | 1997 |
Clinical experience with antagonist-induced opiate withdrawal under anaesthesia.
Topics: Anesthesia; Hospitalization; Humans; Inactivation, Metabolic; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1998 |
Training dose and session time as contextual determinants of heroin self-administration in rats.
Topics: Animals; Dose-Response Relationship, Drug; Heroin; Male; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Rats; Rats, Inbred F344; Self Administration; Time Factors | 1998 |
Outcomes of ultrarapid opiate detoxification combined with naltrexone maintenance and counseling.
Topics: Adult; Anesthesia, General; Clonidine; Combined Modality Therapy; Counseling; Follow-Up Studies; Humans; Intensive Care Units; Israel; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Recurrence; Sympatholytics; Time Factors; Treatment Outcome | 1998 |
Rapid opioid detoxification.
Topics: Anesthesia, General; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk | 1998 |
Rapid opioid detoxification.
Topics: Adult; Drug Implants; Fentanyl; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders | 1998 |
Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine.
Topics: Animals; Drug Tolerance; Male; Morphine; Naltrexone; Narcotics; Opioid-Related Disorders; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Serotonin | 1998 |
Ultra-rapid opioid detoxification increases spontaneous ventilation.
Topics: Anesthetics, Inhalation; Anesthetics, Intravenous; Carbon Dioxide; Evaluation Studies as Topic; Humans; Intubation, Gastrointestinal; Intubation, Intratracheal; Naltrexone; Narcotic Antagonists; Neuromuscular Blockade; Nitrous Oxide; Opioid-Related Disorders; Oxygen Consumption; Propofol; Prospective Studies; Respiration; Tidal Volume; Time Factors | 1998 |
Rapid opioid detoxification under anaesthesia.
Topics: Adult; Anesthesia, General; Atracurium; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Agents; Humans; Hypnotics and Sedatives; Male; Midazolam; Naloxone; Naltrexone; Narcotic Antagonists; Nicotinic Antagonists; Octreotide; Opioid-Related Disorders; Propofol | 1998 |
Reentry using naltrexone: one anesthesia department's experience.
Topics: Humans; Kentucky; Licensure, Nursing; Naltrexone; Narcotic Antagonists; Narcotics; Nurse Anesthetists; Occupational Health Services; Opioid-Related Disorders; Peer Group; Professional Impairment; Program Evaluation; Sufentanil | 1998 |
Heart rate variability and plasma catecholamines in patients during opioid detoxification.
Topics: Adult; Analysis of Variance; Anesthetics, Intravenous; Blood Pressure; Electroencephalography; Epinephrine; Female; Heart Rate; Humans; Male; Naltrexone; Narcotic Antagonists; Norepinephrine; Opioid-Related Disorders; Propofol; Signal Processing, Computer-Assisted; Substance Withdrawal Syndrome; Sympathetic Nervous System; Sympathomimetics; Wakefulness | 1999 |
First, do no harm: naltrexone-accelerated detoxification.
Topics: Australia; Ethics, Medical; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1999 |
Risks associated with the inappropriate use of naltrexone in the treatment of opioid dependence.
Topics: Adolescent; Adult; Confusion; Delirium; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1999 |
Active surveillance of adverse events associated with naltrexone in New South Wales.
Topics: Adult; Data Collection; Female; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; New South Wales; Opioid-Related Disorders | 1999 |
Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination.
Topics: Adult; Buprenorphine; Chi-Square Distribution; Female; Hostility; Humans; Logistic Models; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Patient Dropouts; Personality Inventory; Psychometrics; Severity of Illness Index; Sex Factors | 2000 |
Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts.
Topics: Adult; Anesthesia, General; Codeine; Female; Heroin Dependence; Humans; Male; Methadone; Morphine Dependence; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Prospective Studies; Substance Withdrawal Syndrome | 2000 |
Acute opioid but not benzodiazepine dependence in rats responding for intracranial self-stimulation.
Topics: Animals; Benzodiazepines; Brain; Diazepam; Dose-Response Relationship, Drug; Flumazenil; Male; Morphine; Naltrexone; Opioid-Related Disorders; Rats; Rats, Sprague-Dawley; Reinforcement Schedule; Self Stimulation; Substance-Related Disorders | 2000 |
[Multiple visceral lesions of internal organs in opioid dependency].
Topics: Adult; Brain Diseases; Candidiasis; Combined Modality Therapy; Endocarditis, Bacterial; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Staphylococcal Infections; Treatment Refusal | 2000 |
[The development of coma after the use of naltrexone in a patient with opioid addiction].
Topics: Adult; Coma; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 2000 |
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.
Topics: Adrenocorticotropic Hormone; Adult; Analgesics, Opioid; Analysis of Variance; Anesthesia, General; Blood Pressure; Female; Fentanyl; Follow-Up Studies; Heart Rate; Humans; Hydrocortisone; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Respiration; Statistics, Nonparametric; Substance Withdrawal Syndrome | 2001 |
Injections of an opioid antagonist into the locus coeruleus and periaqueductal gray but not the amygdala precipitates morphine withdrawal in the 7-day-old rat.
Topics: Age Factors; Amygdala; Animals; Animals, Newborn; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Locus Coeruleus; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Neural Pathways; Opioid-Related Disorders; Periaqueductal Gray; Quaternary Ammonium Compounds; Rats; Rats, Long-Evans; Substance Withdrawal Syndrome | 2001 |
[Evolution and update of detoxification techniques for opiate addicts].
Topics: Animals; Buprenorphine; Humans; Methadone; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2000 |
Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Anxiety Agents; Behavior Therapy; Benzodiazepines; Cocaine-Related Disorders; Female; Humans; Male; Marijuana Smoking; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Abuse Detection; Treatment Outcome | 2001 |
Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence.
Topics: Adjuvants, Immunologic; Administration, Oral; Analgesics, Opioid; Animals; Cells, Cultured; Cholera Toxin; Drug Administration Schedule; Drug Tolerance; Hot Temperature; Hyperalgesia; Injections, Subcutaneous; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pain Measurement; Receptors, Opioid; Substance Withdrawal Syndrome | 2001 |
Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon.
Topics: Buprenorphine; Electrocardiography; Heroin Dependence; Humans; Methadone; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Time Factors | 2001 |
Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets.
Topics: Administration, Cutaneous; Adult; Delayed-Action Preparations; Drug Implants; Emergency Treatment; Epilepsy, Tonic-Clonic; Fatal Outcome; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pulmonary Edema; Risk Assessment; Substance Withdrawal Syndrome; Time Factors; Unconsciousness; Vomiting | 2002 |
Effect of opioid dependence pharmacotherapies on zidovudine disposition.
Topics: Anti-HIV Agents; Buprenorphine; Drug Interactions; Female; HIV Infections; Humans; Male; Methadyl Acetate; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Radioimmunoassay; Substance Abuse Detection; Time Factors; Zidovudine | 2001 |
Selective postoperative inhibition of gastrointestinal opioid receptors.
Topics: Humans; Intestinal Obstruction; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Postoperative Complications; Postoperative Nausea and Vomiting; Quaternary Ammonium Compounds | 2002 |
Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification.
Topics: Adult; Analgesics; Clonidine; Humans; Inactivation, Metabolic; Israel; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Compliance; Recurrence; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome | 2002 |
[Documented effect of methadone, but not naltrexone].
Topics: Heroin Dependence; Humans; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Treatment Outcome | 2002 |
Cocaine and amphetamine attenuate the discriminative stimulus effects of naltrexone in opioid-dependent rhesus monkeys.
Topics: Amphetamine; Animals; Cocaine; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Female; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2002 |
Conditioned drug responses to naturalistic stimuli.
Topics: Conditioning, Psychological; Heart Rate; Humans; Hydromorphone; Methadone; Naltrexone; Opioid-Related Disorders; Personality Tests; Self Administration; Skin Temperature | 1979 |
Clonidine hydrochloride: a nonopiate treatment for opiate withdrawal.
Topics: Clonidine; Humans; Methadone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1979 |
Measurement of urine temperature as an alternative to observed urination in a narcotic treatment program.
Topics: Adult; Female; Humans; Male; Methadyl Acetate; Naltrexone; Narcotics; Opioid-Related Disorders; Specimen Handling; Temperature; Urine | 1979 |
Elevated basal firing rates and enhanced responses to 8-Br-cAMP in locus coeruleus neurons in brain slices from opiate-dependent rats.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Dose-Response Relationship, Drug; In Vitro Techniques; Locus Coeruleus; Male; Microelectrodes; Naltrexone; Opioid-Related Disorders; Rats; Rats, Inbred Strains | 1992 |
Opioid-dependent behaviors in infant rats: effects of prenatal exposure to ethanol.
Topics: Aging; Analgesia; Animals; Animals, Newborn; Behavior, Animal; Birth Weight; Diet; Ethanol; Female; Morphine; Naltrexone; Nociceptors; Opioid-Related Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Inbred Strains; Social Isolation; Stress, Psychological; Vocalization, Animal | 1991 |
Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methadone; Midazolam; Naloxone; Naltrexone; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1991 |
Drugs to decrease alcohol drinking.
Topics: Alcohol Drinking; Alcoholism; Animals; Extinction, Psychological; Male; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Inbred Strains | 1990 |
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Topics: Adult; Buprenorphine; Dose-Response Relationship, Drug; Humans; Hydromorphone; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pupil; Respiration | 1988 |
Evidence of single dose opioid dependence in 12- to 14-day-old chicken embryos.
Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Chick Embryo; Methadone; Morphine Dependence; Motor Activity; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Pyrrolidines; Receptors, Opioid; Substance Withdrawal Syndrome | 1989 |
From theory to practice: the planned treatment of drug users. Interview by Stanley Einstein.
Topics: Aftercare; Combined Modality Therapy; Humans; Methadone; Motivation; Naltrexone; Opioid-Related Disorders; Referral and Consultation; Substance-Related Disorders; Therapeutic Community | 1989 |
Simultaneous identification and quantification of several opiates and derivatives by capillary gas chromatography and nitrogen selective detection.
Topics: Chromatography, Gas; Humans; Nalorphine; Naloxone; Naltrexone; Narcotics; Opioid-Related Disorders | 1989 |
A multicentre study to introduce naltrexone for opiate dependence in Spain.
Topics: Adult; Combined Modality Therapy; Female; Humans; Male; MMPI; Naltrexone; Narcotics; Opioid-Related Disorders; Prospective Studies; Psychotherapy; Psychotherapy, Group; Spain; Substance-Related Disorders | 1989 |
A naturalistic analytic study of veterans using naltrexone in Puerto Rico.
Topics: Humans; Male; Mental Disorders; Naltrexone; Opioid-Related Disorders; Patient Compliance; Patient Dropouts; Puerto Rico; Sexual Behavior; Veterans | 1989 |
Naltrexone treatment--the problem of patient acceptance.
Topics: Adult; Clonidine; Female; Follow-Up Studies; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Patient Acceptance of Health Care | 1989 |
Urine testing in impaired physicians.
Topics: Fentanyl; Humans; Naltrexone; Opioid-Related Disorders; Patient Compliance; Physician Impairment | 1989 |
Role of the spinal cord in the development of opiate tolerance and dependence.
Topics: Animals; Drug Tolerance; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Rats; Receptors, Opioid; Spinal Cord | 1987 |
The role of drugs in the treatment of opioid addicts.
Topics: Alcoholism; Anxiety; Clonidine; Dextropropoxyphene; Heroin; Humans; Inactivation, Metabolic; Kinetics; Methadone; Mood Disorders; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders | 1986 |
Role of opioid antagonists in treating intravenous cocaine abuse.
Topics: Adult; Buprenorphine; Cocaine; Female; Humans; Injections, Intravenous; Male; Methadone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance-Related Disorders | 1989 |
Opiate addiction and plasma beta-endorphin-like immunoreactivity: methadone maintained, recently detoxified and early naltrexone treated ex-addicts.
Topics: Adult; beta-Endorphin; Endorphins; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Time Factors | 1987 |
Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
Topics: Animals; Brain; Corticosterone; Cyclazocine; Ethylketocyclazocine; Humans; Hypothalamo-Hypophyseal System; Male; Morphine; Naloxone; Naltrexone; Opioid-Related Disorders; Phenazocine; Pituitary-Adrenal System; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Receptors, sigma | 1985 |
Naltrexone.
Topics: Humans; Methadone; Naltrexone; Opioid-Related Disorders; Pain; Pituitary Gland; Receptors, Opioid; Substance Withdrawal Syndrome | 1985 |
Acute supersensitivity to the discriminative stimulus effects of naltrexone in pigeons.
Topics: Animals; Binding Sites; Columbidae; Diprenorphine; Discrimination Learning; Dose-Response Relationship, Drug; Generalization, Stimulus; Morphine; Nalorphine; Naloxone; Naltrexone; Opioid-Related Disorders | 1988 |
Idiosyncratic reaction to naltrexone augmented by thioridazine.
Topics: Adult; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Schizophrenia; Sleep Stages; Thioridazine | 1988 |
Naltrexone in the treatment of opiate dependence.
Topics: Humans; Naltrexone; Opioid-Related Disorders | 1987 |
[Naltrexone].
Topics: Humans; Naltrexone; Opioid-Related Disorders | 1987 |
The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study.
Topics: Adult; Combined Modality Therapy; Female; Follow-Up Studies; Hospitals, University; Humans; Male; Methadone; Naltrexone; Opioid-Related Disorders; Psychiatric Department, Hospital; Recurrence; Social Adjustment | 1987 |
Relationship of marital structure and interactions to opiate abuse relapse.
Topics: Adult; Family; Female; Humans; Male; Marriage; Naltrexone; Opioid-Related Disorders; Recurrence | 1987 |
The effect of multiple family therapy on addict family functioning: a pilot study.
Topics: Adult; Combined Modality Therapy; Family; Family Therapy; Female; Follow-Up Studies; Humans; Male; Naltrexone; Opioid-Related Disorders; Psychotherapy, Group | 1986 |
Retention and outcome in a narcotic antagonist treatment program.
Topics: Adult; Ambulatory Care; Follow-Up Studies; Humans; Male; Naltrexone; Opioid-Related Disorders; Patient Dropouts | 1986 |
Psychosocial adjustment, modality choice, and outcome in naltrexone versus methadone treatment.
Topics: Adult; Female; Follow-Up Studies; Humans; Male; Methadone; Middle Aged; Naltrexone; Opioid-Related Disorders; Social Adjustment | 1986 |
Psychosocial factors in outcome in two opiate addiction treatments.
Topics: Adult; Family; Female; Humans; Life Change Events; Male; Methadone; Middle Aged; Motivation; Naltrexone; Opioid-Related Disorders; Patient Compliance; Psychophysiologic Disorders; Social Support; Somatoform Disorders | 1986 |
Naltrexone for opioid addiction.
Topics: Drug Interactions; Humans; Kinetics; Naloxone; Naltrexone; Opioid-Related Disorders; Socioeconomic Factors | 1985 |